{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vnCyzeeJDUJd",
        "outputId": "c3b53893-5f3f-42e6-d30b-2e9a2476d79f"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ],
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import torch\n",
        "import matplotlib.pyplot as plt\n",
        "import numpy as np\n",
        "import re"
      ],
      "metadata": {
        "id": "VyFm1eGgufPX"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "imna7Zj7DqmW"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "train_data = pd.read_json('/content/drive/MyDrive/training_data/train.json').T"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def Faithfulness(original_preds, contrast_preds):\n",
        "    if len(original_preds) != len(contrast_preds):\n",
        "        raise ValueError(\"The lists of predictions must have the same length.\")\n",
        "    faithfulness = sum(abs(o - c) for o, c in zip(original_preds, contrast_preds)) / len(original_preds)\n",
        "    return faithfulness\n",
        "\n",
        "def Consistency(original_preds, contrast_preds):\n",
        "    if len(original_preds) != len(contrast_preds):\n",
        "        raise ValueError(\"The lists of predictions must have the same length.\")\n",
        "    consistency = sum(1-abs(o - c) for o, c in zip(original_preds, contrast_preds)) / len(original_preds)\n",
        "    return consistency"
      ],
      "metadata": {
        "id": "T-wcM7fIbx7Q"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 379
        },
        "id": "1CH-TDCvlmyB",
        "outputId": "e099d282-8779-4642-dd3d-e581fd321609"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Comparison    Intervention  NCT01928186   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed      Single     Eligibility  NCT00662129   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Comparison  Adverse Events  NCT00093145   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de      Single     Eligibility  NCT01097642   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Comparison    Intervention  NCT00852930   \n",
              "\n",
              "                                     Secondary_id  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  NCT00684983   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed          NaN   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  NCT00703326   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de          NaN   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  NCT02308020   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  All the primary trial participants do not rece...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Patients with Platelet count over 100,000/mm¬¨...   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Heart-related adverse events were recorded in ...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Adult Patients with histologic confirmation of...   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Laser Therapy is in each cohort of the primary...   \n",
              "\n",
              "                                              Label  \n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Contradiction  \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Contradiction  \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37     Entailment  \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Contradiction  \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Contradiction  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-396b514c-4ddf-447a-a975-ac96dfaa3b5e\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>5bc844fc-e852-4270-bfaf-36ea9eface3d</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT01928186</td>\n",
              "      <td>NCT00684983</td>\n",
              "      <td>All the primary trial participants do not rece...</td>\n",
              "      <td>Contradiction</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>86b7cb3d-6186-4a04-9aa6-b174ab764eed</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00662129</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
              "      <td>Contradiction</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>dbed5471-c2fc-45b5-b26f-430c9fa37a37</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00093145</td>\n",
              "      <td>NCT00703326</td>\n",
              "      <td>Heart-related adverse events were recorded in ...</td>\n",
              "      <td>Entailment</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20c35c89-8d23-4be3-b603-ac0ee0f3b4de</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT01097642</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Adult Patients with histologic confirmation of...</td>\n",
              "      <td>Contradiction</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>f17cb242-419d-4f5d-bfa4-41494ed5ac0e</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00852930</td>\n",
              "      <td>NCT02308020</td>\n",
              "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
              "      <td>Contradiction</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-396b514c-4ddf-447a-a975-ac96dfaa3b5e')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-396b514c-4ddf-447a-a975-ac96dfaa3b5e button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-396b514c-4ddf-447a-a975-ac96dfaa3b5e');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-e3fedbc7-2523-4703-b8dc-0aacbf5bd03d\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-e3fedbc7-2523-4703-b8dc-0aacbf5bd03d')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-e3fedbc7-2523-4703-b8dc-0aacbf5bd03d button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "train_data",
              "summary": "{\n  \"name\": \"train_data\",\n  \"rows\": 1700,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Eligibility\",\n          \"Results\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 850,\n        \"samples\": [\n          \"NCT01271725\",\n          \"NCT00615901\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 352,\n        \"samples\": [\n          \"NCT00305448\",\n          \"NCT00121134\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1692,\n        \"samples\": [\n          \"the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups.\",\n          \"More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Entailment\",\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 4
        }
      ],
      "source": [
        "train_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KYByBVkcwuPD",
        "outputId": "cf9ceb63-6525-4fb6-bb81-fc82053afb0a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Type  -  0\n",
            "Section_id  -  0\n",
            "Primary_id  -  0\n",
            "Secondary_id  -  1035\n",
            "Statement  -  0\n",
            "Label  -  0\n"
          ]
        }
      ],
      "source": [
        "for i in train_data.columns:\n",
        "  print(i, ' - ',train_data[i].isna().sum())"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "pN6WQXLXvUox"
      },
      "outputs": [],
      "source": [
        "import os\n",
        "import json"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "xRGdM7ecuAIo"
      },
      "outputs": [],
      "source": [
        "# Path to the folder containing JSON files\n",
        "json_folder_path = '/content/drive/MyDrive/training_data/CT json'"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "LWBrA7WFvkX_"
      },
      "outputs": [],
      "source": [
        "# Function to load JSON data\n",
        "def load_json_data(filename):\n",
        "    with open(filename, 'r') as file:\n",
        "        data = json.load(file)\n",
        "    return data"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "p8WPEuXJaTXw"
      },
      "outputs": [],
      "source": [
        "import re"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "SPkHF2Mr69kt"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "from transformers import BertTokenizer\n",
        "from sklearn.model_selection import train_test_split\n",
        "import torch"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "48MsP2r5U6Nc"
      },
      "outputs": [],
      "source": [
        "def remove_non_alphabetic(text):\n",
        "    return re.sub(r'[^a-zA-Z0-9\\s]', '', text)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "eqOCaYtyLvMs"
      },
      "outputs": [],
      "source": [
        "data=pd.read_json('/content/drive/MyDrive/training_data/gold_practice_test.json')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "7ueHO6wZL-sT"
      },
      "outputs": [],
      "source": [
        "data = data.T"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "EcHo9eCGMCiQ",
        "outputId": "29027c6c-7200-4ab7-aa0e-16efbec18435"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['Contradiction', 'Paraphrase', 'Text_appended',\n",
              "       'Numerical_contradiction', nan, 'Numerical_paraphrase'],\n",
              "      dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 14
        }
      ],
      "source": [
        "data['Intervention'].unique()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "Fj4NIpAeMFiX"
      },
      "outputs": [],
      "source": [
        "contradict_index = []\n",
        "contradict2=[]\n",
        "for i in range(0, data.shape[0]):\n",
        "  if data['Intervention'][i] in ['Contradiction']:\n",
        "    contradict_index.append(data.index.tolist()[i])\n",
        "    contradict2.append(data['Causal_type'][i][1])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "lNVE1iaxMIqa"
      },
      "outputs": [],
      "source": [
        "original = []\n",
        "for i in range(data.shape[0]):\n",
        "    if data['Intervention'][i] in ['Text_appended']:\n",
        "      if data['Causal_type'][i][1] in contradict2:\n",
        "        original.append(data.index[i])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "f7I_C9pjMLxc",
        "outputId": "2e248e22-44a6-448d-b7fe-1957a82a786e"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(600, 600)"
            ]
          },
          "metadata": {},
          "execution_count": 17
        }
      ],
      "source": [
        "len(original),len(contradict_index)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "AYvs8maSMQwS"
      },
      "outputs": [],
      "source": [
        "contradict_data = data.loc[contradict_index]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 538
        },
        "id": "13E-LDnNMRJm",
        "outputId": "e480b012-4518-4c98-83a8-5611da06db38"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                        Type      Section_id   Primary_id  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Single  Adverse Events  NCT00328783   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  Single    Intervention  NCT00374322   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  Single         Results  NCT01644890   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  Single     Eligibility  NCT02186015   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  Single  Adverse Events  NCT00191815   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  the primary trial documents a comprehensive li...   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  the patient cohorts in the primary clinical tr...   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  cohort 1 of the primary clinical trial had an ...   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  children are allowed to participate in the pri...   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  none of the participants in the first group of...   \n",
              "\n",
              "                                              Label   Intervention  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Contradiction  Contradiction   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  Contradiction  Contradiction   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  Contradiction  Contradiction   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  Contradiction  Contradiction   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  Contradiction  Contradiction   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667   [Altering, fef5aedb-21c0-4130-b8a3-cb1df5017c7a]   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7   [Altering, c40fdf91-9f81-454a-bba9-ec5c950cef6e]   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909   [Altering, 8c6314f7-34f5-42a7-ba66-b95d050a6315]   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14   [Altering, a805f174-2707-4302-a195-05153ea8523e]   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  [Preserving, 8e91e404-086e-4063-8d54-83d1b8ebd...   \n",
              "\n",
              "                                     Secondary_id  \n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667          NaN  \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7          NaN  \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909          NaN  \n",
              "11073b50-f135-48a1-a8ac-333375a49c14          NaN  \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff          NaN  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-a1dec9a3-222a-4a79-bf37-14711ea64bce\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>14e55d50-c012-4f32-afc5-6f5f7a030667</th>\n",
              "      <td>Single</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00328783</td>\n",
              "      <td>the primary trial documents a comprehensive li...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, fef5aedb-21c0-4130-b8a3-cb1df5017c7a]</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>64ab5bcd-229a-4aac-8d01-609e514400d7</th>\n",
              "      <td>Single</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00374322</td>\n",
              "      <td>the patient cohorts in the primary clinical tr...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, c40fdf91-9f81-454a-bba9-ec5c950cef6e]</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>f0271e34-7791-441b-ad94-a8e2e7f1f909</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT01644890</td>\n",
              "      <td>cohort 1 of the primary clinical trial had an ...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, 8c6314f7-34f5-42a7-ba66-b95d050a6315]</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11073b50-f135-48a1-a8ac-333375a49c14</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT02186015</td>\n",
              "      <td>children are allowed to participate in the pri...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, a805f174-2707-4302-a195-05153ea8523e]</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>78ac8091-0f1b-44d1-a760-71bfdc2d46ff</th>\n",
              "      <td>Single</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00191815</td>\n",
              "      <td>none of the participants in the first group of...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Preserving, 8e91e404-086e-4063-8d54-83d1b8ebd...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-a1dec9a3-222a-4a79-bf37-14711ea64bce')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-a1dec9a3-222a-4a79-bf37-14711ea64bce button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-a1dec9a3-222a-4a79-bf37-14711ea64bce');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-2e236633-23f8-400d-9a3a-e26d57d6e80b\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-2e236633-23f8-400d-9a3a-e26d57d6e80b')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-2e236633-23f8-400d-9a3a-e26d57d6e80b button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "contradict_data",
              "summary": "{\n  \"name\": \"contradict_data\",\n  \"rows\": 600,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Comparison\",\n          \"Single\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Intervention\",\n          \"Eligibility\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT01808573\",\n          \"NCT00606931\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"the secondary trial utilises progression-free survival as its primary outcome measurement for interventions.\",\n          \"the primary clinical trial and the secondary clinical trial present their findings in identical measurement units\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT01998906\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 19
        }
      ],
      "source": [
        "contradict_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "of6iJStrMTeu"
      },
      "outputs": [],
      "source": [
        "original_data=data.loc[original]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 573
        },
        "id": "5Ig3cqahMWhB",
        "outputId": "92495f24-8a2d-4c36-aa06-65600735dec8"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Comparison  Adverse Events  NCT01852032   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72      Single     Eligibility  NCT00438100   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Comparison  Adverse Events  NCT01216176   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5      Single     Eligibility  NCT00375427   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a      Single    Intervention  NCT00904033   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  the primary trial and the secondary trial repo...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  ongoing flucytosine treatments are not permitt...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  child needs help playing with other children i...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  Patients must have a Life expectancy of at lea...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  neither of the cohorts in the primary trial ar...   \n",
              "\n",
              "                                              Label   Intervention  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Contradiction  Text_appended   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72     Entailment  Text_appended   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Contradiction  Text_appended   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5     Entailment  Text_appended   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  Contradiction  Text_appended   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  [Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  [Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  [Preserving, 9c033072-5f94-4d79-af47-126d531f0...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  [Preserving, 618a3ae1-b22c-4c35-86a6-190c1b5b5...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  [Preserving, 63a0a9fc-80b9-450f-b2c6-7aee37ce2...   \n",
              "\n",
              "                                     Secondary_id  \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  NCT01830933  \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72          NaN  \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  NCT00325234  \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5          NaN  \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a          NaN  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-20ebf475-4d05-4479-83be-19b7713f6f7c\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>6c337426-cff6-4f2c-acab-e7bf15f09cc2</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT01852032</td>\n",
              "      <td>the primary trial and the secondary trial repo...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...</td>\n",
              "      <td>NCT01830933</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>141798cc-9851-4bdf-b8a9-ce688db34e72</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00438100</td>\n",
              "      <td>ongoing flucytosine treatments are not permitt...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ec5ca1ce-8399-4213-9f44-53e55b7352db</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT01216176</td>\n",
              "      <td>child needs help playing with other children i...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 9c033072-5f94-4d79-af47-126d531f0...</td>\n",
              "      <td>NCT00325234</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>95f5af8f-1590-4254-bd9f-885b6720b7b5</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00375427</td>\n",
              "      <td>Patients must have a Life expectancy of at lea...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 618a3ae1-b22c-4c35-86a6-190c1b5b5...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41a49fe6-55b7-4f89-bc8c-b0107350a79a</th>\n",
              "      <td>Single</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00904033</td>\n",
              "      <td>neither of the cohorts in the primary trial ar...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 63a0a9fc-80b9-450f-b2c6-7aee37ce2...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-20ebf475-4d05-4479-83be-19b7713f6f7c')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-20ebf475-4d05-4479-83be-19b7713f6f7c button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-20ebf475-4d05-4479-83be-19b7713f6f7c');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-01014ceb-68f6-4c13-ac86-9bfed75716cb\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-01014ceb-68f6-4c13-ac86-9bfed75716cb')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-01014ceb-68f6-4c13-ac86-9bfed75716cb button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "original_data",
              "summary": "{\n  \"name\": \"original_data\",\n  \"rows\": 600,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Eligibility\",\n          \"Results\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT00820170\",\n          \"NCT00305448\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"unilateral optic nerve hypoplasia is a congenital abnormality characterized by the underdevelopment of one optic nerve. There are more cases of Urosepsis in the primary trial than in the secondary trial.\",\n          \"appearance type code is a coded value specifying the appearance of an entity. the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Entailment\",\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Text_appended\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT01224678\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 21
        }
      ],
      "source": [
        "original_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "zvdtPIVhMZBT"
      },
      "outputs": [],
      "source": [
        "preserving_index = []\n",
        "preserving2=[]\n",
        "for i in range(0, data.shape[0]):\n",
        "  if data['Intervention'][i] in ['Paraphrase']:\n",
        "    preserving_index.append(data.index.tolist()[i])\n",
        "    preserving2.append(data['Causal_type'][i][1])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "PKOCbc8NMdxH"
      },
      "outputs": [],
      "source": [
        "original_preserving = []\n",
        "for i in range(data.shape[0]):\n",
        "    if data['Intervention'][i] in ['Text_appended']:\n",
        "      if data['Causal_type'][i][1] in preserving2:\n",
        "        original_preserving.append(data.index[i])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8eCsIQfWMgUR",
        "outputId": "745d0990-9526-4acd-a5ce-781ce9eea01e"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(600, 600)"
            ]
          },
          "metadata": {},
          "execution_count": 24
        }
      ],
      "source": [
        "len(preserving_index), len(original_preserving)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "5_OcWKMuMjHo"
      },
      "outputs": [],
      "source": [
        "original_preserving_data=data.loc[original_preserving]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 573
        },
        "id": "VaOGytrtMl2j",
        "outputId": "fdd23c0a-b74c-4d61-cc13-aab811f19d36"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Comparison  Adverse Events  NCT01852032   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72      Single     Eligibility  NCT00438100   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Comparison  Adverse Events  NCT01216176   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5      Single     Eligibility  NCT00375427   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a      Single    Intervention  NCT00904033   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  the primary trial and the secondary trial repo...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  ongoing flucytosine treatments are not permitt...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  child needs help playing with other children i...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  Patients must have a Life expectancy of at lea...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  neither of the cohorts in the primary trial ar...   \n",
              "\n",
              "                                              Label   Intervention  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Contradiction  Text_appended   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72     Entailment  Text_appended   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Contradiction  Text_appended   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5     Entailment  Text_appended   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  Contradiction  Text_appended   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  [Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  [Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  [Preserving, 9c033072-5f94-4d79-af47-126d531f0...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  [Preserving, 618a3ae1-b22c-4c35-86a6-190c1b5b5...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  [Preserving, 63a0a9fc-80b9-450f-b2c6-7aee37ce2...   \n",
              "\n",
              "                                     Secondary_id  \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  NCT01830933  \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72          NaN  \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  NCT00325234  \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5          NaN  \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a          NaN  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-3232b4d4-333b-4cfe-b06d-95332215eada\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>6c337426-cff6-4f2c-acab-e7bf15f09cc2</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT01852032</td>\n",
              "      <td>the primary trial and the secondary trial repo...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...</td>\n",
              "      <td>NCT01830933</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>141798cc-9851-4bdf-b8a9-ce688db34e72</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00438100</td>\n",
              "      <td>ongoing flucytosine treatments are not permitt...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ec5ca1ce-8399-4213-9f44-53e55b7352db</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT01216176</td>\n",
              "      <td>child needs help playing with other children i...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 9c033072-5f94-4d79-af47-126d531f0...</td>\n",
              "      <td>NCT00325234</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>95f5af8f-1590-4254-bd9f-885b6720b7b5</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00375427</td>\n",
              "      <td>Patients must have a Life expectancy of at lea...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 618a3ae1-b22c-4c35-86a6-190c1b5b5...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41a49fe6-55b7-4f89-bc8c-b0107350a79a</th>\n",
              "      <td>Single</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00904033</td>\n",
              "      <td>neither of the cohorts in the primary trial ar...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 63a0a9fc-80b9-450f-b2c6-7aee37ce2...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-3232b4d4-333b-4cfe-b06d-95332215eada')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-3232b4d4-333b-4cfe-b06d-95332215eada button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-3232b4d4-333b-4cfe-b06d-95332215eada');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-cce8b1b8-46b5-4cdb-8203-7f9b106ab78e\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-cce8b1b8-46b5-4cdb-8203-7f9b106ab78e')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-cce8b1b8-46b5-4cdb-8203-7f9b106ab78e button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "original_preserving_data",
              "summary": "{\n  \"name\": \"original_preserving_data\",\n  \"rows\": 600,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Eligibility\",\n          \"Results\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT00820170\",\n          \"NCT00305448\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"unilateral optic nerve hypoplasia is a congenital abnormality characterized by the underdevelopment of one optic nerve. There are more cases of Urosepsis in the primary trial than in the secondary trial.\",\n          \"appearance type code is a coded value specifying the appearance of an entity. the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Entailment\",\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Text_appended\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT01224678\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 26
        }
      ],
      "source": [
        "original_preserving_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "i_yM-YbDMoJJ"
      },
      "outputs": [],
      "source": [
        "preserving_data=data.loc[preserving_index]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 608
        },
        "id": "vzF8UVbxMq1S",
        "outputId": "df1fc354-fdf9-4c80-b9ec-6f27d97f0c8f"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type    Section_id   Primary_id  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Comparison  Intervention  NCT01572727   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9      Single       Results  NCT00915603   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  Comparison  Intervention  NCT01572727   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Comparison       Results  NCT00852930   \n",
              "572c52ba-9518-4b72-9a32-a08604808764      Single       Results  NCT00357110   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  in the primary clinical trial, patients receiv...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  in cohort 1 of the primary clinical trial, the...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  the intake of paclitaxel for patients in the p...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  the collection of overall survival metrics of ...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  the primary clinical trial reported 6 losses i...   \n",
              "\n",
              "                                              Label Intervention  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b     Entailment   Paraphrase   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  Contradiction   Paraphrase   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db     Entailment   Paraphrase   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Contradiction   Paraphrase   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  Contradiction   Paraphrase   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  [Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  [Preserving, 0cef8c8e-7986-46c7-a597-c5733a989...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  [Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  [Preserving, dc4c57b0-8c75-494e-81b0-3528df85e...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  [Preserving, f114846e-79d8-4712-add0-bb34b65d4...   \n",
              "\n",
              "                                     Secondary_id  \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  NCT00328783  \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9          NaN  \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  NCT00328783  \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  NCT02915744  \n",
              "572c52ba-9518-4b72-9a32-a08604808764          NaN  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-1816bdc6-8270-45ac-8638-bce3880283f3\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>ea57b54d-1912-4d9f-bcf7-7f423aed195b</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT01572727</td>\n",
              "      <td>in the primary clinical trial, patients receiv...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...</td>\n",
              "      <td>NCT00328783</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>47f4c385-4dd8-4b6e-a365-bb2fac258ab9</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00915603</td>\n",
              "      <td>in cohort 1 of the primary clinical trial, the...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, 0cef8c8e-7986-46c7-a597-c5733a989...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>d31f179f-1253-44c8-8fc6-167f7b3d41db</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT01572727</td>\n",
              "      <td>the intake of paclitaxel for patients in the p...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...</td>\n",
              "      <td>NCT00328783</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>76236597-7a5e-4042-b1c4-ddd5a4aa57e7</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00852930</td>\n",
              "      <td>the collection of overall survival metrics of ...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, dc4c57b0-8c75-494e-81b0-3528df85e...</td>\n",
              "      <td>NCT02915744</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>572c52ba-9518-4b72-9a32-a08604808764</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00357110</td>\n",
              "      <td>the primary clinical trial reported 6 losses i...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, f114846e-79d8-4712-add0-bb34b65d4...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-1816bdc6-8270-45ac-8638-bce3880283f3')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-1816bdc6-8270-45ac-8638-bce3880283f3 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-1816bdc6-8270-45ac-8638-bce3880283f3');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-cd03a55d-8af3-4b98-b893-0a365669a68d\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-cd03a55d-8af3-4b98-b893-0a365669a68d')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-cd03a55d-8af3-4b98-b893-0a365669a68d button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "preserving_data",
              "summary": "{\n  \"name\": \"preserving_data\",\n  \"rows\": 600,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Results\",\n          \"Adverse Events\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT00325234\",\n          \"NCT02370238\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"more total adverse events were observed in cohort 1 of the primary clinical trial than in cohort 2\",\n          \"women presently engaged in endocrine therapy are not eligible for both the secondary clinical trial and the primary clinical trial\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Contradiction\",\n          \"Entailment\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Paraphrase\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT02301988\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 28
        }
      ],
      "source": [
        "preserving_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "aDNnJdo6QFxl",
        "outputId": "669b277b-b2d3-4ea8-c4f2-9362ae0caf2a"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0"
            ]
          },
          "metadata": {},
          "execution_count": 29
        }
      ],
      "source": [
        "c=0\n",
        "for i in original:\n",
        "  if i not in original_preserving:\n",
        "    c+=1\n",
        "c"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "TZS4t2kVT_uP"
      },
      "outputs": [],
      "source": [
        "def pre_processing(data,json_folder_path,remove_non_alphabetic):\n",
        "  data['Primary_id_intervention']=None\n",
        "  data['Primary_id_Eligibility']=None\n",
        "  data['Primary_id_results']=None\n",
        "  data['Primary_id_Adverse_events']=None\n",
        "  for i in range(0,len(data['Primary_id'])):\n",
        "      json_file_path = os.path.join(json_folder_path, data['Primary_id'][i] + '.json')\n",
        "      if os.path.exists(json_file_path):\n",
        "          json_data = load_json_data(json_file_path)\n",
        "          data['Primary_id_intervention'][i] = json_data['Intervention']\n",
        "          data['Primary_id_Eligibility'][i]=json_data['Eligibility']\n",
        "          data['Primary_id_results'][i]=json_data['Results']\n",
        "          data['Primary_id_Adverse_events'][i]=json_data['Adverse Events']\n",
        "      else:\n",
        "          print(f\"File not found: {json_file_path}\")\n",
        "          data['Primary_id_intervention'][i] = None\n",
        "          data['Primary_id_Eligibility'][i]=None\n",
        "          data['Primary_id_results'][i]=None\n",
        "          data['Primary_id_Adverse_events'][i]=None\n",
        "  data['Secondary_id_intervention']=\"None\"\n",
        "  data['Secondary_id_Eligibility']=\"None\"\n",
        "  data['Secondary_id_results']=\"None\"\n",
        "  data['Secondary_id_Adverse_events']=\"None\"\n",
        "  for i in range(0,len(data['Secondary_id'])):\n",
        "      if data['Type'][i]=='Comparison':\n",
        "        json_file_path = os.path.join(json_folder_path, data['Secondary_id'][i] + '.json')\n",
        "        if os.path.exists(json_file_path):\n",
        "          json_data = load_json_data(json_file_path)\n",
        "          data['Secondary_id_intervention'][i] = json_data['Intervention']\n",
        "          data['Secondary_id_Eligibility'][i]=json_data['Eligibility']\n",
        "          data['Secondary_id_results'][i]=json_data['Results']\n",
        "          data['Secondary_id_Adverse_events'][i]=json_data['Adverse Events']\n",
        "        else:\n",
        "          data['Secondary_id_intervention'][i] = \"None\"\n",
        "          data['Secondary_id_Eligibility'][i]=\"None\"\n",
        "          data['Secondary_id_results'][i]=\"None\"\n",
        "          data['Secondary_id_Adverse_events'][i]=\"None\"\n",
        "  for i in range(0,data.shape[0]):\n",
        "    data1=data['Primary_id_intervention'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Primary_id_intervention'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "    data1=data['Primary_id_Eligibility'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Primary_id_Eligibility'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "    data1=data['Primary_id_results'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Primary_id_results'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "    data1=data['Primary_id_Adverse_events'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Primary_id_Adverse_events'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "    data1=data['Secondary_id_intervention'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Secondary_id_intervention'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "    data1=data['Secondary_id_Eligibility'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Secondary_id_Eligibility'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "    data1=data['Secondary_id_results'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Secondary_id_results'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "    data1=data['Secondary_id_Adverse_events'][i]\n",
        "    joined_string = ' '.join(data1)\n",
        "    data['Secondary_id_Adverse_events'][i] = re.sub(r'[^a-zA-Z0-9\\s]', '', joined_string)\n",
        "  for i in range(0,data.shape[0]):\n",
        "    if data['Secondary_id_intervention'][i]==\"N o n e\":\n",
        "      data['Secondary_id_Adverse_events'][i]=\"None\"\n",
        "      data['Secondary_id_Eligibility'][i]=\"None\"\n",
        "      data['Secondary_id_intervention'][i]=\"None\"\n",
        "      data['Secondary_id_results'][i]=\"None\"\n",
        "  data['Concatenated_Text'] = \"None\"\n",
        "  for i in range(data.shape[0]):\n",
        "      if data['Section_id'][i] == \"Intervention\":\n",
        "          primary_id = str(data['Primary_id_intervention'][i])\n",
        "          secondary_id = str(data['Secondary_id_intervention'][i])\n",
        "          statement = str(data['Statement'][i])\n",
        "          data['Concatenated_Text'][i] = 'The primary id intervention is ' + primary_id + ' and the secondary id intervention is ' + secondary_id + ' and the Statement is ' + statement\n",
        "      elif data['Section_id'][i] == 'Eligibility':\n",
        "          primary_id = str(data['Primary_id_Eligibility'][i])\n",
        "          secondary_id = str(data['Secondary_id_Eligibility'][i])\n",
        "          statement = str(data['Statement'][i])\n",
        "          data['Concatenated_Text'][i] = 'The primary id eligibility is ' + primary_id + ' and the secondary id eligibility is ' + secondary_id + ' and the Statement is ' + statement\n",
        "      elif data['Section_id'][i] == 'Adverse Events':\n",
        "          primary_id = str(data['Primary_id_Adverse_events'][i])\n",
        "          secondary_id = str(data['Secondary_id_Adverse_events'][i])\n",
        "          statement = str(data['Statement'][i])\n",
        "          data['Concatenated_Text'][i] = 'The primary id adverse events is ' + primary_id + ' and the secondary id adverse events is ' + secondary_id + ' and the Statement is ' + statement\n",
        "      elif data['Section_id'][i] == 'Results':\n",
        "          primary_id = str(data['Primary_id_results'][i])\n",
        "          secondary_id = str(data['Secondary_id_results'][i])\n",
        "          statement = str(data['Statement'][i])\n",
        "          data['Concatenated_Text'][i] = 'The primary id results is ' + primary_id + ' and the secondary id results is ' + secondary_id + ' and the Statement is ' + statement\n",
        "\n",
        "  data['Concatenated_Text'] = data['Concatenated_Text'].astype('string')\n",
        "  data['Concatenated_Text'] = data['Concatenated_Text'].apply(remove_non_alphabetic)\n",
        "  data['Concatenated_Text'] = data['Concatenated_Text'].str.lower()\n",
        "  return data"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "48E8Db82UnZ8"
      },
      "outputs": [],
      "source": [
        "validation_data=pd.read_json('/content/drive/MyDrive/training_data/dev.json')\n",
        "validation_data=validation_data.T"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "cGd4JUXusEHK"
      },
      "outputs": [],
      "source": [
        "gold_data = pd.read_json('/content/drive/MyDrive/training_data/gold_practice_test.json').T"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "TBGemIXDc5jh"
      },
      "outputs": [],
      "source": [
        "test_data=pd.read_json('/content/drive/MyDrive/training_data/test.json').T"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "0_IQqneqUxnW"
      },
      "outputs": [],
      "source": [
        "train_data=pre_processing(train_data,json_folder_path,remove_non_alphabetic)\n",
        "validation_data=pre_processing(validation_data,json_folder_path,remove_non_alphabetic)\n",
        "contradict_data=pre_processing(contradict_data,json_folder_path,remove_non_alphabetic)\n",
        "original_data=pre_processing(original_data,json_folder_path,remove_non_alphabetic)\n",
        "preserving_data=pre_processing(preserving_data,json_folder_path,remove_non_alphabetic)\n",
        "gold_data = pre_processing(gold_data,json_folder_path,remove_non_alphabetic)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "7s-mzNGwdBGs"
      },
      "outputs": [],
      "source": [
        "test_data = pre_processing(test_data,json_folder_path,remove_non_alphabetic)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 486
        },
        "id": "fvPETCWQnWxj",
        "outputId": "e9369bb1-ebb0-4fc2-9914-cb43787f44b5"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Comparison    Intervention  NCT01928186   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed      Single     Eligibility  NCT00662129   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Comparison  Adverse Events  NCT00093145   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de      Single     Eligibility  NCT01097642   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Comparison    Intervention  NCT00852930   \n",
              "\n",
              "                                     Secondary_id  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  NCT00684983   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed          NaN   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  NCT00703326   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de          NaN   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  NCT02308020   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  All the primary trial participants do not rece...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Patients with Platelet count over 100,000/mm¬¨...   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Heart-related adverse events were recorded in ...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Adult Patients with histologic confirmation of...   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Laser Therapy is in each cohort of the primary...   \n",
              "\n",
              "                                              Label  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Contradiction   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Contradiction   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37     Entailment   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Contradiction   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Contradiction   \n",
              "\n",
              "                                                                Primary_id_intervention  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  INTERVENTION 1    Diagnostic FLT PET   Patient...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  INTERVENTION 1    Paclitaxel  Gemcitabine  Bev...   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  INTERVENTION 1    Albuminbound Paclitaxel Carb...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  INTERVENTION 1    Ixabepilone   Brand name is ...   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  INTERVENTION 1    Laser Therapy Alone   therap...   \n",
              "\n",
              "                                                                 Primary_id_Eligibility  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Inclusion Criteria   A new diagnosis of invasi...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  DISEASE CHARACTERISTICS   Histologically or cy...   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Inclusion Criteria   Confirmed adenocarcinoma ...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Inclusion Criteria   Patients with histologic ...   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Inclusion Criteria   Breast cancer survivors w...   \n",
              "\n",
              "                                                                     Primary_id_results  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Outcome Measurement    Percent Change in Net I...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Outcome Measurement    6month Progressionfree ...   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Outcome Measurement    Percentage of Participa...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Outcome Measurement    Complete Response Rate ...   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Outcome Measurement    LDex Change   Bioimpeda...   \n",
              "\n",
              "                                                              Primary_id_Adverse_events  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d                   Adverse Events 1   Total 028 000   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Adverse Events 1   Total 2049 4082   Febrile n...   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Adverse Events 1   Total 532 1563   Febrile ne...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Adverse Events 1   Total 215 1333   Neutropeni...   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Adverse Events 1   Total 015 000 Adverse Event...   \n",
              "\n",
              "                                                              Secondary_id_intervention  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  INTERVENTION 1    Arm A   Patients receive ora...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed                                               None   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  INTERVENTION 1    Ramucirumab IMC1121B  Doceta...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de                                               None   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  INTERVENTION 1    Part A Abemaciclib HR HER2 B...   \n",
              "\n",
              "                                                               Secondary_id_Eligibility  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Inclusion Criteria   Histologically confirmed ...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed                                               None   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Inclusion Criteria   Participant is able to pr...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de                                               None   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Inclusion Criteria   Have brain metastases sec...   \n",
              "\n",
              "                                                                   Secondary_id_results  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Outcome Measurement    Progressionfree Surviva...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed                                               None   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Outcome Measurement    ProgressionFree Surviva...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de                                               None   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Outcome Measurement    Percentage of Participa...   \n",
              "\n",
              "                                                            Secondary_id_Adverse_events  \\\n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  Adverse Events 1   Total 419 2105   Hemoglobin...   \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed                                               None   \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Adverse Events 1   Total 285752 3790   Anaemia...   \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de                                               None   \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Adverse Events 1   Total 627 2222   Anaemia 02...   \n",
              "\n",
              "                                                                      Concatenated_Text  \n",
              "5bc844fc-e852-4270-bfaf-36ea9eface3d  the primary id intervention is intervention 1 ...  \n",
              "86b7cb3d-6186-4a04-9aa6-b174ab764eed  the primary id eligibility is disease characte...  \n",
              "dbed5471-c2fc-45b5-b26f-430c9fa37a37  the primary id adverse events is adverse event...  \n",
              "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  the primary id eligibility is inclusion criter...  \n",
              "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  the primary id intervention is intervention 1 ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-71c88d2e-895c-44ea-920c-411e2e49acd7\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Primary_id_intervention</th>\n",
              "      <th>Primary_id_Eligibility</th>\n",
              "      <th>Primary_id_results</th>\n",
              "      <th>Primary_id_Adverse_events</th>\n",
              "      <th>Secondary_id_intervention</th>\n",
              "      <th>Secondary_id_Eligibility</th>\n",
              "      <th>Secondary_id_results</th>\n",
              "      <th>Secondary_id_Adverse_events</th>\n",
              "      <th>Concatenated_Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>5bc844fc-e852-4270-bfaf-36ea9eface3d</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT01928186</td>\n",
              "      <td>NCT00684983</td>\n",
              "      <td>All the primary trial participants do not rece...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>INTERVENTION 1    Diagnostic FLT PET   Patient...</td>\n",
              "      <td>Inclusion Criteria   A new diagnosis of invasi...</td>\n",
              "      <td>Outcome Measurement    Percent Change in Net I...</td>\n",
              "      <td>Adverse Events 1   Total 028 000</td>\n",
              "      <td>INTERVENTION 1    Arm A   Patients receive ora...</td>\n",
              "      <td>Inclusion Criteria   Histologically confirmed ...</td>\n",
              "      <td>Outcome Measurement    Progressionfree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 419 2105   Hemoglobin...</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>86b7cb3d-6186-4a04-9aa6-b174ab764eed</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00662129</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>INTERVENTION 1    Paclitaxel  Gemcitabine  Bev...</td>\n",
              "      <td>DISEASE CHARACTERISTICS   Histologically or cy...</td>\n",
              "      <td>Outcome Measurement    6month Progressionfree ...</td>\n",
              "      <td>Adverse Events 1   Total 2049 4082   Febrile n...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is disease characte...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>dbed5471-c2fc-45b5-b26f-430c9fa37a37</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00093145</td>\n",
              "      <td>NCT00703326</td>\n",
              "      <td>Heart-related adverse events were recorded in ...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>INTERVENTION 1    Albuminbound Paclitaxel Carb...</td>\n",
              "      <td>Inclusion Criteria   Confirmed adenocarcinoma ...</td>\n",
              "      <td>Outcome Measurement    Percentage of Participa...</td>\n",
              "      <td>Adverse Events 1   Total 532 1563   Febrile ne...</td>\n",
              "      <td>INTERVENTION 1    Ramucirumab IMC1121B  Doceta...</td>\n",
              "      <td>Inclusion Criteria   Participant is able to pr...</td>\n",
              "      <td>Outcome Measurement    ProgressionFree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 285752 3790   Anaemia...</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20c35c89-8d23-4be3-b603-ac0ee0f3b4de</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT01097642</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Adult Patients with histologic confirmation of...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>INTERVENTION 1    Ixabepilone   Brand name is ...</td>\n",
              "      <td>Inclusion Criteria   Patients with histologic ...</td>\n",
              "      <td>Outcome Measurement    Complete Response Rate ...</td>\n",
              "      <td>Adverse Events 1   Total 215 1333   Neutropeni...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>f17cb242-419d-4f5d-bfa4-41494ed5ac0e</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00852930</td>\n",
              "      <td>NCT02308020</td>\n",
              "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>INTERVENTION 1    Laser Therapy Alone   therap...</td>\n",
              "      <td>Inclusion Criteria   Breast cancer survivors w...</td>\n",
              "      <td>Outcome Measurement    LDex Change   Bioimpeda...</td>\n",
              "      <td>Adverse Events 1   Total 015 000 Adverse Event...</td>\n",
              "      <td>INTERVENTION 1    Part A Abemaciclib HR HER2 B...</td>\n",
              "      <td>Inclusion Criteria   Have brain metastases sec...</td>\n",
              "      <td>Outcome Measurement    Percentage of Participa...</td>\n",
              "      <td>Adverse Events 1   Total 627 2222   Anaemia 02...</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-71c88d2e-895c-44ea-920c-411e2e49acd7')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-71c88d2e-895c-44ea-920c-411e2e49acd7 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-71c88d2e-895c-44ea-920c-411e2e49acd7');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-f22d8dde-7312-4ea0-9123-d9c60782374d\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-f22d8dde-7312-4ea0-9123-d9c60782374d')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-f22d8dde-7312-4ea0-9123-d9c60782374d button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "train_data",
              "summary": "{\n  \"name\": \"train_data\",\n  \"rows\": 1700,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Eligibility\",\n          \"Results\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 850,\n        \"samples\": [\n          \"NCT01271725\",\n          \"NCT00615901\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 352,\n        \"samples\": [\n          \"NCT00305448\",\n          \"NCT00121134\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1692,\n        \"samples\": [\n          \"the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups.\",\n          \"More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Entailment\",\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 847,\n        \"samples\": [\n          \"INTERVENTION 1    Herceptin Trastuzumab   Intravenous administration   Herceptin trastuzuamb Intravenous administration INTERVENTION 2    SB3 Proposed Trastuzumab Biosimilar   Intravenous administration   SB3 proposed trastuzumab biosimilar Intravenous administration\",\n          \"INTERVENTION 1    Zoledronic Acid 5 mg IV   Zometa Zoledronic Acid 5 mg IV given over 15 minutes as a one time dose Followup at month 1  every 2 months to month 12 for serum  urine markers of bone destruction NTx  CTx\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 848,\n        \"samples\": [\n          \"DISEASE CHARACTERISTICS   Current random fine needle breast aspiration FNA evidence of 1 of the following   Hyperplasia with atypia   Hyperplasia without atypia but with a 10year modified Gail risk of at least 4   Hyperplasia without atypia but with a BRCAPRO risk of at least 25   Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2   Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer   FNA must have been taken during days 114 of the menstrual cycle for premenopausal women   Classified as ACR class IIII on mammogram with stepwedge within past 6 months If intact uterus andor ovaries must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal   No ovarian cysts felt to be possibly or probably nonphysiologic that have not resolved to gynecologists satisfaction on repeat sonogram   Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2   No active cancer eg detectable disease   Hormone receptor status   Not specified   PATIENT CHARACTERISTICS   Age   18 and over   Sex   Female   Menopausal status   Any Performance status   Not specified   Life expectancy   At least 12 months   Hematopoietic   Hemoglobin greater than 10 gdL   Granulocyte count greater than 1000mm3   No deficiencies in protein C protein S or antithrombin III   No activated protein C resistance   Hepatic   Albumin greater than 30 gdL   Bilirubin less than 15 mgdL   AST less than 100 UL   Alkaline phosphatase less than 200 UL   Renal   Creatinine less than 15 mgdL   Cardiovascular   No history of deep venous thrombosis not related to trauma or pregnancy   No severe coronary artery disease   No history of prior stroke   Other   Not pregnant or nursing   Negative pregnancy test   Fertile patients must use effective contraception during and for 3 months after study   No other active cancer   No retinal vein thrombosis   No concurrent severe poorly controlled migraine   No factor V Leiden mutation carrier   PRIOR CONCURRENT THERAPY   Biologic therapy   At least 12 months since prior immunotherapy   Chemotherapy   At least 3 months between completion of prior KUMC phase II difluoromethylornithine DFMO study and baseline aspiration   At least 12 months since prior chemotherapy   Endocrine therapy   Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration   Must continue all hormone replacement therapy andor oral contraceptives that were being taken at time of baseline aspiration   At least 12 months since prior tamoxifen raloxifene or other antihormonal therapy   Radiotherapy   At least 3 months since prior radiotherapy   Surgery   At least 6 months between prior oophorectomy and baseline aspiration   Other   At least 2 weeks since the start of other new medication that would be ingested for 1 or more months\",\n          \"Inclusion Criteria   Medical oncology patient Established patient of participating medical oncologist greater than 18 years of age have a diagnosis of early stage or advanced breast cancer are receiving active systemic therapy in the form of IV adjuvant systemic therapy if early stage are English speaking able to provide informed consent themselves and identify a family member who they would like to include in their care   Care partner Family member eg spouse adult child parent adult sibling or other relative or unpaid friend who regularly accompanies patient to medical oncology visits   Medical oncology provider Practicing medical oncology provider at a participating clinic who provides care to patients with breast cancer Exclusion Criteria   Medical oncology patients Younger than 18 years pregnant not being treated for breast cancer do not attend medical oncology visits with family member or unpaid friend or unwilling for their family member or unpaid friend to be contacted   Care partner Paid nonfamily member who accompanies patient to visits\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 850,\n        \"samples\": [\n          \"Outcome Measurement    Percentage of Participants With Objective Response OR Assessed by Response Evaluation Criteria in Solid Tumours Version RECIST 11   Objective response according to RECIST v11 Best overall response of confirmed complete response CR or confirmed partial response PR recorded since first administration of trial medication and until the earliest of disease progression death or start of next treatment in each part separately Per Response Evaluation Criteria In Solid Tumors Criteria RECIST v11 for target lesions and assessed by Magnetic resonance imaging MRI Complete Response CR Disappearance of all target lesions Partial Response PR 30 decrease in the sum of the longest diameter of target lesions Objective Response OR  CR  PR Percentage of participants with OR along with exact 95 Confidence Interval by Clopper and Pearson is presented   Time frame From the initial dose of study drug until 28 days after end of the treatment period up to 1562 days Results 1    ArmGroup Title Afatinib Monotherapy   ArmGroup Description Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram mg filmcoated tablets until progression of their disease unacceptable adverse events or other reason necessitating withdrawal Patients could have dose reduced if 40 mg was not tolerated   Overall Number of Participants Analyzed 74   Measure Type Number   Unit of Measure Percentage of participants  18        10 to 28 Results 2    ArmGroup Title Afatinib and Paclitaxel or Vinorelbine Combination Therapy   ArmGroup Description Patient received Afatinib monotherapy orally once daily at a dose of 40 mg filmcoated tablets until progression of their disease unacceptable adverse events or other reason necessitating withdrawal Patients could have dose reduced if 40 mg was not tolerated and 80 mgsquare meter m2 Paclitaxel concentrate for intravenous infusion or 25 mgm2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy   Overall Number of Participants Analyzed 39   Measure Type Number   Unit of Measure Percentage of participants  31        17 to 48\",\n          \"Outcome Measurement    The Number of Patients Who Completed 8 Cycles   the study regimen is deemed feasible and tolerable for patients with ANC  15 on day 1 of treatment for all 8 cycles and absence of grade 3 or higher nonhematologic toxicity excluding alopecia nauseavomiting and bone pain We will also evaluate the total number of days needed to complete all 8 cycles   Time frame 2 years Results 1    ArmGroup Title Cohort A CMF at 14 Day Intervals   ArmGroup Description This is a pilot study using 8 cycles of CMF cyclophosphamide 600 mgm2 methotrexate 40 mgm2 and fluorouracil 600 mgm2 at 14 day intervals supported by PEGfilgrastim for a cohort of 38 patients A safety analysis will then be performed   cyclophosphamide methotrexate fluorouracil PEGfilgrastim C cyclophosphamide 600 mgm2 M methotrexate 40 mgm2 F fluorouracil 600 mgm2 P PEGfilgrastim  6 mg Eight doses of CMF q 14 days with PEGfilgrastim administered approximately 24 hours after chemotherapy Day 14 is also considered day 1 of the next cycle   Overall Number of Participants Analyzed 29   Measure Type Number   Unit of Measure participants  29\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 801,\n        \"samples\": [\n          \"Adverse Events 1   Total 0260 000 Adverse Events 2   Total 0246 000\",\n          \"Adverse Events 1   Total 2792 2935   FEBRILE NEUTROPENIA 492 435   NEUTROPENIA 392 326   THROMBOCYTOPENIA 092 000   CARDIAC FAILURE CONGESTIVE 392 326   ATRIAL FIBRILLATION 192 109   ABDOMINAL PAIN 192 109   DUODENAL ULCER 192 109   NAUSEA 192 109   NEUTROPENIC COLITIS 192 109   VOMITING 192 109   ADVERSE DRUG REACTION 192 109 Adverse Events 2   Total 734 2059   FEBRILE NEUTROPENIA 034 000   NEUTROPENIA 034 000   THROMBOCYTOPENIA 234 588   CARDIAC FAILURE CONGESTIVE 034 000   ATRIAL FIBRILLATION 034 000   ABDOMINAL PAIN 034 000   DUODENAL ULCER 034 000   NAUSEA 034 000   NEUTROPENIC COLITIS 034 000   VOMITING 034 000   ADVERSE DRUG REACTION 034 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 352,\n        \"samples\": [\n          \"INTERVENTION 1    Pralatrexate   Study drug 190 mgm2 for 2 to 4 weeks\",\n          \"INTERVENTION 1    Letrozole Breast Enhancement Safety   Single arm of healthy postmenopausal women to have two breast MRI baseline and posttreatment Letrozole of 125 mgday is given for three successive days just prior to the second MRI\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 352,\n        \"samples\": [\n          \"Inclusion Criteria   Breast Cancer has continued to grow after having received treatment with an antiestrogen hormonal treatment such as tamoxifen or an aromatase inhibitor   Requiring hormonal treatment   Postmenopausal women defined as a woman who has stopped having menstrual periods Exclusion Criteria   Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced breast cancer   Treatment with more than one previous regimen of endocrine therapy for advanced breast cancer   An existing serious disease illness or condition that will prevent participation or compliance with study procedures\",\n          \"Inclusion Criteria   Women are eligible to participate if they are 40 years or older and have been menopausal had no menstrual bleeding during the past 12 months Exclusion Criteria   History of bilateral mastectomy osteoporosis or renal impairment\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 353,\n        \"samples\": [\n          \"Outcome Measurement    Objective Response Rate ORR the Percentage of Patients Who Experience an Objective Benefit From Treatment   Per Response Evaluation Criteria In Solid Tumors Criteria RECIST v10 for target lesions and assessed by MRI or CT Complete Response CR Disappearance of all target lesions Partial Response PR 30 decrease in the sum of the longest diameter of target lesions Overall Response OR  CR  PR   Time frame 18 months Results 1    ArmGroup Title OxaliplatinTrastuzumab   ArmGroup Description Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mgm2 IV day 1 and trastuzumab 6 mgkg following 8 mgkg loading dose during cycle 1 Cycles were repeated every 21 days Oxaliplatin  Oxaliplatin will be administered at a dose of 130 mg m2 over 120 minutes on day 1 of each cycle following standard antiemetic premedications 21 day cycles For the first cycle trastuzumab will be administered before oxaliplatin however for subsequent cycles oxaliplatin will be infused prior to trastuzumab Trastuzumab  Trastuzumab will be administered as an 8 mgkg loading dose by intravenous IV infusion over 90 minutes on day 1 of cycle 1 Subsequent doses will be administered as a 6 mgkg IV dose over 30 minutes   Overall Number of Participants Analyzed 25   Measure Type Number   Unit of Measure percentage of participants  20        43 to 357\",\n          \"Outcome Measurement    Number of Patients With Objective Treatment Response Complete or Partial in the CNS   Imaging was performed at 8week intervals to assess response to treatment Patients with known or suspected leptomeningeal disease were deemed to have a complete response if CSF cytology converted to negative if positive at baseline and all meningeal enhancement or nodularity of brain andor spine MRI resolved A modified RECIST 10 criteria was used to assess CNS response for patients with new or progressing brain metastases In this modified RECIST criteria CNS lesions 1cm were not considered measurable but were considered evaluable for response and progression Progressive disease for patients with lesions 1 cm was defined as follows growth of a lesion from less than or equal to 5 mm to greater than or equal to 10mm or growth of a 69 mm lesion by at least 5 mm in the case of nontarget parenchymal brain metastases   Time frame Baseline scan prior to study entry was performed within 14 days of cycle 1 day 1 then every 8 weeks from then until disease progression or up to 2 years Results 1    ArmGroup Title Irinotecan and Temozolomide   ArmGroup Description irinotecan hydrochloride administered intravenously IV at a starting dose of 125 mgm2 on days 1 and 15 of a 28 day cycle   temozolomide orally for seven days at a starting dose of 100 mgm2 on days 17 and days 1521 of a 28 day cycle   Overall Number of Participants Analyzed 30   Measure Type Count of Participants   Unit of Measure Participants  2   67\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 342,\n        \"samples\": [\n          \"Adverse Events 1   Total 615 4000   Constipation 115 667   General disorders and administration site conditions  Other disease progression 215 1333   General disorders and administration site conditions  Other failure to thrive 015 000   Infections and infestations  Other unspecified 115 667   Platelet count decreased 115 667   Dehydration 015 000 Adverse Events 2   Total 35 6000   Constipation 05 000   General disorders and administration site conditions  Other disease progression 15 2000   General disorders and administration site conditions  Other failure to thrive 15 2000   Infections and infestations  Other unspecified 05 000   Platelet count decreased 05 000   Dehydration 15 2000   Dysarthria 05 000\",\n          \"Adverse Events 1   Total 11120 917   Acute myocardial infarction 0120 000   Atrial fibrillation 1120 083   Atrioventricular block second degree 0120 000   Cardiac failure congestive 1120 083   Myocardial infarction 0120 000   Myocardial ischaemia 1120 083   Goitre 1120 083   Colitis ischaemic 0120 000   Diverticulum 0120 000   Faecaloma 1120 083 Adverse Events 2   Total 19129 1473   Acute myocardial infarction 1129 078   Atrial fibrillation 0129 000   Atrioventricular block second degree 1129 078   Cardiac failure congestive 0129 000   Myocardial infarction 1129 078   Myocardial ischaemia 0129 000   Goitre 0129 000   Colitis ischaemic 1129 078   Diverticulum 1129 078   Faecaloma 0129 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Concatenated_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1691,\n        \"samples\": [\n          \"the primary id intervention is intervention 1    stratum 1 tac  bevacizumab   her2 negative participants were administered chemotherapy with docetaxel doxorubicin and cyclosphosphamide tac  bevacizumab every 3 weeks for 6 cycles and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks intervention 2    stratum 2 tch  bevacizumab   her2 positive participants were administered chemotherapy with docetaxel carboplatin and trastuzumab tch  bevacizumab every 3 weeks for 6 cycles and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks and the secondary id intervention is intervention 1    triptorelin plus tamoxifen   determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years intervention 2    triptorelin plus exemestane   determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years and the statement is the primary trial and the secondary trial have no overlap in the drugs they use for their interventions however they both have placebo groups\",\n          \"the primary id adverse events is adverse events 1   total 69258 2674   anaemia 3258 116   febrile neutropenia 13258 504   neutropenia 5258 194   thrombocytopenia 1258 039   atrial fibrillation 0258 000   mitral valve incompetence 1258 039   pericardial effusion 0258 000   sinus tachycardia 0258 000   abdominal pain 3258 116   abdominal pain upper 1258 039   colitis 1258 039 adverse events 2   total 64224 2857   anaemia 2224 089   febrile neutropenia 4224 179   neutropenia 1224 045   thrombocytopenia 0224 000   atrial fibrillation 1224 045   mitral valve incompetence 0224 000   pericardial effusion 2224 089   sinus tachycardia 1224 045   abdominal pain 3224 134   abdominal pain upper 0224 000   colitis 0224 000 and the secondary id adverse events is none and the statement is more than a quarter of patients in cohort 1 of the primary trial experienced an adverse event\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 36
        }
      ],
      "source": [
        "train_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "UEwWu9QGnrGG",
        "outputId": "a2d4339f-3ae5-44da-8944-3fc15ba27a0a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Type  -  0\n",
            "Section_id  -  0\n",
            "Primary_id  -  0\n",
            "Secondary_id  -  1035\n",
            "Statement  -  0\n",
            "Label  -  0\n",
            "Primary_id_intervention  -  0\n",
            "Primary_id_Eligibility  -  0\n",
            "Primary_id_results  -  0\n",
            "Primary_id_Adverse_events  -  0\n",
            "Secondary_id_intervention  -  0\n",
            "Secondary_id_Eligibility  -  0\n",
            "Secondary_id_results  -  0\n",
            "Secondary_id_Adverse_events  -  0\n",
            "Concatenated_Text  -  0\n"
          ]
        }
      ],
      "source": [
        "for i in train_data.columns:\n",
        "  print(i, ' - ',train_data[i].isna().sum())"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 573
        },
        "id": "JYrK7_mcsVcW",
        "outputId": "72c41c67-6670-46f1-fdff-087fc7e3e3bd"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667      Single  Adverse Events  NCT00328783   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Comparison    Intervention  NCT01572727   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Comparison  Adverse Events  NCT01852032   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72      Single     Eligibility  NCT00438100   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab      Single         Results  NCT00217399   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  the primary trial documents a comprehensive li...   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  in the primary clinical trial, patients receiv...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  the primary trial and the secondary trial repo...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  ongoing flucytosine treatments are not permitt...   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  all the primary trial patients had a minimum o...   \n",
              "\n",
              "                                              Label             Intervention  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Contradiction            Contradiction   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b     Entailment               Paraphrase   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Contradiction            Text_appended   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72     Entailment            Text_appended   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  Contradiction  Numerical_contradiction   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667   [Altering, fef5aedb-21c0-4130-b8a3-cb1df5017c7a]   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  [Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  [Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  [Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  [Preserving, 985bc5a0-bc21-447f-92f1-150e23ede...   \n",
              "\n",
              "                                     Secondary_id  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667          NaN   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  NCT00328783   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  NCT01830933   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72          NaN   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab          NaN   \n",
              "\n",
              "                                                                Primary_id_intervention  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  INTERVENTION 1    Active Breathing Coordinator...   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  INTERVENTION 1    BKM120 and Paclitaxel   Adul...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  INTERVENTION 1    Breast Cancer Patients   Tom...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  INTERVENTION 1    Capecitabine Arm   Capecitab...   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  INTERVENTION 1    Sorafenib and Anastrozole   ...   \n",
              "\n",
              "                                                                 Primary_id_Eligibility  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Inclusion Criteria   Requiring adjuvant or pos...   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Inclusion Criteria   Breast cancer that is loc...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Inclusion Criteria   35 years of age or older ...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  Inclusion Criteria   Biopsydiagnosed breast ca...   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  Inclusion Criteria   Histologically or cytolog...   \n",
              "\n",
              "                                                                     Primary_id_results  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Outcome Measurement    Dosimetric Evaluation M...   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Outcome Measurement    Progressionfree Surviva...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Outcome Measurement    Beta of CT Coronal View...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  Outcome Measurement    Progression Free Surviv...   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  Outcome Measurement    Complete Response  Part...   \n",
              "\n",
              "                                                              Primary_id_Adverse_events  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                        Adverse Events 1   Total 00   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Adverse Events 1   Total 61202 3020   FEBRILE ...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2                   Adverse Events 1   Total 023 000   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  Adverse Events 1   Total 071 000 Adverse Event...   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  Adverse Events 1   Total 1235 3429   handfoot ...   \n",
              "\n",
              "                                                              Secondary_id_intervention  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                                               None   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  INTERVENTION 1    Active Breathing Coordinator...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  INTERVENTION 1    Usual Care   Usual Care is t...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab                                               None   \n",
              "\n",
              "                                                               Secondary_id_Eligibility  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                                               None   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Inclusion Criteria   Requiring adjuvant or pos...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Inclusion Criteria   Patient component   Women...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab                                               None   \n",
              "\n",
              "                                                                   Secondary_id_results  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                                               None   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Outcome Measurement    Dosimetric Evaluation M...   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Outcome Measurement    Knowledge of Breast Can...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab                                               None   \n",
              "\n",
              "                                                            Secondary_id_Adverse_events  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                                               None   \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b                        Adverse Events 1   Total 00   \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Adverse Events 1   Total 0655 000 Adverse Even...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "fdbb037a-8084-4267-9143-f989d26726ab                                               None   \n",
              "\n",
              "                                                                      Concatenated_Text  \n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  the primary id adverse events is adverse event...  \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  the primary id intervention is intervention 1 ...  \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  the primary id adverse events is adverse event...  \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  the primary id eligibility is inclusion criter...  \n",
              "fdbb037a-8084-4267-9143-f989d26726ab  the primary id results is outcome measurement ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-4f37c5f0-0eab-4681-87ba-55c3a9a93d2d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Primary_id_intervention</th>\n",
              "      <th>Primary_id_Eligibility</th>\n",
              "      <th>Primary_id_results</th>\n",
              "      <th>Primary_id_Adverse_events</th>\n",
              "      <th>Secondary_id_intervention</th>\n",
              "      <th>Secondary_id_Eligibility</th>\n",
              "      <th>Secondary_id_results</th>\n",
              "      <th>Secondary_id_Adverse_events</th>\n",
              "      <th>Concatenated_Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>14e55d50-c012-4f32-afc5-6f5f7a030667</th>\n",
              "      <td>Single</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00328783</td>\n",
              "      <td>the primary trial documents a comprehensive li...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, fef5aedb-21c0-4130-b8a3-cb1df5017c7a]</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Active Breathing Coordinator...</td>\n",
              "      <td>Inclusion Criteria   Requiring adjuvant or pos...</td>\n",
              "      <td>Outcome Measurement    Dosimetric Evaluation M...</td>\n",
              "      <td>Adverse Events 1   Total 00</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ea57b54d-1912-4d9f-bcf7-7f423aed195b</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT01572727</td>\n",
              "      <td>in the primary clinical trial, patients receiv...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...</td>\n",
              "      <td>NCT00328783</td>\n",
              "      <td>INTERVENTION 1    BKM120 and Paclitaxel   Adul...</td>\n",
              "      <td>Inclusion Criteria   Breast cancer that is loc...</td>\n",
              "      <td>Outcome Measurement    Progressionfree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 61202 3020   FEBRILE ...</td>\n",
              "      <td>INTERVENTION 1    Active Breathing Coordinator...</td>\n",
              "      <td>Inclusion Criteria   Requiring adjuvant or pos...</td>\n",
              "      <td>Outcome Measurement    Dosimetric Evaluation M...</td>\n",
              "      <td>Adverse Events 1   Total 00</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6c337426-cff6-4f2c-acab-e7bf15f09cc2</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT01852032</td>\n",
              "      <td>the primary trial and the secondary trial repo...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...</td>\n",
              "      <td>NCT01830933</td>\n",
              "      <td>INTERVENTION 1    Breast Cancer Patients   Tom...</td>\n",
              "      <td>Inclusion Criteria   35 years of age or older ...</td>\n",
              "      <td>Outcome Measurement    Beta of CT Coronal View...</td>\n",
              "      <td>Adverse Events 1   Total 023 000</td>\n",
              "      <td>INTERVENTION 1    Usual Care   Usual Care is t...</td>\n",
              "      <td>Inclusion Criteria   Patient component   Women...</td>\n",
              "      <td>Outcome Measurement    Knowledge of Breast Can...</td>\n",
              "      <td>Adverse Events 1   Total 0655 000 Adverse Even...</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>141798cc-9851-4bdf-b8a9-ce688db34e72</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00438100</td>\n",
              "      <td>ongoing flucytosine treatments are not permitt...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Capecitabine Arm   Capecitab...</td>\n",
              "      <td>Inclusion Criteria   Biopsydiagnosed breast ca...</td>\n",
              "      <td>Outcome Measurement    Progression Free Surviv...</td>\n",
              "      <td>Adverse Events 1   Total 071 000 Adverse Event...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>fdbb037a-8084-4267-9143-f989d26726ab</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00217399</td>\n",
              "      <td>all the primary trial patients had a minimum o...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Numerical_contradiction</td>\n",
              "      <td>[Preserving, 985bc5a0-bc21-447f-92f1-150e23ede...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Sorafenib and Anastrozole   ...</td>\n",
              "      <td>Inclusion Criteria   Histologically or cytolog...</td>\n",
              "      <td>Outcome Measurement    Complete Response  Part...</td>\n",
              "      <td>Adverse Events 1   Total 1235 3429   handfoot ...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-4f37c5f0-0eab-4681-87ba-55c3a9a93d2d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-4f37c5f0-0eab-4681-87ba-55c3a9a93d2d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-4f37c5f0-0eab-4681-87ba-55c3a9a93d2d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-f9a84723-f219-47e9-b312-35b7cde8d159\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-f9a84723-f219-47e9-b312-35b7cde8d159')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-f9a84723-f219-47e9-b312-35b7cde8d159 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "gold_data",
              "summary": "{\n  \"name\": \"gold_data\",\n  \"rows\": 2142,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Comparison\",\n          \"Single\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Intervention\",\n          \"Results\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT00022516\",\n          \"NCT00477464\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 2141,\n        \"samples\": [\n          \"more than half of the patients in cohort 1 of the primary clinical trial experienced adverse events\",\n          \"several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2. several days is a subjective response indicating that something is true or present several days.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Entailment\",\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Paraphrase\",\n          \"Numerical_paraphrase\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT02301988\",\n          \"NCT00876395\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"INTERVENTION 1    NoCM   No further chemotherapy following standard adjuvant chemotherapy INTERVENTION 2    CMMaintenance   12month CMmaintenance regimen C cyclophosphamide 50 mgday orally continuously and M methotrexate 25 mg twiceday orally days 1 and 2 of every week for 1 year   Cyclophosphamide 50 mgday orally continuously for 1 year   Methotrexate 25 mg twiceday orally days 1 and 2 of every week for 1 year\",\n          \"INTERVENTION 1    Lapatinib 1250 mg and Capecitabine 2000 mgm2   Participants took lapatinib and capecitabine Lapatinib was orally administered at 1250 milligrams mg once daily Capecitabine was orally administered at 1000 mg per square meter mgm2 twice daily on the first day through the fourteenth day of each 21day cycle\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"DISEASE CHARACTERISTICS   Histologically confirmed stage I II or III breast cancer   T13 N02 M0   Patients with sentinel node biopsy positive disease must have undergone axillary dissection   Tumor must be confined to the breast without detected metastases elsewhere   T4 disease with minimal dermal invasion allowed   No T4 disease with ulceration of skin infiltration of skin except pathologically minimal dermal involvement peau dorange or inflammatory breast cancer   No bilateral breast cancer except in situ carcinoma or suspicious mass in opposite breast that has not been proven benign   No distant metastases   No skeletal pain of unknown cause elevated alkaline phosphatase or bone scan showing hot spots that cannot be ruled out as metastases by xray MRI andor CT   Must have undergone prior total mastectomy OR breastconserving procedure eg lumpectomy quadrantectomy or partial mastectomy with negative margins with radiotherapy planned   Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery   Negative surgical margins   Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy   Known HER2 status by immunohistochemistry or fluorescence in situ hybridization   Hormone receptor status   Estrogen and progesterone receptor negative   Less than 10 positive tumor cells by immunohistochemistry   PATIENT CHARACTERISTICS   Age Not specified   Sex   Not specified   Menopausal status   Premenopausal defined as less than 6 months since last menstrual period LMP AND no prior bilateral ovariectomy AND not on estrogen replacement OR under age 50 OR   Postmenopausal defined as prior bilateral ovariectomy OR more than 12 months since LMP without prior hysterectomy OR age 50 and over Performance status   Not specified   Life expectancy   Not specified   Hematopoietic   WBC greater than 3000mm3   Platelet count greater than 100000mm3   Hepatic   See Disease Characteristics   Bilirubin less than 20 mgdL   ALT less than 15 times upper limit of normal OR AST less than 60 IUL   Renal   Creatinine less than 12 mgdL   Other   Not pregnant or lactating within the past 6 months   Fertile patients must use effective barrier contraception   No other prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin carcinoma in situ of the cervix or contralateral or ipsilateral in situ breast carcinoma   No psychiatric or addictive disorders that would preclude study   No nonmalignant systemic disease that would preclude study   PRIOR CONCURRENT THERAPY   Biologic therapy   Prior trastuzumab Herceptin allowed   Chemotherapy   See Disease Characteristics   No prior adjuvant or neoadjuvant chemotherapy for breast cancer   Endocrine therapy   No prior endocrine therapy for breast cancer or prevention   No prior tamoxifen or raloxifene for breast cancer   Radiotherapy   No prior radiotherapy for breast cancer except primary irradiation   Surgery   See Disease Characteristics   Other   No prior preventative therapy for breast cancer\",\n          \"Inclusion criteria   Subjects eligible for enrolment in the study must meet all of the following criteria   Patients who have consent to this study participation and signed into Informed consent form   Subjects must have histologically confirmed invasive breast cancer with stage IIIB stage IIIC with T4 lesion or stage IV disease   Documentation of ErbB2 overexpression IHC3 or IHC2 with FISH confirmation is required based on local laboratory   Subjects must have documented progressive advanced or metastatic breast cancer   Subjects must have refractory breast cancer defined as progression in the locally advanced or metastatic setting or relapse within 6 months of completing adjuvant therapy Prior therapies must include but are not limited to   Taxane containing regimen for at least 4 cycles or 2 cycles provided disease progression occurred while on taxane   Anthracycline containing regimen for at least 4 cycles or 2 cycles provided disease progression occurred while on anthracycline   Subjects who relapse 6 months after completion of adjuvant anthracyclinecontaining chemotherapy and for whom further anthracycline is not indicated will be considered to have met the anthracycline prior exposure requirement   Taxanes and anthracyclines may have been administered concurrently or separately   Prior treatment with capecitabine is not permitted   Prior treatment must have contained trastuzumab alone or in combination with other chemotherapy for at least 6 weeks of standard doses in the adjuvant or advancedmetastatic setting   Subjects with hormone receptor positive tumors must have disease progression following hormonal therapy unless intolerant to hormonal therapy or hormonal therapy is not considered to be clinically appropriate   Subjects with stable CNS metastases asymptomatic and off systemic steroids and anticonvulsants for at least 3 months are eligible   Measurable disease according to modified RECIST Response Evaluation Criteria in Solid Tumors see Section 62 Efficacy p49   Subjects must have archived tumor tissue available for biomarker assessment   Female subjects must be 20   ECOG Performance Status of 0 or 1   Life expectancy of 12 weeks   Measurable lesions may be in the field of prior irradiation However there must be at least a 4week period between the last radiation treatment and the baseline scan documenting disease status for the lesion to be measurable   Cardiac ejection fraction within the institutional range of normal as measured by ECHO or MUGA if ECHO is not available If no institutional range is available cardiac ejection fraction must be 50   Adequate hematologic value hepatic and renal function as defined below Hematologic ANC absolute neutrophil count 15109L Hemoglobin 9 gdL Platelets 100 109L Hepatic Serum bilirubin 15ULN   25ULN if subject has Gilberts syndrome AST and ALT 5ULN if documented liver metastases   3ULN without liver metastases Renal Serum creatinine Creatinine clearance 50 mLmin   Calculated by the Cockcroft and Gault Method Exclusion criteria   Subjects meeting any of the following criteria must not be enrolled in the study   Pregnant or lactating females   Malabsorption syndrome disease significantly affecting gastrointestinal function or resection of the stomach or small bowel In addition subjects with ulcerative colitis are excluded   History of other malignancy Subjects who have been diseasefree for at least 5 years or subjects with a history of completely resected nonmelanoma skin cancer or successfully treated in situ carcinoma are eligible   Unresolved or unstable serious toxicity from prior administration of another investigational drug andor of prior anticancer therapy   Active or uncontrolled infection   Dementia altered mental status or any psychiatric condition that would prohibit the understanding or rendering of informed consent   Known history of uncontrolled or symptomatic angina arrhythmia or congestive heart failure   No prior antiErbB1ErbB2 inhibitor for breast cancer other than trastuzumab   Known history or clinical evidence of leptomeningeal carcinomatosis   Concurrent anticancer therapy chemotherapy radiation therapy surgery immunotherapy biologic therapy or tumor embolization other than capecitabine   Bisphosphonates for the treatment of bone metastases should not be initiated following the first dose of study medication Prophylactic use of bisphosphonate in subjects without bone disease is not permitted except for prevention of osteoporosis   Use of an investigational drug within 30 days or 5 halflives whichever is longer preceding the first dose of study medication   Participation in other studies or use of other investigational drugs during this study   Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib or excipients of lapatinib   Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to capecitabine fluorouracil or any excipients   Known dihydropyrimidine dehydrogenase DPD deficiency   Patients who an investigator judges ineligible to this study in consideration of patients safety eg complications\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Outcome Measurement    Diseasefree Survival   Estimated percentage of patients alive and diseasefree at 5 years from randomization where diseasefree survival is defined as the time from randomization to the first appearance of one of the following invasive breast cancer recurrence at local regional or distant site invasive contralateral breast cancer second nonbreast invasive cancer or death without cancer event or censored at date of last followup   Time frame 5year estimates reported at a median followup of 69 years Results 1    ArmGroup Title NoCM   ArmGroup Description No further chemotherapy following standard adjuvant chemotherapy   Overall Number of Participants Analyzed 539   Measure Type Number   Unit of Measure percentage of participants  747        706 to 783 Results 2    ArmGroup Title CMMaintenance   ArmGroup Description 12month CMmaintenance regimen C cyclophosphamide 50 mgday orally continuously and M methotrexate 25 mg twiceday orally days 1 and 2 of every week for 1 year   Cyclophosphamide 50 mgday orally continuously for 1 year   Methotrexate 25 mg twiceday orally days 1 and 2 of every week for 1 year   Overall Number of Participants Analyzed 542   Measure Type Number   Unit of Measure percentage of participants  781        742 to 816\",\n          \"Outcome Measurement    Clinical Benefit Response Independent Reviewerassessed   CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial confirmed tumor response or stable disease for at least 6 months 24 weeks A complete response is defined as the disappearance of all target or nontarget lesions partial response and disease progression as at least a 30 decrease and at least a 20 increase respectively in the sum of the longest diameter of target lesions and stable disease as neither partial response nor disease progression   Time frame Baseline every 6 weeks until Week 24 and then every 12 weeks until disease progression up to Week 119 Results 1    ArmGroup Title Lapatinib 1250 mg and Capecitabine 2000 mgm2   ArmGroup Description Participants took lapatinib and capecitabine Lapatinib was orally administered at 1250 milligrams mg once daily Capecitabine was orally administered at 1000 mg per square meter mgm2 twice daily on the first day through the fourteenth day of each 21day cycle   Overall Number of Participants Analyzed 51   Measure Type Number   Unit of Measure percentage of participants  59\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Adverse Events 1   Total 00   Leukopenia 00   Neutropenia 00   Ocularother 00   Elevated SGPT 00   Arthralgia 00   CNS hemorrhage 00   Neurologicother 00   Radiation dermatitis 00 Adverse Events 2   Total 11473 233   Leukopenia 2473 042   Neutropenia 5473 106   Ocularother 1473 021   Elevated SGPT 1473 021   Arthralgia 1473 021   CNS hemorrhage 1473 021   Neurologicother 1473 021   Radiation dermatitis 1473 021\",\n          \"Adverse Events 1   Total 851 1569   Bone marrow failure 151 196   Left ventricular dysfunction 251 392   Pericardial effusion 151 196   Vertigo 151 196   Dysphagia 151 196   Pulmonary tuberculosis 151 196   Neutrophil count decreased 151 196   Syncope 151 196   Respiratory failure 151 196\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"INTERVENTION 1    Cohort B   Patients with HER2negative ERpositive andor PgRpositive tumours receiving oral dose of Afatinib 50 mg qd\",\n          \"INTERVENTION 1    Laser Therapy Alone   therapist administered laser treatment   laser therapist administered laser INTERVENTION 2    Mld Alone   therapist administered manual lymphatic drainage   manual lymphatic drainage therapist administered massage therapy\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Inclusion criteria Inclusion Criteria   Female patients age 18 years or older   Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant irrespective of prior hormone therapy metastatic disease stage IV   HER2negative patients HER2 1 or negative or HER2 2 and FISH negative   At least one measurable tumour lesion RECIST   Availability of tumour samples   Written informed consent that is consistent with ICHGCP guidelines and local law   Eastern Cooperative Oncology Group ECOG R010787 performance score 0  2 Exclusion criteria Exclusion Criteria   Active infectious disease   Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea   Serious illness concomitant nononcological disease or mental problems considered by the investigator to be incompatible with the protocol   Activesymptomatic brain metastases   Cardiac left ventricular function with resting ejection fraction  50 below upper limit of normal   ANC less than 1500mm3 platelet count less than 100 000mm3   Bilirubin greater than 15 mg dl 26 and61549 mol L SI unit equivalent   AST and ALT greater than 25 times the upper limit of normal or greater 5 times the upper limit of normal in case of known liver metastases   Serum creatinine greater than 15 mgdl 132 and61549 molL SI unit equivalent   Patients who are sexually active and unwilling to use a medically acceptable method of contraception   Pregnancy or breastfeeding   Concomitant treatment with other investigational drugs or other anticancertherapy during this study andor during the past twofour weeks prior to the first treatment with the trial drug Concurrent treatment with biphosphonates is allowed   Previous treatment with trastuzumab EGFR or EGFRHER2inhibitors patients unable to comply with the protocol   Active alcohol or drug abuse   Other malignancy within the past 5 years\",\n          \"Inclusion Criteria   Breast cancer survivors will be included if they   are age 21 or older   require professional treatment for Stage I or II lymphedema as defined by the International Society of Lymphology   have an order for lymphedema treatment and   are willing and able to drive to the study sites Exclusion Criteria   Individuals will not be included if they   are actively undergoing intravenous chemotherapy or radiation therapy   have a history of bilateral lymphedema that prohibits extracellular fluid comparison to an unaffected limb   are unable to stand upright for measurement of height and weight   have activemetastatic cancer   are pregnant   have artificial joints in areas where electrode placement is critical or have a pacemakerinternal defibrillator or   have congestive heart failure CHF chronicacute renal or hepatic disease pulmonary edema thrombophlebitis deep vein thrombosis DVT acute infection of any kind and inflammation in the trunk or arms\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Outcome Measurement    Objective Response OR   OR is defined as complete response CR and partial response PR and was assessed according to the Response Evaluation Criteria in Solid Tumours version 10 RECIST OR was primary endpoint only for Cohort B   Time frame Tumour assessments were performed at screening week 8 week 16 week 24 and every 8 weeks thereafter Results 1    ArmGroup Title Cohort B   ArmGroup Description Patients with HER2negative ERpositive andor PgRpositive tumours receiving oral dose of Afatinib 50 mg qd   Overall Number of Participants Analyzed 21   Measure Type Number   Unit of Measure Participants with OR  0\",\n          \"Outcome Measurement    LDex Change   Bioimpedance measured by units of LDex As extracellular fluid accumulates ie lymphedema develops the LDex value increases   Time frame Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks Results 1    ArmGroup Title Laser Therapy Alone   ArmGroup Description therapist administered laser treatment   laser therapist administered laser   Overall Number of Participants Analyzed 15   Median InterQuartile Range   Unit of Measure LDex  280        17 to 35 Results 2    ArmGroup Title Mld Alone   ArmGroup Description therapist administered manual lymphatic drainage   manual lymphatic drainage therapist administered massage therapy   Overall Number of Participants Analyzed 16   Median InterQuartile Range   Unit of Measure LDex  178        3 to 38\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Adverse Events 1   Total 1329 4483   Anaemia 129 345   Febrile neutropenia 129 345   Menieres disease 129 345   Eyelid ptosis 129 345   Miosis 129 345   Abdominal pain 029 000   Diarrhoea 329 1034   Dysphagia 029 000   Nausea 029 000   Oesophageal stenosis 029 000   Vomiting 229 690   Fatigue 029 000\",\n          \"Adverse Events 1   Total 015 000 Adverse Events 2   Total 016 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Concatenated_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 2140,\n        \"samples\": [\n          \"the primary id results is outcome measurement    number of participants with disease progression pd or death   this endpoint evaluated the progression free survival pfs of participants amongst the total evaluable population progression free survival pfs was defined as the time from randomization to either the date the subject was first recorded as having pd even if the subject went off treatment because of toxicity or the date of death if the subject died due to any causes before progression participants with no recorded postbaseline tumor assessment had pfs censored at the day of randomization participants lost to followup were censored at the last date of contact participants that had not progressed or died had pfs censored at the date of last followup   time frame date of randomization to date of initial disease progression or date of death whichever occurs first up to january 2014 approximately 5 years results 1    armgroup title fulvestrant and dasatinib   armgroup description arm 1 participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib   fulvestrant intramuscular injection im loading dose 500 mg on day 1 followed by 500 mg on day 15 of cycle 1 28day cycle in subsequent cycles 500 mg im administered on day 1 up to 2 years   dasatinib tablets oral 100 mg once daily qd up to 2 years   overall number of participants analyzed 50   measure type number   unit of measure participants  35 results 2    armgroup title fulvestrant   armgroup description arm 2 participants in this group received a drug regimen that consisted of fulvestrant only   fulvestrant intramuscular injection im loading dose 500 mg on day 1 followed by 500 mg on day 15 of cycle 1 28day cycle in subsequent cycles 500 mg im administered on day 1 up to 2 years   overall number of participants analyzed 49   measure type number   unit of measure participants  40 and the secondary id results is none and the statement is patients in the primary clinical trial who were given fulvestrant were predisposed to a higher instance of disease progression or death than those treated with herceptin\",\n          \"the primary id adverse events is adverse events 1   total 135 286   congestive heart failure 135 286 adverse events 2   total 040 000   congestive heart failure 040 000 and the secondary id adverse events is none and the statement is several cases of congestive heart failure in the primary trial occurred in cohort 1 but none in cohort 2 several days is a subjective response indicating that something is true or present several days\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 38
        }
      ],
      "source": [
        "gold_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 608
        },
        "id": "Pj1eDlWGV0jt",
        "outputId": "ba23f01a-3f34-4524-aaef-90262932e776"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2      Single         Results  NCT00066573   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Comparison     Eligibility  NCT00425854   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Comparison  Adverse Events  NCT02273973   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8      Single         Results  NCT00593346   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb      Single     Eligibility  NCT02340221   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2  there is a 13.2% difference between the result...   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Patients with significantly elevated ejection ...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  a significant number of the participants in th...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8  the primary trial does not report the PFS or o...   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb  Prior treatment with fulvestrant or with a pho...   \n",
              "\n",
              "                                              Label Secondary_id  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2  Contradiction          NaN   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Contradiction  NCT01224678   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Contradiction  NCT00281697   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8     Entailment          NaN   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb  Contradiction          NaN   \n",
              "\n",
              "                                                                Primary_id_intervention  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2  INTERVENTION 1    Exemestane   Patients receiv...   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  INTERVENTION 1    Cohort B   Patients with HER...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  INTERVENTION 1    Experimental Taselisib  Letr...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8  INTERVENTION 1    Accelerated Partial Breast B...   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb  INTERVENTION 1    PlaceboFulvestrant   Partici...   \n",
              "\n",
              "                                                                 Primary_id_Eligibility  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2  DISEASE CHARACTERISTICS   Histologically confi...   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Inclusion criteria Inclusion Criteria   Female...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Inclusion Criteria   Female participants   Pos...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8  Inclusion Criteria   AJCC stage 0 I or II TisN...   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb  Inclusion Criteria   Postmenopausal women with...   \n",
              "\n",
              "                                                                     Primary_id_results  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2  Outcome Measurement    Eventfree Survival   Ev...   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Outcome Measurement    Objective Response OR  ...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Outcome Measurement    Percentage of Participa...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8  Outcome Measurement    Local Control Using Ips...   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb  Outcome Measurement    ProgressionFree Surviva...   \n",
              "\n",
              "                                                              Primary_id_Adverse_events  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2  Adverse Events 1   Total 193761 051   Cardiac ...   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Adverse Events 1   Total 1329 4483   Anaemia 1...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Adverse Events 1   Total 20167 1198   Cardiac ...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8                  Adverse Events 1   Total 0151 000   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb  Adverse Events 1   Total 19213 892   Pancytope...   \n",
              "\n",
              "                                                              Secondary_id_intervention  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2                                               None   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  INTERVENTION 1    Placebo   Patients receive o...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  INTERVENTION 1    Standard Chemotherapy  Bevac...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8                                               None   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb                                               None   \n",
              "\n",
              "                                                               Secondary_id_Eligibility  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2                                               None   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Premenopausal women 55 years of age or younger...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Inclusion Criteria   Signed informed consent f...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8                                               None   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb                                               None   \n",
              "\n",
              "                                                                   Secondary_id_results  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2                                               None   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Outcome Measurement    Percent Change Between ...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Outcome Measurement    Progressionfree Surviva...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8                                               None   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb                                               None   \n",
              "\n",
              "                                                            Secondary_id_Adverse_events  \\\n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2                                               None   \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  Adverse Events 1   Total 0150 000 Adverse Even...   \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  Adverse Events 1   Total 112458 2445   Febrile...   \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8                                               None   \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb                                               None   \n",
              "\n",
              "                                                                      Concatenated_Text  \n",
              "1adc970c-d433-44d0-aa09-d3834986f7a2  the primary id results is outcome measurement ...  \n",
              "6b9162d0-0816-46d4-81af-c60028dcc63b  the primary id eligibility is inclusion criter...  \n",
              "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f  the primary id adverse events is adverse event...  \n",
              "cc1f712a-2116-4e40-9810-f315e3fa5ff8  the primary id results is outcome measurement ...  \n",
              "904061c0-14fa-4f13-9118-9a41e24fa8eb  the primary id eligibility is inclusion criter...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-a1129919-cc39-421c-a8e2-6d3ca1fb8c82\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Primary_id_intervention</th>\n",
              "      <th>Primary_id_Eligibility</th>\n",
              "      <th>Primary_id_results</th>\n",
              "      <th>Primary_id_Adverse_events</th>\n",
              "      <th>Secondary_id_intervention</th>\n",
              "      <th>Secondary_id_Eligibility</th>\n",
              "      <th>Secondary_id_results</th>\n",
              "      <th>Secondary_id_Adverse_events</th>\n",
              "      <th>Concatenated_Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>1adc970c-d433-44d0-aa09-d3834986f7a2</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00066573</td>\n",
              "      <td>there is a 13.2% difference between the result...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Exemestane   Patients receiv...</td>\n",
              "      <td>DISEASE CHARACTERISTICS   Histologically confi...</td>\n",
              "      <td>Outcome Measurement    Eventfree Survival   Ev...</td>\n",
              "      <td>Adverse Events 1   Total 193761 051   Cardiac ...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6b9162d0-0816-46d4-81af-c60028dcc63b</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00425854</td>\n",
              "      <td>Patients with significantly elevated ejection ...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>NCT01224678</td>\n",
              "      <td>INTERVENTION 1    Cohort B   Patients with HER...</td>\n",
              "      <td>Inclusion criteria Inclusion Criteria   Female...</td>\n",
              "      <td>Outcome Measurement    Objective Response OR  ...</td>\n",
              "      <td>Adverse Events 1   Total 1329 4483   Anaemia 1...</td>\n",
              "      <td>INTERVENTION 1    Placebo   Patients receive o...</td>\n",
              "      <td>Premenopausal women 55 years of age or younger...</td>\n",
              "      <td>Outcome Measurement    Percent Change Between ...</td>\n",
              "      <td>Adverse Events 1   Total 0150 000 Adverse Even...</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT02273973</td>\n",
              "      <td>a significant number of the participants in th...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>NCT00281697</td>\n",
              "      <td>INTERVENTION 1    Experimental Taselisib  Letr...</td>\n",
              "      <td>Inclusion Criteria   Female participants   Pos...</td>\n",
              "      <td>Outcome Measurement    Percentage of Participa...</td>\n",
              "      <td>Adverse Events 1   Total 20167 1198   Cardiac ...</td>\n",
              "      <td>INTERVENTION 1    Standard Chemotherapy  Bevac...</td>\n",
              "      <td>Inclusion Criteria   Signed informed consent f...</td>\n",
              "      <td>Outcome Measurement    Progressionfree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 112458 2445   Febrile...</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>cc1f712a-2116-4e40-9810-f315e3fa5ff8</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00593346</td>\n",
              "      <td>the primary trial does not report the PFS or o...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Accelerated Partial Breast B...</td>\n",
              "      <td>Inclusion Criteria   AJCC stage 0 I or II TisN...</td>\n",
              "      <td>Outcome Measurement    Local Control Using Ips...</td>\n",
              "      <td>Adverse Events 1   Total 0151 000</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>904061c0-14fa-4f13-9118-9a41e24fa8eb</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT02340221</td>\n",
              "      <td>Prior treatment with fulvestrant or with a pho...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    PlaceboFulvestrant   Partici...</td>\n",
              "      <td>Inclusion Criteria   Postmenopausal women with...</td>\n",
              "      <td>Outcome Measurement    ProgressionFree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 19213 892   Pancytope...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-a1129919-cc39-421c-a8e2-6d3ca1fb8c82')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-a1129919-cc39-421c-a8e2-6d3ca1fb8c82 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-a1129919-cc39-421c-a8e2-6d3ca1fb8c82');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-fd8dbad7-11bd-4648-bdbe-f29bd6a67e7b\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-fd8dbad7-11bd-4648-bdbe-f29bd6a67e7b')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-fd8dbad7-11bd-4648-bdbe-f29bd6a67e7b button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "validation_data",
              "summary": "{\n  \"name\": \"validation_data\",\n  \"rows\": 200,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Comparison\",\n          \"Single\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Eligibility\",\n          \"Intervention\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT00191815\",\n          \"NCT00093795\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 199,\n        \"samples\": [\n          \"the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.\",\n          \"Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Entailment\",\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT01439945\",\n          \"NCT01216176\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"INTERVENTION 1    Gemcitabine  Cisplatin   Gemcitabine 30 min intravenous infusion dose of 1000mgm2 on Day 1 and Day 8 21 day cycle   Cisplatin 30120 min intravenous infusion dose of 35 mgm2 on Day 1 and Day 8 21 day cycle\",\n          \"INTERVENTION 1    Group 1 TAC X 6   Doxorubicin cyclophosphamide and docetaxel   Cyclophosphamide Group 1 cyclophosphamide 500 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 cyclophosphamide 600 mgm2 IV every 14 days for 4 cycles   Docetaxel 75 mgm2 IV every 21 days for 6 cycles   Doxorubicin Group 1 50 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 60 mgm2 IV every 14 days for 4 cycles INTERVENTION 2    Group 2 AC X 4 Then P X 4   Doxorubicin cyclophosphamide and paclitaxel   Cyclophosphamide Group 1 cyclophosphamide 500 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 cyclophosphamide 600 mgm2 IV every 14 days for 4 cycles   Paclitaxel 175 mgm2 IV every 14 days for 4 cycles   Doxorubicin Group 1 50 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 60 mgm2 IV every 14 days for 4 cycles\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Inclusion Criteria   You are female in the age of 18 to 75 years old   You have been diagnosed with the metastatic breast cancer   You have desire and an opportunity to visit your doctor in medical site both during realization of the active treatment program and within 24 months of medical follow up   You must sign this informed consent form Exclusion Criteria   You are pregnant or breastfeeding   Your laboratory parameters fall outside the limits admitted by requirements of the present clinical study   You have been diagnosed with serious concomitant or acute infectious disease   You have used experimental medications within the last month\",\n          \"Inclusion Criteria   The patient must consent to participate in the study and must have signed an approved consent form conforming with federal and institutional guidelines   The patient must have a life expectancy of at least 10 years and a Zubrod performance status of 0 or 1 Comorbid conditions but not the diagnosis of breast cancer should be taken into consideration when determining life expectancy   The interval between the last surgery for breast cancer staging or treatment and randomization must be no more than 84 days   The tumor must be invasive carcinoma of the breast on histologic examination   All of the following staging criteria must be met   By clinical and pathologic evaluation primary tumor must be T13   By clinical evaluation ipsilateral nodes must be cN0 cN1 or cN2a   By pathologic evaluation ipsilateral nodes must be pN1 pN1mi pN1a pN1b pN1c pN2a pN3a or pN3b only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes   Patients must have an estrogen receptor ER analysis performed on the primary tumor prior to randomization If ER analysis is negative then progesterone receptor PgR analysis must be performed If ER analysis is positive PgR analysis is desired but not mandatory Marginal or borderline results ie those not definitely negative will be considered positive regardless of the methodology used   Patients must have had either a lumpectomy or a total mastectomy Patients must have completed one of the following procedures for evaluation of pathologic nodal status   Sentinel lymphadenectomy followed by removal of additional nonsentinel lymph nodes This approach is strongly recommended   Sentinel lymphadenectomy alone if one of the following criteria is met   Pathologic nodal staging based on sentinel lymphadenectomy is pN1mi or pN1b   Surgeon elects not to remove additional nonsentinel nodes This approach is strongly discouraged but will not preclude participation in B38   Axillary lymphadenectomy without sentinel node isolation procedure   Patients must have no clinical or radiologic evidence of metastatic disease   Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than or equal to 25 x ULN are eligible for inclusion in the study if bone scans fail to demonstrate metastatic disease Suspicious findings on bone scan must be confirmed as benign by xray MRI or biopsy   Patients with aspartate transaminase AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging fails to demonstrate metastatic disease and the following requirements are met at the time of randomization   Postoperative absolute granulocyte count AGC must be greater than or equal to 1200mm3   Postoperative platelet count must be greater than or equal to 100000mm3   The following criteria for postoperative evidence of adequate hepatic function must be met   total bilirubin must be less than or equal to ULN for the lab unless the patient has a grade 1 bilirubin elevation greater than ULN to 15 x ULN due to Gilberts disease or similar syndrome due to slow conjugation of bilirubin and   alkaline phosphatase must be less than or equal to 25 x ULN for the lab and   the AST must be less than or equal to 15 x ULN for the lab and   alkaline phosphatase and AST cannot both be greater than ULN   Postoperative serum creatinine must be less than or equal to ULN   At the time of randomization the patient must have had the following history and physical exam EKG and imaging of the chest within the past 3 months and bilateral mammogram within the past 6 months   Within 3 months prior to entry the patient must have a baseline left ventricular ejection fraction LVEF measured by Multiple Gated Acquisition MUGA scan or echocardiogram greater than or equal to lower limit of normal LLN for the facility performing the procedure and no evidence of regional wall abnormalities   Patients with a history of nonbreast malignancies are eligible if they have been diseasefree for 5 or more years prior to randomization and are deemed by their physician to be at low risk for recurrence Patients with the following cancers are eligible if diagnosed and treated within the past 5 years carcinoma in situ of the cervix carcinoma in situ of the colon melanoma in situ and basal cell and squamous cell carcinoma of the skin   Special conditions for eligibility of lumpectomy patients radiation therapy and surgery Patients treated by lumpectomy must meet all the eligibility criteria in addition to the following   Generally lumpectomy should be reserved for tumors less than 5 cm However at the investigators discretion patients treated with lumpectomy for tumors greater than or equal to 5 cm are eligible if eligibility criteria for lumpectomy are met   The margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist In patients for whom pathologic examination demonstrates tumor present at the line of resection additional operative procedures may be performed to obtain clear margins This is permissible even if axillary evaluation has been completed Patients in whom tumor is still present at the resected margin after reexcisions must undergo total mastectomy to be eligible Patients with margins positive for lobular carcinoma in situ LCIS are eligible without additional resection   Irradiation of regional lymph nodes is optional but plans for radiation therapy must be declared by the investigator prior to randomization for stratification purposes   Special conditions for eligibility of mastectomy patients radiation therapy o Postmastectomy chest wall andor regional nodal irradiation is optional Plans for radiation in mastectomy patients must be declared by the investigator prior to randomization for stratification purposes   Ineligibility Criteria   Male patients are not eligible for this study Women with one or more of the following conditions or prior therapies are also ineligible for this study   Tumor that has been determined to be human epidermal growth factor receptor 2 HER2positive by immunohistochemistry 3 or by fluorescent in situ hybridization positive for gene amplification   Contralateral breast cancer invasive or DCIS or a mass or mammographic abnormality in the opposite breast suspicious for malignancy unless there is biopsy proof that the mass is not malignant   Primary tumor staged as T4 for any reason   Clinical nodal stages including cN2b and cN3 or pathologic nodal stages including pN0i pN2b pN3b with clinically apparent internal mammary nodes or pN3c   Suspicious nodes in the contralateral axilla or suspicious supraclavicular nodes Patients with these conditions are considered ineligible unless there is biopsy evidence that these are not involved with tumor   Prior history of breast cancer including DCIS patients with a history of LCIS are eligible   Treatment including radiation therapy chemotherapy andor hormonal therapy administered for the currently diagnosed breast cancer prior to randomization One exception is hormonal therapy which may have been given for up to a total of 28 days anytime after diagnosis and before study entry In such a case hormonal therapy must stop at or before randomization and be restarted if indicated following chemotherapy A second exception is radiation therapy for patients enrolled in NSABP B39 and assigned to partial breast irradiation Group 2 These patients may have received RT prior to B38 study entry   Prior therapy with anthracyclines or taxanes for any malignancy   Any sex hormonal therapy eg birth control pills ovarian hormonal replacement therapy etc These patients are eligible if this therapy is discontinued prior to randomization   Therapy with any hormonal agents such as raloxifene Evista tamoxifen or other selective estrogenreceptor modulators SERMs either for osteoporosis or breast cancer prevention Patients are eligible only if these medications are discontinued prior to randomization   Cardiac disease that would preclude the use of anthracyclines This includes   history of myocardial infarction documented by elevated cardiac enzymes or regional wall abnormalities on assessment of left ventricular LV function   angina pectoris that requires the use of antianginal medication   any history of documented congestive heart failure   serious cardiac arrhythmia requiring medication   severe conduction abnormality   valvular disease with documented cardiac function compromise and   uncontrolled hypertension defined as blood pressure greater than 160100 on antihypertensive therapy   Conditions that would prohibit administration of corticosteroids   Sensorymotor neuropathy greater than or equal to grade 2 as defined by the NCIs Common Terminology Criteria for Adverse Events Version 30   Nonmalignant systemic disease cardiovascular renal hepatic etc that would preclude a patient from receiving any of the treatment options or would prevent prolonged followup   History of hepatitis B or C   Pregnancy or lactation at the time of proposed randomization Women of reproductive potential must agree to use an effective nonhormonal method of contraception   Concurrent treatment with other investigational agents for the treatment of breast cancer   Psychiatric or addictive disorders or other conditions that in the opinion of the investigator would preclude the patient from meeting the study requirements   Special conditions for ineligibility of lumpectomy patients radiation therapy and surgery   For patients treated by lumpectomy whole breast irradiation is required   The following patients will be ineligible   Patients with diffuse tumors as demonstrated on mammography treated with lumpectomy These patients are eligible if they undergo mastectomy   Patients treated with lumpectomy in whom there is another clinically dominant mass or mammographically suspicious abnormality within the ipsilateral breast remnant Such a mass must be biopsied and demonstrated to be histologically benign prior to randomization or if malignant must be surgically removed with clear margins   Patients in whom the margins of the resected specimen are involved with invasive tumor or DCIS\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Outcome Measurement    Objective Tumor Response   Best response recorded from the start of treatment until disease progressionrecurrence using World Health Organization WHO criteria that defines when participants improve respond stay the same stable or worsen progression during treatment   Time frame baseline to measured progressive disease eight 21day cycles of therapy and followup period was 24 months starting from the date of the last drug administration Data collected every 4 months Results 1    ArmGroup Title Gemcitabine  Cisplatin   ArmGroup Description Gemcitabine 30 min intravenous infusion dose of 1000mgm2 on Day 1 and Day 8 21 day cycle   Cisplatin 30120 min intravenous infusion dose of 35 mgm2 on Day 1 and Day 8 21 day cycle   Overall Number of Participants Analyzed 54   Measure Type Number   Unit of Measure participants  Complete Response 7   Partial Response 19   Stable Disease 19   Progressive Disease 5 Not Assessable 4\",\n          \"Outcome Measurement    Diseasefree Survival Any Recurrence Contralateral Breast Cancer Second Primary Cancer Death From Any Cause Prior to Recurrence or Second Primary Cancer   The percentage of patients alive and cancerfree   Time frame 5 years Results 1    ArmGroup Title Group 1 TAC X 6   ArmGroup Description Doxorubicin cyclophosphamide and docetaxel   Cyclophosphamide Group 1 cyclophosphamide 500 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 cyclophosphamide 600 mgm2 IV every 14 days for 4 cycles   Docetaxel 75 mgm2 IV every 21 days for 6 cycles   Doxorubicin Group 1 50 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 60 mgm2 IV every 14 days for 4 cycles   Overall Number of Participants Analyzed 1610   Measure Type Number   Unit of Measure percentage of patients  801        780 to 820 Results 2    ArmGroup Title Group 2 AC X 4 Then P X 4   ArmGroup Description Doxorubicin cyclophosphamide and paclitaxel   Cyclophosphamide Group 1 cyclophosphamide 500 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 cyclophosphamide 600 mgm2 IV every 14 days for 4 cycles   Paclitaxel 175 mgm2 IV every 14 days for 4 cycles   Doxorubicin Group 1 50 mgm2 IV every 21 days for 6 cycles   Group 2 and Group 3 60 mgm2 IV every 14 days for 4 cycles   Overall Number of Participants Analyzed 1618   Measure Type Number   Unit of Measure percentage of patients  822        802 to 840\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Adverse Events 1   Total 6   Atrial fibrillation 167 149   Ventricular fibrillation 167 149   Gastrointestinal perforation 167 149   Periproctitis 167 149   General physical health deterioration 167 149   Escherichia sepsis 167 149   Pneumonia 167 149   Tumour pain 167 149   Renal failure acute 167 149   Pleurisy 167 149\",\n          \"Adverse Events 1   Total 2771601 1730   Disseminated intravascular coagulation 11601 006   Febrile neutropenia 401601 250   Atrial fibrillation 21601 012   Pericardial effusion 11601 006   Pericarditis 11601 006   Sinus tachycardia 21601 012   Supraventricular tachycardia 21601 012   Ventricular tachycardia 11601 006   Glaucoma 11601 006 Adverse Events 2   Total 1581612 980   Disseminated intravascular coagulation 01612 000   Febrile neutropenia 451612 279   Atrial fibrillation 31612 019   Pericardial effusion 01612 000   Pericarditis 01612 000   Sinus tachycardia 01612 000   Supraventricular tachycardia 11612 006   Ventricular tachycardia 01612 000   Glaucoma 01612 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"INTERVENTION 1    Treatment Vaccine Therapy 1methyldtryptophan   Participants receive adenovirusp53 transduced dendritic cell Adp53DC vaccine ID in weeks 1 3 5 and 10 and then every 3 weeks for 6 total doses Participants also receive 1methyldtryptophan indoximod orally PO daily QD on days 121 Treatment with 1methyldtryptophan repeats every 28 days patients with stable disease for up to 12 courses in the absence of disease progression or unacceptable toxicity   adenovirusp53 transduced dendritic cell DC vaccine Given intradermally ID   1methyldtryptophan Given orally PO   Laboratory biomarker analysis Correlative studies\",\n          \"INTERVENTION 1    Exemestane   Patients receive oral exemestane 25 mg once daily for 5 years   exemestane Given orally INTERVENTION 2    Anastrozole   Patients receive oral anastrozole 1 mg once daily for 5 years   anastrozole Given orally\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Inclusion Criteria   In the phase I patients with any solid tumor positive for p53 by IHC  5 of cells with any degree of nuclear staining staining for the phase II patients must have histologically or cytologically confirmed metastatic invasive breast cancer that is positive for p53 staining by IHC  5 of cells with any degree of nuclear staining patients will sign a separate consent for the p53 testing and those that meet the above requirements will then be allowed to sign the vaccine trial consent   Patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded as  20 mm with conventional techniques or as  10 mm with spiral computed tomography CT scan   There are no restrictions on prior therapies for the phase I part of the trial for the phase II patients may have received up to 2 prior lines of chemotherapy not counting endocrine therapy lines with the last dose of chemotherapy given 3 weeks 6 weeks for nitrosoureas and mitomycin C prior to initiation on this study   Life expectancy of greater than 4 months   Eastern Cooperative Oncology Group ECOG performance status  1 Karnofsky  70   Leukocytes  3000L   Absolute neutrophil count  1500L   Platelets  100000L   Total bilirubin within normal institutional limits unless patient has Gilberts disease   Aspartate aminotransferase AST serum glutamic oxaloacetic transaminase SGOT alanine aminotransferase ALT serum glutamic pyruvate transaminase SGPT  25 X institutional upper limit of normal   Creatinine within normal institutional limits OR creatinine clearance  60 mLmin173 m2 for patients with creatinine levels above institutional normal   Thyroidstimulating hormone TSH luteinizing hormone LH folliclestimulating hormone FSH adrenocorticotropic hormone ACTH showing normal pituitary function these values may deviate if in the opinion of the investigator these are normal pituitary responses to another endocrine condition such as suboptimally treated hypothyroidism   Patients with known brain metastases will only be eligible after their tumors have been treated with definitive resection andor radiotherapy and they are neurologically stable for at least 1 month off steroids   No history of gastrointestinal disease causing malabsorption or obstruction such as but not limited to Crohns disease celiac sprue tropical sprue bacterial overgrowthblind loop syndrome gastric bypass surgery strictures adhesions achalasia bowel obstruction or extensive small bowel resection   Sexually active women of childbearing potential must agree to use two forms of contraception hormonal and barrier method of birth control or abstinence prior to study entry and for the duration of study participation males should use barrier contraception or abstinence during the study use of contraception or abstinence should continue for a minimum of 1 month after completion of the study should a woman become pregnant or suspect she is pregnant while participating in this study she should discontinue the study drug and inform her treating physician immediately a pregnancy test is required prior to study enrollment and monthly while on treatment with 1MT for all women of childbearing potential also men should be discouraged from fathering children while on treatment   Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria   Patients who have had chemotherapy or radiotherapy within 3 weeks 6 weeks for nitrosoureas or mitomycin C prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier   Patients may not receive any other investigational agents or chemotherapy to treat their underlying malignancy while on study patients who are stable on prior endocrine therapies ie aromatase inhibitors tamoxifen and fulvestrant may stay on these treatments   Patients with known untreated brain metastases are excluded from this clinical trial patients with stable previously treated lesions in a patient off steroids and radiation for 1 month are not excluded   History of allergic reactions significant urticaria angioedema anaphylaxis attributed to compounds of similar chemical or biologic composition to 1methylDtryptophan this would include Ltryptophan or 5hydroxytryptophan supplements   No supplements containing Ltryptophan or derivatives thereof are allowed to be taken while on study also ingestion of antacid compounds should be timed a minimum of 2 hours before or after ingestion of 1MT   Patients with any active autoimmune disease ie psoriasis extensive atopic dermatitis asthma inflammatory bowel disease IBD multiple sclerosis MS uveitis vasculitis chronic inflammatory condition or any condition requiring concurrent use of any systemic immunosuppressants or steroids for any reason would be excluded from the study any patient with an allotransplant of any kind would be excluded as well this would include those with a xenograft heart valve to avoid the potential risk of any immune reaction causing valvular degeneration mildintermittent asthma requiring only occasional betaagonist inhaler use or mild localized eczema will not be excluded   Uncontrolled concurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris myocardial infarction or percutaneous coronary interventions within the last 6 months cardiac arrhythmia active autoimmune diseases or major psychiatric illnesssocial situations that would limit compliance with study requirements as judged by the primary investigator at each site those with well controlled chronic medical conditions under the supervision of the patients primary physician ie hypertension hyperlipidemia coronary heart disease diabetes mellitus would not be excluded   Pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with 1methylDtryptophan   Human immunodeficiency virus HIVpositive patients and those with other acquiredinherited immunodeficiencies are ineligible   Patients with more than one active malignancy at the time of enrollment   Patients who have received any prior experimental active immunotherapy consisting of targeted monoclonal antibodies or pharmaceutical compounds are excluded prior experimental vaccine patients may be enrolled if approved by the principal investigator PI patients who have received commercially available active immunotherapies such as adjuvant interferon must have completed therapy over 1 year prior to enrollment and have no evidence of autoimmune sequelae prior therapy with approved monoclonal antibodies such as bevacizumab cetuximab panitumumab or trastuzumab is allowed concurrent treatment with these agents and the study treatment is not allowed   Human epidermal growth factor receptor 2 positive HER2 patients IHC 3 andor fluorescent in situ hybridization FISH HER2centromere portion of chromosome 17 CEP17 ratio  2 who require treatment with trastuzumab or lapatinib are not eligible for this study\",\n          \"DISEASE CHARACTERISTICS   Histologically confirmed invasive breast cancer   pT13 pNX pN02 or pN3 M0   Neoadjuvant patients are eligible no earlier than 3 weeks or later than 3 months after excisional surgery provided both the clinicaldiagnostic staging of cancer and postsurgical resectionpathologic staging of cancer meet the requirements for primary tumor regional lymph nodes and distant metastasis classification NOTE Only when the sole basis for this classification is the presence of 10 or more involved axillary lymph nodes   Completely resected disease   Primary surgery performed at least 3 weeks but no more than 3 months before study entry if no chemotherapy was given   Primary surgery is defined as the last surgery at which histologic evidence of invasive or in situ disease was present in the pathology specimen   Patients with positive sentinel lymph node biopsy are eligible provided they have had a subsequent axillary lymph node dissection   No metachronous breast cancer   Bilateral mammogram within the past 12 months unless initial surgery was a total mastectomy in which case only a mammogram of the remaining breast is required   No metastases confirmed by 1 of the following methods   Bone scan required only if alkaline phosphatase is at least 2 times normal andor there are symptoms of metastatic disease   Abdominal ultrasound or CT scan required only if ASTALT or alkaline phosphatase is at least 2 times normal unless the elevation is in the bone fraction   Chest xray NOTE Confirmatory xray CT scan or MRI required if the bone scan results are questionable   No locally recurrent disease   No prior or concurrent carcinoma in situ of the contralateral breast treated with partial mastectomy andor hormonal therapy   Patients with prior or concurrent carcinoma in situ of the ipsilateral breast are eligible provided the tumor was completely excised AND they have not received prior hormonal therapy   Hormone receptor status   Estrogen receptor andor progesterone receptorpositive by immunohistochemistry or tumor receptor content  10 fmolmg protein   PATIENT CHARACTERISTICS   Age   Postmenopausal   Sex   Female   Menopausal status   Postmenopausal prior to chemotherapy defined as 1 of the following   Over 60 years of age   Age 4559 with spontaneous cessation of menses for more than 1 year prior to study entry   Age 4559 with menses ceasing secondary to hysterectomy or spontaneously within the past year AND a folliclestimulating hormone FSH level prior to study entry in the postmenopausal range   Age 4559 previously on hormone replacement therapy HRT and have discontinued HRT upon diagnosis of this malignancy AND has an FSH level prior to study entry in the postmenopausal range   Has undergone bilateral oophorectomy NOTE By institutional standards OR  344 IUL if institutional range is not available   Performance status   ECOG 02   Life expectancy   At least 5 years   Hematopoietic   WBC at least 3000mm3 OR   Granulocyte count at least 1500mm3 AND   Platelet count at least 100000mm3   Hepatic   See Disease Characteristics   AST andor ALT less than 2 times upper limit of normal ULN   Alkaline phosphatase less than 2 times ULN NOTE Unless imaging examinations have ruled out metastatic disease   Renal   Not specified   Other   Able to swallow study medication and have adequate unassisted oral intake in order to maintain reasonable nutrition status   No other nonbreast malignancy within the past 5 years except adequately treated nonmelanoma skin cancer curatively treated carcinoma in situ of the cervix or other curatively treated solid tumors with no evidence of disease for at least 5 years   No other concurrent medical or psychiatric condition that would preclude study participation andor interfere with results   PRIOR CONCURRENT THERAPY   Biologic therapy   Prior and concurrent trastuzumab Herceptin allowed   Chemotherapy   See Disease Characteristics   At least 3 weeks but no more than 3 months since prior chemotherapy   Prior adjuvant chemotherapy allowed   Endocrine therapy   See Disease Characteristics   No prior aromatase inhibitor   No prior tamoxifen or other selective estrogen receptor modulators SERMs except raloxifene   At least 3 weeks since prior raloxifene   At least 3 weeks since prior and no concurrent overthecounter products or supplements considered to have an estrogenic effect including any of the following   Ginseng   Ginkgo biloba   Black cohosh   Dong quai   Fortified soy supplements eg phytoestrogen preparations   At least 3 weeks since other prior hormonal therapy or steroids considered to have an estrogenic effect   No concurrent estrogens progesterones androgens or SERMs   Concurrent intermittent vaginal estrogens eg vagifem estrogen vaginal cream testosterone estradiol vaginal gel or Estring allowed if other local measures for intractable vaginal atrophy are insufficient   No other concurrent therapy that would have an estrogenic effect including endocrine therapy hormonal therapy or steroid therapy   Radiotherapy   See Disease Characteristics   Prior adjuvant radiotherapy allowed   Concurrent radiotherapy allowed   Surgery   See Disease Characteristics\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Outcome Measurement    Phase 1  Maximum Tolerated Dose MTD in Milligrams mg   MTD of 1methyldtryptophan indoximod given by mouth PO twice a day BID with up to 6 fixed doses Adp53 DC vaccinations every 2 weeks q2wks This phase 1 study used a 33 design with 7 indoximod dose levels DL 100 mg 200 mg 400 mg 800 mg daily QD then 800 mg 1200 mg and 1600 mg PO BID up to 6 fixed dose Adp53 DC vaccinations q2wks Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events NCI CTCAE v40 The MTD is the highest dose level below the maximally administered dose MAD that is safely tolerated among 6 treated patients that is 0 or 1 out of 6 patients experiences a dose limiting toxicity DLT   Time frame Up to 4 weeks Results 1    ArmGroup Title Treatment Vaccine Therapy 1methyldtryptophan   ArmGroup Description Participants receive adenovirusp53 transduced dendritic cell Adp53DC vaccine ID in weeks 1 3 5 and 10 and then every 3 weeks for 6 total doses Participants also receive 1methyldtryptophan indoximod orally PO daily QD on days 121 Treatment with 1methyldtryptophan repeats every 28 days patients with stable disease for up to 12 courses in the absence of disease progression or unacceptable toxicity   adenovirusp53 transduced dendritic cell DC vaccine Given intradermally ID   1methyldtryptophan Given orally PO   Laboratory biomarker analysis Correlative studies   Overall Number of Participants Analyzed 30   Measure Type Number   Unit of Measure indoximod dose in mg  1600\",\n          \"Outcome Measurement    Eventfree Survival   Event free survival the primary endpoint of this study is defined as the time from randomization to the time of documented locoregional or distant recurrence new primary breast cancer or death from any cause   Time frame 5 years Results 1    ArmGroup Title Exemestane   ArmGroup Description Patients receive oral exemestane 25 mg once daily for 5 years   exemestane Given orally   Overall Number of Participants Analyzed 3789   Measure Type Number   Unit of Measure percentage of participants  88        87 to 89 Results 2    ArmGroup Title Anastrozole   ArmGroup Description Patients receive oral anastrozole 1 mg once daily for 5 years   anastrozole Given orally   Overall Number of Participants Analyzed 3787   Measure Type Number   Unit of Measure percentage of participants  89        88 to 90\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Adverse Events 1   Total 1441 3415   Anemia 141 244   Febrile neutropenia 141 244   Eye disorders  Other Visual disturbance 141 244   Abdominal pain 141 244   Constipation 141 244   Nausea 141 244   Fever 141 244   Pain 141 244   Skin infection 241 488   Alkaline phosphatase increased 141 244   Aspartate aminotransferase increased 141 244\",\n          \"Adverse Events 1   Total 193761 051   Cardiac ischemiainfarction 33761 008   Left ventricular systolic dysfunction 13761 003   Restrictive cardiomyopathy 13761 003   Supravenarrhyth Atrial flutter 13761 003   Ventricarrhyth Trigeminy 13761 003   Hypothyroidism 03761 000   Blurred vision 13761 003   Nyctalopia 03761 000   Ocular  Other 13761 003 Adverse Events 2   Total 73759 019   Cardiac ischemiainfarction 03759 000   Left ventricular systolic dysfunction 03759 000   Restrictive cardiomyopathy 03759 000   Supravenarrhyth Atrial flutter 03759 000   Ventricarrhyth Trigeminy 03759 000   Hypothyroidism 13759 003   Blurred vision 03759 000   Nyctalopia 13759 003   Ocular  Other 03759 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Concatenated_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 198,\n        \"samples\": [\n          \"the primary id intervention is intervention 1    nktr102   in group a nktr102 will be administered at a dose level of 145 mgm2 on a q21d schedule as a 90minute intravenous iv infusion on day 1 of each treatment cycle intervention 2    treatment of physicians choice tpc   in group b tpc will be administered per standard of care patients randomized to tpc will receive singleagent iv chemotherapy limited to choice of one of the following 7 agents eribulin ixabepilone vinorelbine gemcitabine paclitaxel docetaxel or nabpaclitaxel and the secondary id intervention is none and the statement is cohort 1 and 2 of the primary trial do not receive the same intervention\",\n          \"the primary id intervention is intervention 1    her2 tc   participants with her2 breast cancer received treatment as follows   cycles 13 3week cycles trastuzumab 8 mgkg iv on day 1 cycle 1 only 6 mgkg in cycles 2 and 3 doxorubicin 60 mgm2 iv and paclitaxel 150 mgm2 iv on day 1 followed by 2 weeks off   cycles 47 3week cycles trastuzumab 6 mgkg iv paclitaxel 175 mgm2 iv on day 1 followed by 2 weeks off   cycles 810 3week cycles trastuzumab 6 mgkg iv on day 1 and cyclophosphamide 600 mgm2 iv methotrexate 40 mgm2 iv and 5fluorouracil 600 mgm2 iv collectively cmf on days 1 and 8 followed by 2 weeks off   cycles 1117 3week cycles postoperatively participants received trastuzumab 6 mgkg iv on day 1 followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab adjuvant tamoxifen 20 mgday was administered for up to 5 years intervention 2    her2 c   participants with her2 breast cancer received treatment as follows   cycles 13 3week cycles doxorubicin 60 mgm2 iv and paclitaxel 150 mgm2 iv on day 1 followed by 2 weeks off   cycles 47 3week cycles paclitaxel 175 mgm2 iv on day 1 followed by 2 weeks off   cycles 810 3week cycles cyclophosphamide 600 mgm2 iv methotrexate 40 mgm2 iv and 5fluorouracil 600 mgm2 iv on days 1 and 8 followed by 1 week off and the secondary id intervention is none and the statement is both cohorts of the primary trial undergo a total of 17 cycles each lasting 3 weeks  patients receive the same types and dosages of medication throughout all 17 cycles\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 39
        }
      ],
      "source": [
        "validation_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 538
        },
        "id": "e-XoSI0DalLV",
        "outputId": "fb92c40f-602d-4f72-fc3e-9d553d498486"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                        Type      Section_id   Primary_id  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Single  Adverse Events  NCT00328783   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  Single    Intervention  NCT00374322   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  Single         Results  NCT01644890   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  Single     Eligibility  NCT02186015   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  Single  Adverse Events  NCT00191815   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  the primary trial documents a comprehensive li...   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  the patient cohorts in the primary clinical tr...   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  cohort 1 of the primary clinical trial had an ...   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  children are allowed to participate in the pri...   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  none of the participants in the first group of...   \n",
              "\n",
              "                                              Label   Intervention  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Contradiction  Contradiction   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  Contradiction  Contradiction   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  Contradiction  Contradiction   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  Contradiction  Contradiction   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  Contradiction  Contradiction   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667   [Altering, fef5aedb-21c0-4130-b8a3-cb1df5017c7a]   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7   [Altering, c40fdf91-9f81-454a-bba9-ec5c950cef6e]   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909   [Altering, 8c6314f7-34f5-42a7-ba66-b95d050a6315]   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14   [Altering, a805f174-2707-4302-a195-05153ea8523e]   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  [Preserving, 8e91e404-086e-4063-8d54-83d1b8ebd...   \n",
              "\n",
              "                                     Secondary_id  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667          NaN   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7          NaN   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909          NaN   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14          NaN   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff          NaN   \n",
              "\n",
              "                                                                Primary_id_intervention  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  INTERVENTION 1    Active Breathing Coordinator...   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  INTERVENTION 1    Lapatinib 1500 mg   Particip...   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  INTERVENTION 1    NK105   received NK105 65 mg...   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  INTERVENTION 1    Cholecalciferol   Enrolled w...   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  INTERVENTION 1    Gemcitabine  Cisplatin   Gem...   \n",
              "\n",
              "                                                                 Primary_id_Eligibility  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Inclusion Criteria   Requiring adjuvant or pos...   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  Inclusion Criteria   Have histologically or cy...   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  Inclusion Criteria   Written informed consent ...   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  Inclusion Criteria   Metastatic breast cancer ...   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  Inclusion Criteria   You are female in the age...   \n",
              "\n",
              "                                                                     Primary_id_results  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  Outcome Measurement    Dosimetric Evaluation M...   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  Outcome Measurement    Number of Participants ...   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  Outcome Measurement    Progression Free Surviv...   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  Outcome Measurement    Change in Serum 25OHD  ...   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  Outcome Measurement    Objective Tumor Respons...   \n",
              "\n",
              "                                                              Primary_id_Adverse_events  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                        Adverse Events 1   Total 00   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  Adverse Events 1   Total 991573 629   Neutrope...   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  Adverse Events 1   Total 34214 1589   Leukocyt...   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  Adverse Events 1   Total 011 000 Adverse Event...   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  Adverse Events 1   Total 6   Atrial fibrillati...   \n",
              "\n",
              "                                     Secondary_id_intervention  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                      None   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7                      None   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909                      None   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14                      None   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff                      None   \n",
              "\n",
              "                                     Secondary_id_Eligibility  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                     None   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7                     None   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909                     None   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14                     None   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff                     None   \n",
              "\n",
              "                                     Secondary_id_results  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                 None   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7                 None   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909                 None   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14                 None   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff                 None   \n",
              "\n",
              "                                     Secondary_id_Adverse_events  \\\n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667                        None   \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7                        None   \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909                        None   \n",
              "11073b50-f135-48a1-a8ac-333375a49c14                        None   \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff                        None   \n",
              "\n",
              "                                                                      Concatenated_Text  \n",
              "14e55d50-c012-4f32-afc5-6f5f7a030667  the primary id adverse events is adverse event...  \n",
              "64ab5bcd-229a-4aac-8d01-609e514400d7  the primary id intervention is intervention 1 ...  \n",
              "f0271e34-7791-441b-ad94-a8e2e7f1f909  the primary id results is outcome measurement ...  \n",
              "11073b50-f135-48a1-a8ac-333375a49c14  the primary id eligibility is inclusion criter...  \n",
              "78ac8091-0f1b-44d1-a760-71bfdc2d46ff  the primary id adverse events is adverse event...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-c044a951-ff10-4ad7-a589-72a7bc444650\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Primary_id_intervention</th>\n",
              "      <th>Primary_id_Eligibility</th>\n",
              "      <th>Primary_id_results</th>\n",
              "      <th>Primary_id_Adverse_events</th>\n",
              "      <th>Secondary_id_intervention</th>\n",
              "      <th>Secondary_id_Eligibility</th>\n",
              "      <th>Secondary_id_results</th>\n",
              "      <th>Secondary_id_Adverse_events</th>\n",
              "      <th>Concatenated_Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>14e55d50-c012-4f32-afc5-6f5f7a030667</th>\n",
              "      <td>Single</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00328783</td>\n",
              "      <td>the primary trial documents a comprehensive li...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, fef5aedb-21c0-4130-b8a3-cb1df5017c7a]</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Active Breathing Coordinator...</td>\n",
              "      <td>Inclusion Criteria   Requiring adjuvant or pos...</td>\n",
              "      <td>Outcome Measurement    Dosimetric Evaluation M...</td>\n",
              "      <td>Adverse Events 1   Total 00</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>64ab5bcd-229a-4aac-8d01-609e514400d7</th>\n",
              "      <td>Single</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00374322</td>\n",
              "      <td>the patient cohorts in the primary clinical tr...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, c40fdf91-9f81-454a-bba9-ec5c950cef6e]</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Lapatinib 1500 mg   Particip...</td>\n",
              "      <td>Inclusion Criteria   Have histologically or cy...</td>\n",
              "      <td>Outcome Measurement    Number of Participants ...</td>\n",
              "      <td>Adverse Events 1   Total 991573 629   Neutrope...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>f0271e34-7791-441b-ad94-a8e2e7f1f909</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT01644890</td>\n",
              "      <td>cohort 1 of the primary clinical trial had an ...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, 8c6314f7-34f5-42a7-ba66-b95d050a6315]</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    NK105   received NK105 65 mg...</td>\n",
              "      <td>Inclusion Criteria   Written informed consent ...</td>\n",
              "      <td>Outcome Measurement    Progression Free Surviv...</td>\n",
              "      <td>Adverse Events 1   Total 34214 1589   Leukocyt...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11073b50-f135-48a1-a8ac-333375a49c14</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT02186015</td>\n",
              "      <td>children are allowed to participate in the pri...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Altering, a805f174-2707-4302-a195-05153ea8523e]</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Cholecalciferol   Enrolled w...</td>\n",
              "      <td>Inclusion Criteria   Metastatic breast cancer ...</td>\n",
              "      <td>Outcome Measurement    Change in Serum 25OHD  ...</td>\n",
              "      <td>Adverse Events 1   Total 011 000 Adverse Event...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>78ac8091-0f1b-44d1-a760-71bfdc2d46ff</th>\n",
              "      <td>Single</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00191815</td>\n",
              "      <td>none of the participants in the first group of...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>[Preserving, 8e91e404-086e-4063-8d54-83d1b8ebd...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Gemcitabine  Cisplatin   Gem...</td>\n",
              "      <td>Inclusion Criteria   You are female in the age...</td>\n",
              "      <td>Outcome Measurement    Objective Tumor Respons...</td>\n",
              "      <td>Adverse Events 1   Total 6   Atrial fibrillati...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-c044a951-ff10-4ad7-a589-72a7bc444650')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-c044a951-ff10-4ad7-a589-72a7bc444650 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-c044a951-ff10-4ad7-a589-72a7bc444650');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-50deb586-557e-4f1e-a5ff-e397d3dfd6ad\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-50deb586-557e-4f1e-a5ff-e397d3dfd6ad')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-50deb586-557e-4f1e-a5ff-e397d3dfd6ad button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "contradict_data",
              "summary": "{\n  \"name\": \"contradict_data\",\n  \"rows\": 600,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Comparison\",\n          \"Single\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Intervention\",\n          \"Eligibility\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT01808573\",\n          \"NCT00606931\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"the secondary trial utilises progression-free survival as its primary outcome measurement for interventions.\",\n          \"the primary clinical trial and the secondary clinical trial present their findings in identical measurement units\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT01998906\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"INTERVENTION 1    Neratinib Plus Capecitabine   neratinib 240 mg orally once daily with food continuously in 21 day cycles and capecitabine 1500 mgm2 daily in 2 evenly divided doses orally with water within 30 minutes after a meal taken on days 1 to 14 of each 21 day cycle INTERVENTION 2    Lapatinib Plus Capecitabine   lapatinib 1250 mg orally once daily continuously in 21 day cycles and capecitabine 2000 mgm2 daily in 2 evenly divided doses orally with water within 30 minutes after a meal taken on days 1 to 14 of each 21 day cycle\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Inclusion Criteria   Aged 18 years at signing of informed consent   Histologically confirmed MBC current stage IV   Documented HER2 overexpression or geneamplified tumor immunohistochemistry 3 or 2 with confirmatory fluorescence in situ hybridization FISH    Prior treatment with at least two 2 HER2directed regimens for metastatic breast cancer Exclusion Criteria   Received previous therapy with capecitabine neratinib lapatinib or any other HER2 directed tyrosine kinase inhibitor   Note There are additional inclusion and exclusion criteria The study center will determine if you meet all of the criteria\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Outcome Measurement    Centrally Assessed Progression Free Survival   Progression Free Survival PFS Measured in Months for Randomized Subjects of the Central Assessment The time interval from the date of randomization until the first date on which recurrence progression per Response Evaluation Criteria in Solid Tumors Criteria RECIST v11 or death due to any cause is documented For subjects without recurrence progression or death it is censored at the last valid tumor assessment Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria RECIST v11 as a 20 increase in the sum of the longest diameter of target lesions or a measurable increase in a nontarget lesion or the appearance of new lesions Here the time to event was reported as the restricted mean survival time The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months   Time frame From randomization date to recurrence progression or death assessed up to 38 months The result is based on primary analysis data cut Results 1    ArmGroup Title Neratinib Plus Capecitabine   ArmGroup Description neratinib 240 mg orally once daily with food continuously in 21 day cycles and capecitabine 1500 mgm2 daily in 2 evenly divided doses orally with water within 30 minutes after a meal taken on days 1 to 14 of each 21 day cycle   Overall Number of Participants Analyzed 307   Mean 95 Confidence Interval   Unit of Measure months  88        78 to 98 Results 2    ArmGroup Title Lapatinib Plus Capecitabine   ArmGroup Description lapatinib 1250 mg orally once daily continuously in 21 day cycles and capecitabine 2000 mgm2 daily in 2 evenly divided doses orally with water within 30 minutes after a meal taken on days 1 to 14 of each 21 day cycle   Overall Number of Participants Analyzed 314   Mean 95 Confidence Interval   Unit of Measure months  66        59 to 74\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Adverse Events 1   Total 103303 3399   Anaemia 1303 033   Febrile neutropenia 1303 033   Neutropenia 1303 033   Acute myocardial infarction 0303 000   Atrial fibrillation 1303 033   Cardiac arrest 0303 000   Cardiac tamponade 1303 033   Cardiomyopathy 1303 033   Palpitations 2303 066   Pericardial effusion 1303 033   Tachycardia 0303 000 Adverse Events 2   Total 93311 2990   Anaemia 2311 064   Febrile neutropenia 3311 096   Neutropenia 0311 000   Acute myocardial infarction 1311 032   Atrial fibrillation 0311 000   Cardiac arrest 1311 032   Cardiac tamponade 1311 032   Cardiomyopathy 0311 000   Palpitations 0311 000   Pericardial effusion 1311 032   Tachycardia 1311 032\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"INTERVENTION 1    Diagnostic Indocyanine Green 99mTclabeled Radiotracer   Participants receive technetium Tc99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice Prior to surgery participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin Participants then undergo Axillary Lymph Node Biopsy and surgery\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Inclusion Criteria   Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer   Participants who are undergoing breast cancer surgery with lumpectomy or mastectomy   Participants with planned axillary sentinel node biopsy procedure Exclusion Criteria   Participants with cancer  3 cm   Participants with clinically positive nodes   Participants with prior surgery for breast cancer in the index breast   Participants who have had bilateral breast surgeries   Thyroid dysfunction   Hypersensitivity to iodine   Hepatic insufficiency   Renal insufficiency\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Outcome Measurement    Proportion of Sentinel Lymph Nodes SLNs Flagged by the Two Methods   Let A be the number of Tcpositive and ICGpositive sentinel nodes SNs detected B be the number of Tcpositive and ICGnegative SNs detected and C be the number of Tcnegative and ICGpositive SNs detected The total number N of SNs detected is therefore N  A  B  C the proportion of SNs detected by the Tc method PTc is A  BN and the proportion of SNs detected by the ICG method PICG is A  CN Differences in the proportions of SLNs flagged will be compared using a twosided 95 confidence interval   Time frame Baseline Results 1    ArmGroup Title Diagnostic Indocyanine Green 99mTclabeled Radiotracer   ArmGroup Description Participants receive technetium Tc99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice Prior to surgery participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin Participants then undergo Axillary Lymph Node Biopsy and surgery   Overall Number of Participants Analyzed 92   Measure Type Number   Unit of Measure proportion of nodes  Proportion of SNs PTc detected by Tc method 086   Proportion of SNs PICG detected by ICG method 095\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Adverse Events 1   Total 0102 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Concatenated_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"the primary id results is outcome measurement    objective response rate orr   an objective response or is defined as a patient having a best overall response of either complete response cr or partial response pr a patient has best overall response of cr if she had overall response of cr or pr on one visit and met the confirmation criteria per recist orr is defined as percentage of patients with objective response   each patient with measurable disease at baseline was assessed for or from the sequence of response evaluation criteria in solid tumors recist scan data up to data cutoff recist scans were performed every 12 weeks  2weeks from randomization   time frame baseline and every 12 weeks  2weeks from randomization data up to data cutoff 19th march 2008 results 1    armgroup title fulvestrant 250 mg   armgroup description fulvestrant 250 mg   overall number of participants analyzed 45   measure type number   unit of measure percentage of participants  111 results 2    armgroup title fulvestrant 250 mg  loading dose   armgroup description fulvestrant 250 mg  loading dose   overall number of participants analyzed 51   measure type number   unit of measure percentage of participants  176 and the secondary id results is outcome measurement    objective response or   or is defined as complete response cr and partial response pr and was assessed according to the response evaluation criteria in solid tumours version 10 recist or was primary endpoint only for cohort b   time frame tumour assessments were performed at screening week 8 week 16 week 24 and every 8 weeks thereafter results 1    armgroup title cohort b   armgroup description patients with her2negative erpositive andor pgrpositive tumours receiving oral dose of afatinib 50 mg qd   overall number of participants analyzed 21   measure type number   unit of measure participants with or  0 and the statement is the secondary trial utilises progressionfree survival as its primary outcome measurement for interventions\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 40
        }
      ],
      "source": [
        "contradict_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 573
        },
        "id": "6W8yYe11anF5",
        "outputId": "8a2bb4a1-f8da-4674-c540-ca84e85f74c5"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Comparison  Adverse Events  NCT01852032   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72      Single     Eligibility  NCT00438100   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Comparison  Adverse Events  NCT01216176   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5      Single     Eligibility  NCT00375427   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a      Single    Intervention  NCT00904033   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  the primary trial and the secondary trial repo...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  ongoing flucytosine treatments are not permitt...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  child needs help playing with other children i...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  Patients must have a Life expectancy of at lea...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  neither of the cohorts in the primary trial ar...   \n",
              "\n",
              "                                              Label   Intervention  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Contradiction  Text_appended   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72     Entailment  Text_appended   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Contradiction  Text_appended   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5     Entailment  Text_appended   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  Contradiction  Text_appended   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  [Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  [Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  [Preserving, 9c033072-5f94-4d79-af47-126d531f0...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  [Preserving, 618a3ae1-b22c-4c35-86a6-190c1b5b5...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  [Preserving, 63a0a9fc-80b9-450f-b2c6-7aee37ce2...   \n",
              "\n",
              "                                     Secondary_id  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  NCT01830933   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72          NaN   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  NCT00325234   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5          NaN   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a          NaN   \n",
              "\n",
              "                                                                Primary_id_intervention  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  INTERVENTION 1    Breast Cancer Patients   Tom...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  INTERVENTION 1    Capecitabine Arm   Capecitab...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  INTERVENTION 1    Phase 1  Cohort A   Dual tre...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  INTERVENTION 1    Zoledronic Acid Every 3 Mont...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  INTERVENTION 1    No Exercise   Multivitamin A...   \n",
              "\n",
              "                                                                 Primary_id_Eligibility  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Inclusion Criteria   35 years of age or older ...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  Inclusion Criteria   Biopsydiagnosed breast ca...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Inclusion Criteria  Phase 1 Cohort A   Female ...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  Inclusion criteria   Female patients  18 years...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  Inclusion Criteria   Must be female   Women of...   \n",
              "\n",
              "                                                                     Primary_id_results  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Outcome Measurement    Beta of CT Coronal View...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  Outcome Measurement    Progression Free Surviv...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Outcome Measurement    Phase I Cohort A Maximu...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  Outcome Measurement    Annual Overall Skeletal...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  Outcome Measurement    Bone Resorption Exercis...   \n",
              "\n",
              "                                                              Primary_id_Adverse_events  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2                   Adverse Events 1   Total 023 000   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  Adverse Events 1   Total 071 000 Adverse Event...   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Adverse Events 1   Total 312 2500   Atrial fib...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  Adverse Events 1   Total 21209 1005   Anaemia ...   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  Adverse Events 1   Total 010 000 Adverse Event...   \n",
              "\n",
              "                                                              Secondary_id_intervention  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  INTERVENTION 1    Usual Care   Usual Care is t...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  INTERVENTION 1    PemetrexedCarboplatin   Peme...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5                                               None   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a                                               None   \n",
              "\n",
              "                                                               Secondary_id_Eligibility  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Inclusion Criteria   Patient component   Women...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Inclusion Criteria   Females with histologic o...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5                                               None   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a                                               None   \n",
              "\n",
              "                                                                   Secondary_id_results  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Outcome Measurement    Knowledge of Breast Can...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Outcome Measurement    Tumor Response Rate   P...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5                                               None   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a                                               None   \n",
              "\n",
              "                                                            Secondary_id_Adverse_events  \\\n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  Adverse Events 1   Total 0655 000 Adverse Even...   \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72                                               None   \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  Adverse Events 1   Total 1865 2769   Anaemia 5...   \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5                                               None   \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a                                               None   \n",
              "\n",
              "                                                                      Concatenated_Text  \n",
              "6c337426-cff6-4f2c-acab-e7bf15f09cc2  the primary id adverse events is adverse event...  \n",
              "141798cc-9851-4bdf-b8a9-ce688db34e72  the primary id eligibility is inclusion criter...  \n",
              "ec5ca1ce-8399-4213-9f44-53e55b7352db  the primary id adverse events is adverse event...  \n",
              "95f5af8f-1590-4254-bd9f-885b6720b7b5  the primary id eligibility is inclusion criter...  \n",
              "41a49fe6-55b7-4f89-bc8c-b0107350a79a  the primary id intervention is intervention 1 ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-033c0cdb-bfd5-41b4-9d71-ce97aa9fe94a\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Primary_id_intervention</th>\n",
              "      <th>Primary_id_Eligibility</th>\n",
              "      <th>Primary_id_results</th>\n",
              "      <th>Primary_id_Adverse_events</th>\n",
              "      <th>Secondary_id_intervention</th>\n",
              "      <th>Secondary_id_Eligibility</th>\n",
              "      <th>Secondary_id_results</th>\n",
              "      <th>Secondary_id_Adverse_events</th>\n",
              "      <th>Concatenated_Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>6c337426-cff6-4f2c-acab-e7bf15f09cc2</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT01852032</td>\n",
              "      <td>the primary trial and the secondary trial repo...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, c7a953b0-ac96-4e0a-9c1d-98cf8af28...</td>\n",
              "      <td>NCT01830933</td>\n",
              "      <td>INTERVENTION 1    Breast Cancer Patients   Tom...</td>\n",
              "      <td>Inclusion Criteria   35 years of age or older ...</td>\n",
              "      <td>Outcome Measurement    Beta of CT Coronal View...</td>\n",
              "      <td>Adverse Events 1   Total 023 000</td>\n",
              "      <td>INTERVENTION 1    Usual Care   Usual Care is t...</td>\n",
              "      <td>Inclusion Criteria   Patient component   Women...</td>\n",
              "      <td>Outcome Measurement    Knowledge of Breast Can...</td>\n",
              "      <td>Adverse Events 1   Total 0655 000 Adverse Even...</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>141798cc-9851-4bdf-b8a9-ce688db34e72</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00438100</td>\n",
              "      <td>ongoing flucytosine treatments are not permitt...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, f10f3b84-e039-4a02-a98b-86d149d9a...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Capecitabine Arm   Capecitab...</td>\n",
              "      <td>Inclusion Criteria   Biopsydiagnosed breast ca...</td>\n",
              "      <td>Outcome Measurement    Progression Free Surviv...</td>\n",
              "      <td>Adverse Events 1   Total 071 000 Adverse Event...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ec5ca1ce-8399-4213-9f44-53e55b7352db</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT01216176</td>\n",
              "      <td>child needs help playing with other children i...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 9c033072-5f94-4d79-af47-126d531f0...</td>\n",
              "      <td>NCT00325234</td>\n",
              "      <td>INTERVENTION 1    Phase 1  Cohort A   Dual tre...</td>\n",
              "      <td>Inclusion Criteria  Phase 1 Cohort A   Female ...</td>\n",
              "      <td>Outcome Measurement    Phase I Cohort A Maximu...</td>\n",
              "      <td>Adverse Events 1   Total 312 2500   Atrial fib...</td>\n",
              "      <td>INTERVENTION 1    PemetrexedCarboplatin   Peme...</td>\n",
              "      <td>Inclusion Criteria   Females with histologic o...</td>\n",
              "      <td>Outcome Measurement    Tumor Response Rate   P...</td>\n",
              "      <td>Adverse Events 1   Total 1865 2769   Anaemia 5...</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>95f5af8f-1590-4254-bd9f-885b6720b7b5</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT00375427</td>\n",
              "      <td>Patients must have a Life expectancy of at lea...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 618a3ae1-b22c-4c35-86a6-190c1b5b5...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Zoledronic Acid Every 3 Mont...</td>\n",
              "      <td>Inclusion criteria   Female patients  18 years...</td>\n",
              "      <td>Outcome Measurement    Annual Overall Skeletal...</td>\n",
              "      <td>Adverse Events 1   Total 21209 1005   Anaemia ...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41a49fe6-55b7-4f89-bc8c-b0107350a79a</th>\n",
              "      <td>Single</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00904033</td>\n",
              "      <td>neither of the cohorts in the primary trial ar...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Text_appended</td>\n",
              "      <td>[Preserving, 63a0a9fc-80b9-450f-b2c6-7aee37ce2...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    No Exercise   Multivitamin A...</td>\n",
              "      <td>Inclusion Criteria   Must be female   Women of...</td>\n",
              "      <td>Outcome Measurement    Bone Resorption Exercis...</td>\n",
              "      <td>Adverse Events 1   Total 010 000 Adverse Event...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-033c0cdb-bfd5-41b4-9d71-ce97aa9fe94a')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-033c0cdb-bfd5-41b4-9d71-ce97aa9fe94a button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-033c0cdb-bfd5-41b4-9d71-ce97aa9fe94a');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-4e00077a-0946-4a01-8fed-f6a03abd6eed\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-4e00077a-0946-4a01-8fed-f6a03abd6eed')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-4e00077a-0946-4a01-8fed-f6a03abd6eed button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "original_data",
              "summary": "{\n  \"name\": \"original_data\",\n  \"rows\": 600,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Eligibility\",\n          \"Results\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT00820170\",\n          \"NCT00305448\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"unilateral optic nerve hypoplasia is a congenital abnormality characterized by the underdevelopment of one optic nerve. There are more cases of Urosepsis in the primary trial than in the secondary trial.\",\n          \"appearance type code is a coded value specifying the appearance of an entity. the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Entailment\",\n          \"Contradiction\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Text_appended\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT01224678\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"INTERVENTION 1    Dasatinib and Paclitaxel   The phase I portion is a standard threepatient per cohort dose escalation schedule will be used Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel   The phase II portion of this trial has a Simon twostage design to determine the efficacy of dasatinib when administered in combination with paclitaxel   Dasatinib and Paclitaxel A treatment cycle will consist of 28 days according to the following schedule   Dasatinib 120MG PO once daily Weekly paclitaxel 80 mgm2 given intravenously over 1 hour on day 1 8 and 15 of a 28 day cycle   The trial will initially test the combination of weekly paclitaxel and dasatinib given PO once daily  continuously In case of 2 doselimiting toxicities DLT in the first cohort 0 the next cohort will test dasatinib given with a different schedule 5 days on and 2 days off omitting dasatinib the day prior and the day of administration of paclitaxel\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Inclusion Criteria   Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC   For the phase I portion patients with any ERPRHER2 disease status no longer eligible for hormonal therapy or HER2targeted therapy will be eligible   For the phase II portion there needs to be documentation of negative HER2 IHC 01 or FISHCISH negative status Patients with any ERPR disease status are eligible   A paraffinembedded tissue block or unstained slides from prior surgery must be available   Evidence of recurrent or progressive locally advanced or metastatic breast cancer   Presence of   For the phase I portion at least one evaluable or measurable metastatic lesion    For the phase II portion at least one measurable metastatic lesion according to the RECIST criteria which has not been irradiated ie newly arising lesions in previously irradiated areas are accepted Ascites pleural effusion and bone metastases are not considered measurable Minimum indicator lesion size  or  to 10 mm measured by spiral CT or  or  to 20 mm measured by conventional techniques   Prior therapies   For the phase I portion Any number of prior endocrine or biologic therapies is permitted  In addition patients may be untreated in the metastatic setting or have received any number of prior cytotoxic regimens   For the phase II portion 02 prior therapies for metastatic disease are allowed   Prior taxane therapy either in the adjuvant or in the metastatic setting either deliver weekly q 2 weeks or q 3 weeks will be permitted Prior therapy with bevacizumab will be allowed All previous chemotherapy radiotherapy and intravenous biphosphonates must have been discontinued at least 3 weeks prior to study entry 3 weeks also for trastuzumab and bevacizumab All acute toxic effects excluding alopecia of any prior therapy must have resolved to NCI CTC Version 3 Grade 1   Endocrine therapy with an aromatase inhibitor SERM ie tamoxifen or fulvestrant is permitted however it must be discontinued before enrolling in the study   ECOG performance status of 0 or 1   Age  or  to 18 years old Adequate Organ Function   Total bilirubin  15 times the institutional Upper Limit of Normal ULN   Hepatic enzymes AST ALT   25 times the institutional ULN   Serum Na K Mg2 Phosphate and Ca2 Lower Limit of Normal LLN   Serum Creatinine  15 time the institutional ULN   Neutrophil count Platelets both Grade 01   PT INR and PTT Grade 01 except for patients on Coumadin or low molecular weight heparin   Ability to take oral medication dasatinib must be swallowed whole   Concomitant Medications   Patient agrees to discontinue St Johns Wort while receiving dasatinib therapy   Patient agrees that IV biphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia Concomitant Medications any of the following should be considered for exclusion   Patient agrees to discontinue QTprolonging agents strongly associated with Torsades de Pointes including patients must discontinue drug  7 days prior to starting dasatinib such as   quinidine procainamide disopyramide   amiodarone sotalol ibutilide dofetilide   erythromycin clarithromycin   chlorpromazine haloperidol mesoridazine thioridazine pimozide   cisapride bepridil droperidol methadone arsenic chloroquine domperidone halofantrine levomethadyl pentamidine sparfloxacin lidoflazine   The concomitant use of H2 blockers or proton pump inhibitors with dasatinib is not recommended The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy If antacid therapy is needed the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of dasatinib   Patient may not be receiving any potent CYP3A4 inhibitors These are prohibited patients must discontinue drug 7 days prior to starting dasatinib and include   itraconazole ketoconazole miconazole coriconazole   amprenavir atazanavir fosamprenavir indinavir nelfinavir ritonavir   ciprofloxacin clarithromycin diclofenac doxycycline enoxacin imatinib isoniazid   ketamine nefazodone nicardipine propofol quinidine telithromycin   Women of childbearing potential WOCBP must have   A negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration   Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped   Pregnant or nursing women may not participate Patients of reproductive potential may not participate unless they have agreed to use an effective method of contraception and to continue contraception for 30 days from the date of the last study drug administration Postmenopausal woman must be amenorrheic for at least 12 months to be considered of nonchildbearing potential   Signed written informed consent including a HIPAA form according to institutional guidelines Exclusion Criteria   Life expectancy  3 months   Prior severe allergic reaction to paclitaxel therapy   Presence of new or recurrent pleural effusion which is symptomatic andor requiring medical intervention NCI CTC Grade 2 3 or 4   Completion of previous chemotherapy regimen  3 weeks prior to the start of study treatment   Prior hormonal therapy must be discontinued prior to treatment start Biologic therapy eg bevacizumab trastuzumab for the treatment of metastatic disease must be discontinued  or  to 3 weeks from the start of protocol treatment   Concurrent medical condition which may increase the risk of toxicity   Patients may not have any clinically significant cardiovascular disease including the following   myocardial infarction or ventricular tachyarrhythmia within 6 months   prolonged QTc 480 msec Fridericia correction   ejection fraction less than institutional normal   major conduction abnormality unless a cardiac pacemaker is present   Patients with any cardiopulmonary symptoms of unknown cause eg shortness of breath chest pain etc should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram EKG to rule out QTc prolongation The patient may be referred to a cardiologist at the discretion of the principal investigator Patients with underlying cardiopulmonary dysfunction should be excluded from the study   Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration   History of significant bleeding disorder unrelated to cancer including   Diagnosed congenital bleeding disorders eg von Willebrands disease   Diagnosed acquired bleeding disorder within one year eg acquired antifactor VIII antibodies   Ongoing or recent  3 months significant gastrointestinal bleeding Other medical condition which in the opinion of the Investigator might confer an unacceptable increase in risk   Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial The presence of asymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion   History of uncontrolled seizures central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance of oral drug intake   Presence of uncontrolled gastrointestinal malabsorption syndrome   Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study Willingness and ability to comply with scheduled visits treatment plan laboratory tests and other study procedures are necessary for participation in this clinical trial   Concurrent radiotherapy is not permitted for disease progression on treatment on protocol but might allowed for preexisting nontarget lesions with approval from the principal investigator of the trial   Patients with  Grade 1 neuropathy will be excluded form this trial\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Outcome Measurement    Phase I Portion Maximum Tolerated DoseMTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel   Not Specified   Time frame Through completion of Phase I up to 1 year Results 1    ArmGroup Title Dasatinib and Paclitaxel   ArmGroup Description The phase I portion is a standard threepatient per cohort dose escalation schedule will be used Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel   The phase II portion of this trial has a Simon twostage design to determine the efficacy of dasatinib when administered in combination with paclitaxel   Dasatinib and Paclitaxel A treatment cycle will consist of 28 days according to the following schedule   Dasatinib 120MG PO once daily Weekly paclitaxel 80 mgm2 given intravenously over 1 hour on day 1 8 and 15 of a 28 day cycle   The trial will initially test the combination of weekly paclitaxel and dasatinib given PO once daily  continuously In case of 2 doselimiting toxicities DLT in the first cohort 0 the next cohort will test dasatinib given with a different schedule 5 days on and 2 days off omitting dasatinib the day prior and the day of administration of paclitaxel   Overall Number of Participants Analyzed 15   Measure Type Number   Unit of Measure mg of dasatinib  120\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Adverse Events 1   Total 33 10000   Hemoglobin decreasedAnemia  13 3333   Arrhythmia supraventricular  13 3333   Fatigue  13 3333   Pain  03 000   Infection  03 000   Pneumonia  03 000   Skin infection  03 000   Laboratory test abnormal  03 000   Serum phosphate decreased  03 000   Bone pain  03 000   Syncope vasovagal  03 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"INTERVENTION 1    Cetuximab   Patients receive cetuximab IV over 60120 minutes once a week Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity Patients not responding to treatment may cross over to arm II   cetuximab Given IV INTERVENTION 2    Cetuximab and Carboplatin After Cetuximab Alone   Patients from Arm 1 who progressed on cetuximab alone who went on to receive cetuximab  carboplatin\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"DISEASE CHARACTERISTICS   Histologically confirmed breast cancer   Metastatic stage IV disease   Measurable disease by RECIST criteria   Irradiated lesions are not considered measurable disease   Central nervous system CNS metastases allowed if disease is stable no evidence of progression  3 months after local therapy   No lesions identifiable only by positron emission tomography PET scan   HER2 nonoverexpressing disease by IHC 0 or 1 or nongene amplified by Fluorescence In Situ Hybridization FISH   HER2 2 by IHC allowed   Hormone receptor status   Estrogen receptornegative and progesterone receptornegative tumor   Inclusion Criteria   At least 18 years of age   Metastatic breast cancer Stage IV with measurable disease by RECIST criteria   No more than three prior chemotherapy regimens either in the adjuvant or metastatic setting   Histologically documented either primary or metastatic site breast cancer that is estrogen receptor ER negative PRnegative and HER2 nonoverexpressing by immunohistochemistry 01 or nongene amplified by FISH performed upon the primary tumor or metastatic lesion HER2 2 by immunohistochemistry is usually negative by FISH and this confirmatory test should be performed when possible however may participate if fulfill other criteria   Completion of prior chemotherapy at least 3 weeks prior to study entry   Patients may have received therapy ies in the adjuvant or metastatic setting however must have discontinued prior to entry Patients may receive concurrent bisphosphonates however if taking bisphosphonates bone lesions may not be used for progression or response   Radiation therapy must be completed at least 2 weeks prior to study entry and radiated lesions may not serve as measurable disease   Patients may have CNS metastases if stable no evidence of progression  3 months after local therapy   Eastern Cooperative Oncology Group ECOG performance status 02 and life expectancy of at least 6 months   Adequate organ function defined asabsolute neutrophil count ANC  1500mm3 plts  100000mm3 creatinine clearance 50 mLmin alanine aminotransferase ALT and aspartate aminotransferase AST 25 x upper limit of normal ULN or 5 x ULN in case of liver metastases total bilirubin 15 mgdL   Tissue block available for EGFR studies is recommended although will not exclude patients from participating   Pregnant or lactating women will be excluded Women of child bearing potential must have documented negative pregnancy test within two weeks of study entry and agree to acceptable birth control during the duration of the study therapy   Signed written informed consent   Exclusion Criteria   Lesions identifiable only by PET   More than three prior chemotherapy regimens including adjuvant Sequential regimens such as doxorubicin and cyclophosphamide followed by paclitaxel ACpaclitaxel are considered one regimen   Prior therapy which specifically and directly targets the EGFR pathway with therapeutic intent   Prior platinum agent for metastatic disease If platinum agent was used adjuvantly the patient must have had at least 12 months diseasefree interval prior to relapse   Prior severe infusion reaction to a monoclonal antibody   Major medical conditions that might affect study participation uncontrolled pulmonary renal or hepatic dysfunction uncontrolled infection   Significant history of uncontrolled cardiac disease ie uncontrolled hypertension unstable angina recent myocardial infarction within prior 6 months uncontrolled congestive heart failure and cardiomyopathy that is either symptomatic or asymptomatic but with decreased ejection fraction 45   Other significant comorbid condition which the investigator feels might compromise effective and safe participation in the study   Inability to comply with the requirements of the study\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Outcome Measurement    Overall Disease Response Rate   Overall response rate of single agent cetuximab and cetuximab  carboplatin will be measured by radiographic response using Response Evaluation Criteria In Solid Tumors RECIST criteria every 8 weeks until subject experiences disease progression Overall response will be measured as complete response CR partial response PR stable disease SD or progressive disease PDPer RECIST v10 for target lesions and assessed by CT spiral Complete Response CR Disappearance of all target lesions Partial Response PR 30 decrease in the sum of the longest diameter of target lesions Progression as a 20 increase in the sum of the longest diameter of target lesions or a measurable increase in a nontarget lesion or the appearance of new lesions Stable Disease SD neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression   Time frame 5 years Results 1    ArmGroup Title Cetuximab   ArmGroup Description Patients receive cetuximab IV over 60120 minutes once a week Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity Patients not responding to treatment may cross over to arm II   cetuximab Given IV   Overall Number of Participants Analyzed 31   Measure Type Count of Participants   Unit of Measure Participants  Complete response 0   00   Partial response 2   65   Stable disease 3   97   Stable disease  6 months 1   32   Progressive disease 26  839   Not evaluable 0   00 Results 2    ArmGroup Title Cetuximab and Carboplatin After Cetuximab Alone   ArmGroup Description Patients from Arm 1 who progressed on cetuximab alone who went on to receive cetuximab  carboplatin   Overall Number of Participants Analyzed 25   Measure Type Count of Participants   Unit of Measure Participants  Complete response 0   00   Partial response 4  160   Stable disease 7  280   Stable disease  6 months 3  120   Progressive disease 12  480   Not evaluable 2   80\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Adverse Events 1   Total 331 968   Edema limb  231 645   Neutrophilsgranulocytes ANCAGC  031 000   Cardiac General  Other Specify    1031 000   Cardiac General  Other Specify    2031 000   Left ventricular diastolic dysfunction  031 000   Supraventricular and nodal arrhythmia  Atrial tachycardiaParoxysmal Atrial Tachycardia  031 000 Adverse Events 2   Total 825 3200   Edema limb  125 400   Neutrophilsgranulocytes ANCAGC  025 000   Cardiac General  Other Specify    1125 400   Cardiac General  Other Specify    2025 000   Left ventricular diastolic dysfunction  125 400   Supraventricular and nodal arrhythmia  Atrial tachycardiaParoxysmal Atrial Tachycardia  025 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Concatenated_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"the primary id adverse events is adverse events 1   total 312 2500   atrial fibrillation 012 000   cardiac ischemiainfarction  1012 000   congestive heart failure  2012 000   diverticulitis 012 000   cholecystitis 012 000   hyperbilirubinemia 012 000   urosepsis 212 1667   brain hemorrhage complicating cns metastasis 112 833   rash  3012 000 and the secondary id adverse events is adverse events 1   total 1865 2769   anaemia 565 769   febrile neutropenia 165 154   leukocytosis 065 000   neutropenia 465 615   thrombocytopenia 665 923   cardiac failure congestive 065 000   epigastric discomfort 065 000   nausea 165 154   vomiting 365 462   condition aggravated 065 000   medical device complication 065 000 adverse events 2   total 2266 3333   anaemia 166 152   febrile neutropenia 266 303   leukocytosis 166 152   neutropenia 266 303   thrombocytopenia 066 000   cardiac failure congestive 166 152   epigastric discomfort 166 152   nausea 066 000   vomiting 166 152   condition aggravated 166 152   medical device complication 166 152 and the statement is unilateral optic nerve hypoplasia is a congenital abnormality characterized by the underdevelopment of one optic nerve there are more cases of urosepsis in the primary trial than in the secondary trial\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 41
        }
      ],
      "source": [
        "original_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 608
        },
        "id": "GKc538qOarZ0",
        "outputId": "6d350d01-cc71-402f-db38-d0bcf12c2d02"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type    Section_id   Primary_id  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Comparison  Intervention  NCT01572727   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9      Single       Results  NCT00915603   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  Comparison  Intervention  NCT01572727   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Comparison       Results  NCT00852930   \n",
              "572c52ba-9518-4b72-9a32-a08604808764      Single       Results  NCT00357110   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  in the primary clinical trial, patients receiv...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  in cohort 1 of the primary clinical trial, the...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  the intake of paclitaxel for patients in the p...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  the collection of overall survival metrics of ...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  the primary clinical trial reported 6 losses i...   \n",
              "\n",
              "                                              Label Intervention  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b     Entailment   Paraphrase   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  Contradiction   Paraphrase   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db     Entailment   Paraphrase   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Contradiction   Paraphrase   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  Contradiction   Paraphrase   \n",
              "\n",
              "                                                                            Causal_type  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  [Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  [Preserving, 0cef8c8e-7986-46c7-a597-c5733a989...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  [Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  [Preserving, dc4c57b0-8c75-494e-81b0-3528df85e...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  [Preserving, f114846e-79d8-4712-add0-bb34b65d4...   \n",
              "\n",
              "                                     Secondary_id  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  NCT00328783   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9          NaN   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  NCT00328783   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  NCT02915744   \n",
              "572c52ba-9518-4b72-9a32-a08604808764          NaN   \n",
              "\n",
              "                                                                Primary_id_intervention  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  INTERVENTION 1    BKM120 and Paclitaxel   Adul...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  INTERVENTION 1    PaclitaxelBevacizumabEveroli...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  INTERVENTION 1    BKM120 and Paclitaxel   Adul...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  INTERVENTION 1    Laser Therapy Alone   therap...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  INTERVENTION 1    Fulvestrant  Anastrozole   f...   \n",
              "\n",
              "                                                                 Primary_id_Eligibility  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Inclusion Criteria   Breast cancer that is loc...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  Inclusion Criteria   Female or male patients 1...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  Inclusion Criteria   Breast cancer that is loc...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Inclusion Criteria   Breast cancer survivors w...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  Inclusion Criteria   Postmenopausal women with...   \n",
              "\n",
              "                                                                     Primary_id_results  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Outcome Measurement    Progressionfree Surviva...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  Outcome Measurement    ProgressionFree Surviva...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  Outcome Measurement    Progressionfree Surviva...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Outcome Measurement    LDex Change   Bioimpeda...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  Outcome Measurement    Patients Eventfree at 1...   \n",
              "\n",
              "                                                              Primary_id_Adverse_events  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Adverse Events 1   Total 61202 3020   FEBRILE ...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  Adverse Events 1   Total 1655 2909   NEUTROPEN...   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  Adverse Events 1   Total 61202 3020   FEBRILE ...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Adverse Events 1   Total 015 000 Adverse Event...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764  Adverse Events 1   Total 16 1667   Goitre 06 0...   \n",
              "\n",
              "                                                              Secondary_id_intervention  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  INTERVENTION 1    Active Breathing Coordinator...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9                                               None   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  INTERVENTION 1    Active Breathing Coordinator...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  INTERVENTION 1    NKTR102   In Group A NKTR102...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764                                               None   \n",
              "\n",
              "                                                               Secondary_id_Eligibility  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Inclusion Criteria   Requiring adjuvant or pos...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9                                               None   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  Inclusion Criteria   Requiring adjuvant or pos...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Inclusion Criteria   Female or male age  18 ye...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764                                               None   \n",
              "\n",
              "                                                                   Secondary_id_results  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  Outcome Measurement    Dosimetric Evaluation M...   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9                                               None   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  Outcome Measurement    Dosimetric Evaluation M...   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Outcome Measurement    Overall Survival OS of ...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764                                               None   \n",
              "\n",
              "                                                            Secondary_id_Adverse_events  \\\n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b                        Adverse Events 1   Total 00   \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9                                               None   \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db                        Adverse Events 1   Total 00   \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  Adverse Events 1   Total 3390 3667   Febrile N...   \n",
              "572c52ba-9518-4b72-9a32-a08604808764                                               None   \n",
              "\n",
              "                                                                      Concatenated_Text  \n",
              "ea57b54d-1912-4d9f-bcf7-7f423aed195b  the primary id intervention is intervention 1 ...  \n",
              "47f4c385-4dd8-4b6e-a365-bb2fac258ab9  the primary id results is outcome measurement ...  \n",
              "d31f179f-1253-44c8-8fc6-167f7b3d41db  the primary id intervention is intervention 1 ...  \n",
              "76236597-7a5e-4042-b1c4-ddd5a4aa57e7  the primary id results is outcome measurement ...  \n",
              "572c52ba-9518-4b72-9a32-a08604808764  the primary id results is outcome measurement ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-1a75a99d-0cc7-49d2-9c3e-5169a9ebcabd\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Label</th>\n",
              "      <th>Intervention</th>\n",
              "      <th>Causal_type</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Primary_id_intervention</th>\n",
              "      <th>Primary_id_Eligibility</th>\n",
              "      <th>Primary_id_results</th>\n",
              "      <th>Primary_id_Adverse_events</th>\n",
              "      <th>Secondary_id_intervention</th>\n",
              "      <th>Secondary_id_Eligibility</th>\n",
              "      <th>Secondary_id_results</th>\n",
              "      <th>Secondary_id_Adverse_events</th>\n",
              "      <th>Concatenated_Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>ea57b54d-1912-4d9f-bcf7-7f423aed195b</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT01572727</td>\n",
              "      <td>in the primary clinical trial, patients receiv...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...</td>\n",
              "      <td>NCT00328783</td>\n",
              "      <td>INTERVENTION 1    BKM120 and Paclitaxel   Adul...</td>\n",
              "      <td>Inclusion Criteria   Breast cancer that is loc...</td>\n",
              "      <td>Outcome Measurement    Progressionfree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 61202 3020   FEBRILE ...</td>\n",
              "      <td>INTERVENTION 1    Active Breathing Coordinator...</td>\n",
              "      <td>Inclusion Criteria   Requiring adjuvant or pos...</td>\n",
              "      <td>Outcome Measurement    Dosimetric Evaluation M...</td>\n",
              "      <td>Adverse Events 1   Total 00</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>47f4c385-4dd8-4b6e-a365-bb2fac258ab9</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00915603</td>\n",
              "      <td>in cohort 1 of the primary clinical trial, the...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, 0cef8c8e-7986-46c7-a597-c5733a989...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    PaclitaxelBevacizumabEveroli...</td>\n",
              "      <td>Inclusion Criteria   Female or male patients 1...</td>\n",
              "      <td>Outcome Measurement    ProgressionFree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 1655 2909   NEUTROPEN...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>d31f179f-1253-44c8-8fc6-167f7b3d41db</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT01572727</td>\n",
              "      <td>the intake of paclitaxel for patients in the p...</td>\n",
              "      <td>Entailment</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, 3ba42f68-a643-4d10-afd0-cbb358d05...</td>\n",
              "      <td>NCT00328783</td>\n",
              "      <td>INTERVENTION 1    BKM120 and Paclitaxel   Adul...</td>\n",
              "      <td>Inclusion Criteria   Breast cancer that is loc...</td>\n",
              "      <td>Outcome Measurement    Progressionfree Surviva...</td>\n",
              "      <td>Adverse Events 1   Total 61202 3020   FEBRILE ...</td>\n",
              "      <td>INTERVENTION 1    Active Breathing Coordinator...</td>\n",
              "      <td>Inclusion Criteria   Requiring adjuvant or pos...</td>\n",
              "      <td>Outcome Measurement    Dosimetric Evaluation M...</td>\n",
              "      <td>Adverse Events 1   Total 00</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>76236597-7a5e-4042-b1c4-ddd5a4aa57e7</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00852930</td>\n",
              "      <td>the collection of overall survival metrics of ...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, dc4c57b0-8c75-494e-81b0-3528df85e...</td>\n",
              "      <td>NCT02915744</td>\n",
              "      <td>INTERVENTION 1    Laser Therapy Alone   therap...</td>\n",
              "      <td>Inclusion Criteria   Breast cancer survivors w...</td>\n",
              "      <td>Outcome Measurement    LDex Change   Bioimpeda...</td>\n",
              "      <td>Adverse Events 1   Total 015 000 Adverse Event...</td>\n",
              "      <td>INTERVENTION 1    NKTR102   In Group A NKTR102...</td>\n",
              "      <td>Inclusion Criteria   Female or male age  18 ye...</td>\n",
              "      <td>Outcome Measurement    Overall Survival OS of ...</td>\n",
              "      <td>Adverse Events 1   Total 3390 3667   Febrile N...</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>572c52ba-9518-4b72-9a32-a08604808764</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT00357110</td>\n",
              "      <td>the primary clinical trial reported 6 losses i...</td>\n",
              "      <td>Contradiction</td>\n",
              "      <td>Paraphrase</td>\n",
              "      <td>[Preserving, f114846e-79d8-4712-add0-bb34b65d4...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTION 1    Fulvestrant  Anastrozole   f...</td>\n",
              "      <td>Inclusion Criteria   Postmenopausal women with...</td>\n",
              "      <td>Outcome Measurement    Patients Eventfree at 1...</td>\n",
              "      <td>Adverse Events 1   Total 16 1667   Goitre 06 0...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-1a75a99d-0cc7-49d2-9c3e-5169a9ebcabd')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-1a75a99d-0cc7-49d2-9c3e-5169a9ebcabd button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-1a75a99d-0cc7-49d2-9c3e-5169a9ebcabd');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-9e96062b-b2eb-421b-a157-01ef1c8a6cc2\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-9e96062b-b2eb-421b-a157-01ef1c8a6cc2')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-9e96062b-b2eb-421b-a157-01ef1c8a6cc2 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "preserving_data",
              "summary": "{\n  \"name\": \"preserving_data\",\n  \"rows\": 600,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Results\",\n          \"Adverse Events\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT00325234\",\n          \"NCT02370238\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"more total adverse events were observed in cohort 1 of the primary clinical trial than in cohort 2\",\n          \"women presently engaged in endocrine therapy are not eligible for both the secondary clinical trial and the primary clinical trial\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Label\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Contradiction\",\n          \"Entailment\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Paraphrase\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Causal_type\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 30,\n        \"samples\": [\n          \"NCT02301988\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"INTERVENTION 1    PemetrexedCarboplatin   Pemetrexed 600 mgm2 was administered intravenously over approximately 10 minutes on Day 1 Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion consistent with a target of AUC 50 The cycle of treatment was 21 days INTERVENTION 2    GemcitabineVinorelbine   Vinorelbine 30 mgm2 was given over approximately 610 minutes on Day 1 and Day 8 Gemcitabine 1200 mgm2 will be given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion The cycle of treatment was 21 days\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Inclusion Criteria   Females with histologic or cytologic diagnosis of advanced breast cancer Lesions should not be amenable to surgery or radiation of curative intent   Performance status of 0 to 2 on the Eastern Cooperative Oncology Group ECOG performance status scale   One prior chemotherapy containing anthracyclines as neoadjuvant or palliative 1stline treatment   One prior chemotherapy containing taxanes as neo adjuvant or palliative 1stline treatment   Prior radiation therapy is allowed to less than 25 of the bone marrow Participants must have recovered from the toxic effects of the treatment prior to study enrollment except for alopecia Prior radiotherapy must be completed 30 days before study entry Lesions that have been radiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy   At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors RECIST criteria Positron emission tomography PET scans and ultrasounds may not be used   Antitumoral hormonal treatment must be discontinued prior to enrollment   Estimated life expectancy of at least 3 months   Participant compliance and geographic proximity that allow adequate followup   Adequate organ function   Female participants of childbearing potential must test negative for pregnancy within 7 days of enrollment based on a urine andor serum pregnancy test and agree to use a reliable method of birth control during and for 6 months following the last dose of study drug   Participants must sign an informed consent document   Female participants must be at least 18 years of age Exclusion Criteria   Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry   Have previously completed or withdrawn from this study or any other study investigating Pemetrexed Gemcitabine Carboplatin or Vinorelbine   Have received more than one line of chemotherapy in Metastatic Breast Cancer Participants having received more than one combination of anthracycline plus taxane   Are pregnant or breastfeeding   Have serious concomitant systemic disorders eg active infection that in the opinion of the investigator would compromise the safety of the participant or compromise the participants ability to complete the study   Have a prior malignancy other than breast cancer carcinoma in situ of the cervix or nonmelanoma skin cancer unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence   Are unable to interrupt aspirin or other nonsteroidal antiinflammatory agents for a 5day period 8day period for longacting agents such as piroxicam unless the Creatinine Clearance is greater than or equal to 80 mlmin   Have central nervous system CNS metastases   Have clinically relevant by physical exam thirdspace fluid collections for example ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry   Are unable or unwilling to take folic acid vitamin B12 supplementation or dexamethasone   Concurrent administration of any other antitumor therapy\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Outcome Measurement    Tumor Response Rate   Participants with best overall response determined from complete response CR or partial response PR according to Response Criteria in Solid Tumors RECIST criteria For CR or PR best response must be confirmed A second assessment performed at 28 days Two determinations of CR before progression required for rate toCR Evaluations include CRDisappearance of lesions PR  30 size decrease of lesions Progressive Disease PD  20 size increase of lesions Stable Disease SDNot enough shrinkage for PR nor enough increase for PD Overall Response RatePRCRQualified Participants100   Time frame Baseline up to 30 days of followup after 21 cycles of treatment Results 1    ArmGroup Title PemetrexedCarboplatin   ArmGroup Description Pemetrexed 600 mgm2 was administered intravenously over approximately 10 minutes on Day 1 Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion consistent with a target of AUC 50 The cycle of treatment was 21 days   Overall Number of Participants Analyzed 64   Measure Type Number   Unit of Measure percentage of participants  Overall Response 266        163 to 391   Complete Response 00        00 to 56   Partial Response 266        163 to 391   Stable Disease 359        243 to 489   Progressive Disease 266        163 to 391   Unknown 109        45 to 212 Results 2    ArmGroup Title GemcitabineVinorelbine   ArmGroup Description Vinorelbine 30 mgm2 was given over approximately 610 minutes on Day 1 and Day 8 Gemcitabine 1200 mgm2 will be given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion The cycle of treatment was 21 days   Overall Number of Participants Analyzed 61   Measure Type Number   Unit of Measure percentage of participants  Overall Response 295        185 to 426   Complete Response 33        04 to 113   Partial Response 262        158 to 391   Stable Disease 344        227 to 477   Progressive Disease 279        171 to 408   Unknown 82        27 to 181\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Adverse Events 1   Total 1865 2769   Anaemia 565 769   Febrile neutropenia 165 154   Leukocytosis 065 000   Neutropenia 465 615   Thrombocytopenia 665 923   Cardiac failure congestive 065 000   Epigastric discomfort 065 000   Nausea 165 154   Vomiting 365 462   Condition aggravated 065 000   Medical device complication 065 000 Adverse Events 2   Total 2266 3333   Anaemia 166 152   Febrile neutropenia 266 303   Leukocytosis 166 152   Neutropenia 266 303   Thrombocytopenia 066 000   Cardiac failure congestive 166 152   Epigastric discomfort 166 152   Nausea 066 000   Vomiting 166 152   Condition aggravated 166 152   Medical device complication 166 152\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"INTERVENTION 1    Fulvestrant 500 mg Fulvestrant 500 mg INTERVENTION 2    Anastrozole 1 mg Anastrozole 1 mg\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Inclusion Criteria   Confirmed hormone receptor positive advanced breast cancer postmenopausal women Exclusion Criteria   Previous treatment for advanced breast cancer previous treatment for early breast cancer is allowed\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Outcome Measurement    Clinical Benefit Rate   A Clinical Benefit CB responder is defined as a patient having a best overall response of either complete response CR partial response PR or stable disease SD for at least 24 weeks evaluated according to modified RECIST The Clinical Benefit Rate is the percentage of patients with CB   Time frame From randomisation to data cut off DCO for primary analysis The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively The DCO for primary analysis was on 10th Jan 2008 6 months after the last patient was enrolled Results 1    ArmGroup Title Fulvestrant 500 mg   ArmGroup Description Fulvestrant 500 mg   Overall Number of Participants Analyzed 102   Measure Type Number   Unit of Measure Percentage of Participants  725 Results 2    ArmGroup Title Anastrozole 1 mg   ArmGroup Description Anastrozole 1 mg   Overall Number of Participants Analyzed 103   Measure Type Number   Unit of Measure Percentage of Participants  670\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 31,\n        \"samples\": [\n          \"Adverse Events 1   Total 24101 2376   LYMPHADENOPATHY 0101 000   FEBRILE NEUTROPENIA 20101 000   ATRIAL FIBRILLATION 1101 099   ARRHYTHMIA 20101 000   CARDIAC FAILURE 22101 198   CARDIAC FAILURE CONGESTIVE 20101 000   CORONARY OSTIAL STENOSIS 20101 000   LACRIMAL DISORDER 0101 000   BLINDNESS 21101 099   GASTRIC ULCER 1101 099   NAUSEA 1101 099 Adverse Events 2   Total 22103 2136   LYMPHADENOPATHY 1103 097   FEBRILE NEUTROPENIA 21103 097   ATRIAL FIBRILLATION 1103 097   ARRHYTHMIA 21103 097   CARDIAC FAILURE 20103 000   CARDIAC FAILURE CONGESTIVE 21103 097   CORONARY OSTIAL STENOSIS 21103 097   LACRIMAL DISORDER 1103 097   BLINDNESS 20103 000   GASTRIC ULCER 0103 000   NAUSEA 0103 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Concatenated_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 600,\n        \"samples\": [\n          \"the primary id adverse events is adverse events 1   total 1361 2131   anaemia 161 164   febrile neutropenia 161 164   cardiac failure congestive 061 000   pericardial effusion 061 000   constipation 161 164   intestinal perforation 161 164   stomatitis 061 000   noncardiac chest pain 261 328   condition aggravated 161 164   general physical health deterioration 161 164 adverse events 2   total 1260 2000   anaemia 160 167   febrile neutropenia 060 000   cardiac failure congestive 160 167   pericardial effusion 160 167   constipation 060 000   intestinal perforation 060 000   stomatitis 160 167   noncardiac chest pain 060 000   condition aggravated 060 000   general physical health deterioration 160 167 and the secondary id adverse events is none and the statement is more total adverse events were observed in cohort 1 of the primary clinical trial than in cohort 2\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 42
        }
      ],
      "source": [
        "preserving_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 556
        },
        "id": "AKr_34vjdiH2",
        "outputId": "25e44cc8-068d-4333-d132-07b6fb0de5ad"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                            Type      Section_id   Primary_id  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  Comparison  Adverse Events  NCT00687102   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa      Single     Eligibility  NCT01772004   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c      Single    Intervention  NCT00118157   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04      Single         Results  NCT01106898   \n",
              "7df66c3f-de87-4542-9797-06325684db65  Comparison  Adverse Events  NCT02002533   \n",
              "\n",
              "                                     Secondary_id  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  NCT00819182   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa          NaN   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c          NaN   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04          NaN   \n",
              "7df66c3f-de87-4542-9797-06325684db65  NCT02734979   \n",
              "\n",
              "                                                                              Statement  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  the record shows 5 total cases of asthenia and...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa  'the primary clinical trial is open for partic...   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c  patients participating in the primary trial re...   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04  in the primary clinical trial, 97% of patients...   \n",
              "7df66c3f-de87-4542-9797-06325684db65  the primary trial has 4 more adverse events re...   \n",
              "\n",
              "                                                                Primary_id_intervention  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  INTERVENTION 1    Star Participants Assigned t...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa  INTERVENTION 1    Dose Escalation Cohort Avelu...   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c  INTERVENTION 1    Arm 1   Patients receive ora...   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04  INTERVENTION 1    Treatment Chemotherapy With ...   \n",
              "7df66c3f-de87-4542-9797-06325684db65  INTERVENTION 1    All Participants   All peopl...   \n",
              "\n",
              "                                                                 Primary_id_Eligibility  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  Inclusion Criteria   Women enrolled in STAR tr...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa  Inclusion Criteria for dose escalation and exp...   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c  Inclusion Criteria   Primary adenocarcinoma of...   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04  Inclusion Criteria   Histologically confirmed ...   \n",
              "7df66c3f-de87-4542-9797-06325684db65  Inclusion Criteria   Newly diagnosed breast ca...   \n",
              "\n",
              "                                                                     Primary_id_results  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  Outcome Measurement    Mean Change From Baseli...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa  Outcome Measurement    Dose Escalation Cohort ...   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c  Outcome Measurement    Tumor Response Rate Com...   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04  Outcome Measurement    Recurrencefree Survival...   \n",
              "7df66c3f-de87-4542-9797-06325684db65  Outcome Measurement    Percentage of Eligible ...   \n",
              "\n",
              "                                                              Primary_id_Adverse_events  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  Adverse Events 1   Total 0733 000 Adverse Even...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa  Adverse Events 1   Total 34 7500   Anaemia  04...   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c  Adverse Events 1   Total 1919 10000   Hemolysi...   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04  Adverse Events 1   Total 16102 1569   Febrile ...   \n",
              "7df66c3f-de87-4542-9797-06325684db65                   Adverse Events 1   Total 034 000   \n",
              "\n",
              "                                                              Secondary_id_intervention  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  INTERVENTION 1    Paced Respiration   The pace...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa                                               None   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c                                               None   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04                                               None   \n",
              "7df66c3f-de87-4542-9797-06325684db65  INTERVENTION 1    Biobridge and Lymph Node Tra...   \n",
              "\n",
              "                                                               Secondary_id_Eligibility  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  Inclusion Criteria   At least 18 years of age ...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa                                               None   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c                                               None   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04                                               None   \n",
              "7df66c3f-de87-4542-9797-06325684db65  Inclusion Criteria   The subject must be a bre...   \n",
              "\n",
              "                                                                   Secondary_id_results  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  Outcome Measurement    Hot Flash Frequency   P...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa                                               None   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c                                               None   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04                                               None   \n",
              "7df66c3f-de87-4542-9797-06325684db65  Outcome Measurement    Change in Limb Volume  ...   \n",
              "\n",
              "                                                            Secondary_id_Adverse_events  \\\n",
              "47468741-3624-4321-90ee-1c680a293b25  Adverse Events 1   Total 088 000 Adverse Event...   \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa                                               None   \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c                                               None   \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04                                               None   \n",
              "7df66c3f-de87-4542-9797-06325684db65                    Adverse Events 1   Total 01 000   \n",
              "\n",
              "                                                                      Concatenated_Text  \n",
              "47468741-3624-4321-90ee-1c680a293b25  the primary id adverse events is adverse event...  \n",
              "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa  the primary id eligibility is inclusion criter...  \n",
              "ad9fe1aa-9798-4c53-ab23-23ac2924918c  the primary id intervention is intervention 1 ...  \n",
              "cdcb40f6-994c-4085-869a-dab87e67ba04  the primary id results is outcome measurement ...  \n",
              "7df66c3f-de87-4542-9797-06325684db65  the primary id adverse events is adverse event...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-29845c67-ea09-4b93-a3af-7ee4d51f5519\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Type</th>\n",
              "      <th>Section_id</th>\n",
              "      <th>Primary_id</th>\n",
              "      <th>Secondary_id</th>\n",
              "      <th>Statement</th>\n",
              "      <th>Primary_id_intervention</th>\n",
              "      <th>Primary_id_Eligibility</th>\n",
              "      <th>Primary_id_results</th>\n",
              "      <th>Primary_id_Adverse_events</th>\n",
              "      <th>Secondary_id_intervention</th>\n",
              "      <th>Secondary_id_Eligibility</th>\n",
              "      <th>Secondary_id_results</th>\n",
              "      <th>Secondary_id_Adverse_events</th>\n",
              "      <th>Concatenated_Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>47468741-3624-4321-90ee-1c680a293b25</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT00687102</td>\n",
              "      <td>NCT00819182</td>\n",
              "      <td>the record shows 5 total cases of asthenia and...</td>\n",
              "      <td>INTERVENTION 1    Star Participants Assigned t...</td>\n",
              "      <td>Inclusion Criteria   Women enrolled in STAR tr...</td>\n",
              "      <td>Outcome Measurement    Mean Change From Baseli...</td>\n",
              "      <td>Adverse Events 1   Total 0733 000 Adverse Even...</td>\n",
              "      <td>INTERVENTION 1    Paced Respiration   The pace...</td>\n",
              "      <td>Inclusion Criteria   At least 18 years of age ...</td>\n",
              "      <td>Outcome Measurement    Hot Flash Frequency   P...</td>\n",
              "      <td>Adverse Events 1   Total 088 000 Adverse Event...</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa</th>\n",
              "      <td>Single</td>\n",
              "      <td>Eligibility</td>\n",
              "      <td>NCT01772004</td>\n",
              "      <td>NaN</td>\n",
              "      <td>'the primary clinical trial is open for partic...</td>\n",
              "      <td>INTERVENTION 1    Dose Escalation Cohort Avelu...</td>\n",
              "      <td>Inclusion Criteria for dose escalation and exp...</td>\n",
              "      <td>Outcome Measurement    Dose Escalation Cohort ...</td>\n",
              "      <td>Adverse Events 1   Total 34 7500   Anaemia  04...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id eligibility is inclusion criter...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>ad9fe1aa-9798-4c53-ab23-23ac2924918c</th>\n",
              "      <td>Single</td>\n",
              "      <td>Intervention</td>\n",
              "      <td>NCT00118157</td>\n",
              "      <td>NaN</td>\n",
              "      <td>patients participating in the primary trial re...</td>\n",
              "      <td>INTERVENTION 1    Arm 1   Patients receive ora...</td>\n",
              "      <td>Inclusion Criteria   Primary adenocarcinoma of...</td>\n",
              "      <td>Outcome Measurement    Tumor Response Rate Com...</td>\n",
              "      <td>Adverse Events 1   Total 1919 10000   Hemolysi...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id intervention is intervention 1 ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>cdcb40f6-994c-4085-869a-dab87e67ba04</th>\n",
              "      <td>Single</td>\n",
              "      <td>Results</td>\n",
              "      <td>NCT01106898</td>\n",
              "      <td>NaN</td>\n",
              "      <td>in the primary clinical trial, 97% of patients...</td>\n",
              "      <td>INTERVENTION 1    Treatment Chemotherapy With ...</td>\n",
              "      <td>Inclusion Criteria   Histologically confirmed ...</td>\n",
              "      <td>Outcome Measurement    Recurrencefree Survival...</td>\n",
              "      <td>Adverse Events 1   Total 16102 1569   Febrile ...</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>the primary id results is outcome measurement ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7df66c3f-de87-4542-9797-06325684db65</th>\n",
              "      <td>Comparison</td>\n",
              "      <td>Adverse Events</td>\n",
              "      <td>NCT02002533</td>\n",
              "      <td>NCT02734979</td>\n",
              "      <td>the primary trial has 4 more adverse events re...</td>\n",
              "      <td>INTERVENTION 1    All Participants   All peopl...</td>\n",
              "      <td>Inclusion Criteria   Newly diagnosed breast ca...</td>\n",
              "      <td>Outcome Measurement    Percentage of Eligible ...</td>\n",
              "      <td>Adverse Events 1   Total 034 000</td>\n",
              "      <td>INTERVENTION 1    Biobridge and Lymph Node Tra...</td>\n",
              "      <td>Inclusion Criteria   The subject must be a bre...</td>\n",
              "      <td>Outcome Measurement    Change in Limb Volume  ...</td>\n",
              "      <td>Adverse Events 1   Total 01 000</td>\n",
              "      <td>the primary id adverse events is adverse event...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-29845c67-ea09-4b93-a3af-7ee4d51f5519')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-29845c67-ea09-4b93-a3af-7ee4d51f5519 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-29845c67-ea09-4b93-a3af-7ee4d51f5519');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-244dedac-b226-448e-aec6-82e3d0ca3c02\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-244dedac-b226-448e-aec6-82e3d0ca3c02')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-244dedac-b226-448e-aec6-82e3d0ca3c02 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "test_data",
              "summary": "{\n  \"name\": \"test_data\",\n  \"rows\": 5500,\n  \"fields\": [\n    {\n      \"column\": \"Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Single\",\n          \"Comparison\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Section_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Eligibility\",\n          \"Results\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 249,\n        \"samples\": [\n          \"NCT00659373\",\n          \"NCT01194440\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 136,\n        \"samples\": [\n          \"NCT02550795\",\n          \"NCT02038218\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Statement\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5495,\n        \"samples\": [\n          \"pericardial effusions were a less common condition among patients in the primary trial\",\n          \"although cudc-101 dosage remains consistent for both cohort 1 and cohort 2 in the primary clinical trial, it is dispensed more frequently to cohort 1.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 249,\n        \"samples\": [\n          \"INTERVENTION 1    Tamoxifen   Tamoxifen 20mg orally daily for 5 years INTERVENTION 2    Ovarian Function Suppression   Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression OFS triptorelin GnRH analogue 375 mg by im injection q28 days for 5 years or surgical oophorectomy or ovarian irradiation   Note Data were collected separately for the TOFS and EOFS participants in the parent study IBCSG 2402 SOFT The sample size for this CoSOFT substudy was small so the analysis plan was revised to prespecify collective analysis for all patients receiving OFS\",\n          \"INTERVENTION 1    Arm I   Patients receive zoledronic acid IV at months 1 and 6 Beginning 14 days after first zoledronic acid infusion patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity   letrozole Given orally   zoledronic acid Given IV   laboratory biomarker analysis Correlative studies   enzymelinked immunosorbent assay Correlative studies   mass spectrometry Correlative studies   bone scan Correlative studies   qualityoflife assessment Ancillary studies   questionnaire administration Ancillary studies   pharmacogenomic studies Correlative studies   high performance liquid chromatography Correlative studies\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 249,\n        \"samples\": [\n          \"DISEASE CHARACTERISTICS   Histologically confirmed breast cancer   Completely resected disease   Registered for clinical trial IBCSG2402 but not yet started protocol hormonal therapy   Has not yet received any of the following adjuvant endocrine therapy either before or after registration on IBCSG2402   Tamoxifen exemestane or gonadotropinreleasing hormone GnRH agonist   Ovarian irradiation   Bilateral oophorectomy   Hormone receptor status   Estrogen andor progesterone receptor positive   Each tumor must be hormone receptor positive   PATIENT CHARACTERISTICS   Premenopausal   Can speak and read the local languages fluently   PRIOR CONCURRENT THERAPY   See Disease Characteristics\",\n          \"Inclusion Criteria   Patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast that is estrogen andor progesterone receptor positive by immunohistochemical staining who are considering aromatase inhibitor therapy women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen patients must have completed any adjuvant chemotherapy patients may have received preoperative chemotherapy   Postmenopausal status defined as  60 years of age or  60 years of age and amenorrheic for  12 months prior to day 1 if intact uterusovaries or  60 years of age and the last menstrual period 612 months prior to day 1 if intact uterusovaries and meets biochemical criteria for menopause FSH and estradiol within institutional standards for postmenopausal status or  60 years of age without a uterus and meets biochemical criteria for menopause FSH and estradiol within institutional standards for postmenopausal status or  60 years of age and history of bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months  60 years of age and taking medication designed to suppress ovarian function and meets biochemical criteria for menopause estradiol levels within institutional standards for postmenopausal status women would have had to be taking the drug for at least 30 days prior to day 1   ECOG performance status 02   Patient is aware of the nature of her diagnosis understands the study regimen its requirements risks and discomforts and is able and willing to sign an informed consent form   Exclusion Criteria   Concurrent use of hormone replacement therapy   Concurrent use of tamoxifen patients taking tamoxifen must discontinue the drug prior to first dose of zoledronic acid   Concurrent use of other selective estrogen receptor modulator SERM such as raloxifene   Concurrent consumption of soy supplements routine dietary consumption of soy containing foods will be permitted   Prior use of an aromatase inhibitor in any setting   Current bisphosphonate use oral or intravenous prior bisphosphonate users would be eligible as long as the use was  1 month ago for oral bisphosphonates andor  12 months ago for intravenous bisphosphonates prior to starting study treatment   Moderate to severe renal impairment serum creatinine greater than 2 mgdL or creatinine clearance less than 50 mLmin   Hypersensitivity to letrozole or zoledronic acid or any of its excipients   Concomitant treatment with oral or intravenous corticosteroids   Current active dental problems including infection or the teeth or jawbone maxilla or mandibular dental or fixture trauma or a current or prior diagnosis of osteonecrosis of the jaw ONJ of exposed bone in the mouth or of slow healing after dental procedures   Recent within 6 weeks or planned dental or jaw surgery eg extraction implants\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 249,\n        \"samples\": [\n          \"Outcome Measurement    Change in Cognitive Function Over 1 Year in Premenopausal Breast Cancer Patients Who Receive Adjuvant Tamoxifen T Alone Against Those Receive Adjuvant Tamoxifen TOFS or Exemestane EOFS With Ovarian Function Suppression OFS   Objective cognitive function measured with CogState a computerized test battery of 7 tasks Detection Identification Monitoring Memory Learning International Shopping List Task ISLT and ISLTDelayed Recall Performance speed is measured for DetectionIdentificationMonitoring and performance accuracy is measured for MemoryLearningISLTISLTDelayed Recall Performance speed calculated as mean of the log10 transformed reaction time for correct responses lower scorebetter performance accuracy calculated as arcsine transformation of the proportion of correct responses higher scoresbetter Main outcome measure is a composite score average of task scores after transformation and standardization by agespecific norms A positive standardized score indicates that a patient performed better than average a negative standardized score indicates below average results Patients complete assessments at baseline and 1 year after randomization to parent IBCSG 2402 SOFT study   Time frame 1 year after patient randomization to parent IBCSG 2402 study Results 1    ArmGroup Title Tamoxifen   ArmGroup Description Tamoxifen 20mg orally daily for 5 years   Overall Number of Participants Analyzed 20   Mean Standard Deviation   Unit of Measure standardized units  04         049 Results 2    ArmGroup Title Ovarian Function Suppression   ArmGroup Description Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression OFS triptorelin GnRH analogue 375 mg by im injection q28 days for 5 years or surgical oophorectomy or ovarian irradiation   Note Data were collected separately for the TOFS and EOFS participants in the parent study IBCSG 2402 SOFT The sample size for this CoSOFT substudy was small so the analysis plan was revised to prespecify collective analysis for all patients receiving OFS   Overall Number of Participants Analyzed 54   Mean Standard Deviation   Unit of Measure standardized units  021         092\",\n          \"Outcome Measurement    Number of Participants With Aromatase Inhibitor Associated Musculoskeletal Symptoms AIMSS   Not Specified   Time frame 12 months Results 1    ArmGroup Title Arm I   ArmGroup Description Patients receive zoledronic acid IV at months 1 and 6 Beginning 14 days after first zoledronic acid infusion patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity   letrozole Given orally   zoledronic acid Given IV   laboratory biomarker analysis Correlative studies   enzymelinked immunosorbent assay Correlative studies   mass spectrometry Correlative studies   bone scan Correlative studies   qualityoflife assessment Ancillary studies   questionnaire administration Ancillary studies   pharmacogenomic studies Correlative studies   high performance liquid chromatography Correlative studies   Overall Number of Participants Analyzed 59   Measure Type Count of Participants   Unit of Measure Participants  22  373\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 244,\n        \"samples\": [\n          \"Adverse Events 1   Total 0127 000 Adverse Events 2   Total \",\n          \"Adverse Events 1   Total 059 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_intervention\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 137,\n        \"samples\": [\n          \"INTERVENTION 1    Nuevo Amanecer Peer Support Program   Nuevo Amanecer is a cognitivebehavioral stress management program delivered by peers Spanishspeaking Latinas who have had breast cancer designed to address the first year of survivorship   Peer Support Program   Work with a trained counselor who is a breast cancer survivor   Meet 8 times inperson over the 8 week program with the counselor   Counselor helps participant develop a personalized support program to help her improve her quality of life   Receives information on breast cancer its treatments stress management and cognitive refraining INTERVENTION 2    Waitlist Control   Waits six months and at the end of the six months is offered the option of participating in the peer support program\",\n          \"INTERVENTION 1    Curcumin   4 Curcumin C3 Complex 500mg capsules 20 g taken orally 3 timesday throughout course of radiation treatments plus one week   Curcumin 4 Curcumin C3 Complex 500mg capsules 20 g taken orally 3 timesday throughout course of radiation treatments plus one week INTERVENTION 2    Placebo   4 placebo capsules taken orally 3 timesday throughout course of radiation treatments plus one week   Placebo 4 placebo capsules taken orally 3 timesday throughout course of radiation treatments plus one week\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Eligibility\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 137,\n        \"samples\": [\n          \"Inclusion Criteria   Selfidentifies as Latina   Diagnosed with Stage 0 I II or III in the prior month   Primarily Spanishspeaking or Spanish monolingual   Aged 18 or older   Diagnosed in Alameda Contra Costa San Mateo San Francisco or Santa Clara counties California Exclusion Criteria   Previous cancer diagnosis except for nonmelanoma skin cancer   Terminal illness   Stage IV breast cancer distant metastasis\",\n          \"Inclusion Criteria   a diagnosis of noninflammatory breast adenocarcinoma including in situ and bilateral   scheduled to begin radiotherapy without concurrent chemotherapy concurrent hormone or Herceptin trastuzumabtreatment is okay   can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment   can have had breast reconstruction   scheduled to receive 2535 radiation treatment sessions 1 session per day using standard irradiation fractionation 1820 Gy per sessions OR 1620 radiation treatment sessions 1 session per day using Canadian irradiation fractionation 2230 Gy per session100 101   able to swallow medication   three weeks must have elapsed after chemotherapy and surgery before the patient can begin the study   able to understand English Exclusion Criteria   inflammatory breast cancer   previous radiation therapy to the breast or chest   concurrent chemotherapy treatment   concurrent treatment with anticoagulants eg coumadin warfarin or antiEGFR human epidermal growth factor receptor drugs eg Iressa gefitinib Erbitux cetuximab C225 aspirin is allowed   known radiosensitivity syndromes eg Ataxiatelangiectasia   collagen vascular disease unhealed surgical sites or breast infections\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 137,\n        \"samples\": [\n          \"Outcome Measurement    Physical Wellbeing a Subcale of the Functional Assessment of Cancer TherapyBreast Quality of Life Instrument FACTB   FACTB was used as the breast cancerspecific qualityoflife measure FACTB consists of 5 subscale scores pertaining to 4 wellbeing dimensions physical socialfamily emotional functional and additional breast cancer concerns A total overall score is the sum of all subscales Response options were 0not at all 1a little bit 2somewhat 3quite a bit and 4very much   Psychometric analysis in our Spanishspeaking Latina sample resulted in modifications to FACTB physical wellbeing subscale Of 7 items 1 was dropped because it was conceptually different from other items on that scale Modified subscale was scored by summing items Possible score ranges for physical wellbeing were 024 Higher scores indicated greater wellbeing   Time frame Baseline and 6 month assessment Results 1    ArmGroup Title Nuevo Amanecer Peer Support Program   ArmGroup Description Nuevo Amanecer is a cognitivebehavioral stress management program delivered by peers Spanishspeaking Latinas who have had breast cancer designed to address the first year of survivorship   Peer Support Program   Work with a trained counselor who is a breast cancer survivor   Meet 8 times inperson over the 8 week program with the counselor   Counselor helps participant develop a personalized support program to help her improve her quality of life   Receives information on breast cancer its treatments stress management and cognitive refraining   Overall Number of Participants Analyzed 76   Mean Standard Deviation   Unit of Measure units on a scale  Baseline 1529         578   6 month 1944         426 Results 2    ArmGroup Title Waitlist Control   ArmGroup Description Waits six months and at the end of the six months is offered the option of participating in the peer support program   Overall Number of Participants Analyzed 75   Mean Standard Deviation   Unit of Measure units on a scale  Baseline 1676         502   6 month 1844         458\",\n          \"Outcome Measurement    Mean Radiation Dermatitis Severity Score   The outcome measures will be the severity of radiation dermatitis using the Radiation Dermatitis Score RDS at the end of treatment in each treatment arm Objective To examine the efficacy of curcumin in preventing andor reducing the severity of dermatitis in radiation treatment site in breast cancer patients The RDS score ranges from 04 with higher scores indicating worse outcome   Time frame 6 weeks Results 1    ArmGroup Title Curcumin   ArmGroup Description 4 Curcumin C3 Complex 500mg capsules 20 g taken orally 3 timesday throughout course of radiation treatments plus one week   Curcumin 4 Curcumin C3 Complex 500mg capsules 20 g taken orally 3 timesday throughout course of radiation treatments plus one week   Overall Number of Participants Analyzed 283   Mean Standard Deviation   Unit of Measure units on a scale  202         005 Results 2    ArmGroup Title Placebo   ArmGroup Description 4 placebo capsules taken orally 3 timesday throughout course of radiation treatments plus one week   Placebo 4 placebo capsules taken orally 3 timesday throughout course of radiation treatments plus one week   Overall Number of Participants Analyzed 295   Mean Standard Deviation   Unit of Measure units on a scale  199         006\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_id_Adverse_events\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 133,\n        \"samples\": [\n          \"Adverse Events 1   Total 46 6667   Diarrhoea 16 1667   Chest pain 16 1667   General physical health deterioration 06 000   Biliary colic 16 1667   Clostridium difficile colitis 06 000   Infusion related reaction 16 1667   Hypokalaemia 06 000   Tumour lysis syndrome 06 000   Spinal cord compression 06 000   Acute kidney injury 06 000\",\n          \"Adverse Events 1   Total 180 125   Gastritis  180 125 Adverse Events 2   Total 078 000   Gastritis  078 000\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Concatenated_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5486,\n        \"samples\": [\n          \"the primary id results is outcome measurement    percentage change from baseline in serum beta cterminal crosslinking telopeptide of type i collagen betactx at week 4   result at week 4 minus result at baseline as a percentage of the result at baseline based on log transformed data back transformation of the least squares ls mean   time frame baseline to week 4 results 1    armgroup title azd0530 175 mg   armgroup description azd0530 saracatinib 175 mg once daily   overall number of participants analyzed 46   geometric mean 95 confidence interval   unit of measure percentage change in betactx  711        759 to 654 results 2    armgroup title zoledronic acid 4 mg   armgroup description zoledronic acid 4 mg on day 1 of the 4week treatment period   overall number of participants analyzed 65   geometric mean 95 confidence interval   unit of measure percentage change in betactx  684        730 to 632 and the secondary id results is none and the statement is congenital candidiasis is a fungal infection by any of the candida species that is present at birth the azd0530 175 mg group of the primary trial experienced a more significant percentage change in betactx at week 4 than the zoledronic acid 4 mg group\",\n          \"the primary id intervention is intervention 1    dendritic cell vaccine   therapeutic autologous dendritic cells dendritic cell vaccine id injection 20 x 106 dcs given per treatment trastuzumab infusion vinorelbine ditartrate infusion   sargramostim all patients will receive leukine gmcsf at 250 mcgm2 starting one day after the administration of chemotherapy x 7 days patients with neutrophil counts below 1000mm3 on day 8 will continue gmcsf therapy until the neutrophil count is greater than 1000mm3   therapeutic autologous dendritic cells patients will receive 10 x 106 peptidepulsed dcs given by id injection into either axilla or the inguinal region with each peptide given into a separate site the total dose will be 20 x 106 dcs given per treatment   trastuzumab trastuzumab will be infused in the sideport of a freely flowing iv over 90 minutes and at 6mgkg if the subject has not previously received trastuzumab or if it has been more than 30 days since any prior trastuzumab administration and the secondary id intervention is none and the statement is the primary clinical trial does not involve the use of any injections for its patients\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 43
        }
      ],
      "source": [
        "test_data.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "6iuwlP8TV5da"
      },
      "outputs": [],
      "source": [
        "def embeddings(data, tokenizer):\n",
        "  inputs = tokenizer(data['Concatenated_Text'].tolist(), padding=True, truncation=True, return_tensors=\"pt\")\n",
        "  label_mapping = {'Contradiction': 0, 'Entailment': 1}\n",
        "  labels = data['Label'].replace(label_mapping).values\n",
        "  labels = torch.tensor(labels)\n",
        "  train_inputs=inputs['input_ids']\n",
        "  train_labels=labels\n",
        "  train_masks=inputs['attention_mask']\n",
        "  return train_inputs, train_labels, train_masks"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "2LyCcrrIkilw"
      },
      "outputs": [],
      "source": [
        "import torch\n",
        "from transformers import AutoTokenizer\n",
        "\n",
        "def preprocess_data(data, tokenizer):\n",
        "    inputs = tokenizer(data['Concatenated_Text'].tolist(), padding=True, truncation=True, return_tensors=\"pt\")\n",
        "    train_inputs = inputs['input_ids']\n",
        "    train_masks = inputs['attention_mask']\n",
        "\n",
        "    return train_inputs, train_masks\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "6jHuZtF3gMD7"
      },
      "outputs": [],
      "source": [
        "label_mapping = {'Contradiction': 0, 'Entailment': 1}"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "13f66c68-524d-44b5-f7ed-4b878a88d976",
        "id": "rRqj04TAw9Ni"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Using device: cuda\n"
          ]
        }
      ],
      "source": [
        "device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
        "print(\"Using device:\", device)"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Longer Former"
      ],
      "metadata": {
        "id": "lYrOtlaqmw_d"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from transformers import AutoTokenizer, AutoModelForSequenceClassification\n",
        "tokenizer = AutoTokenizer.from_pretrained(\"nbroad/longformer-base-health-fact\")\n",
        "model = AutoModelForSequenceClassification.from_pretrained(\"nbroad/longformer-base-health-fact\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 422,
          "referenced_widgets": [
            "6ea463461f0349ff84a1342d329d972f",
            "6758fe65f2cc47ee8344669ca79487ab",
            "191ef987c75c45c2bb8ff4eb013a5397",
            "79cc24516ea746c783e9ee093737be61",
            "0a821f336eac43119f72f42b0dc8f77b",
            "31f40965a8b644a58913efa63150ac1a",
            "aa7bb4f07ef34e3eb55ad4a63712619e",
            "6f44d979b1dc469cbd9bcce162df8242",
            "47a7cc4c6ae94509ab55f9facd397ec7",
            "9fbba43e8abd427e8f60118afa1ae6b8",
            "882963e71a534d8ab811bbd1167af99f",
            "df91ea5ee26942638cc47c927e5b8b5a",
            "2c8c1cdb63f849b6b2692970794d2ac9",
            "98c4347fb4d84e5495895a1f0a213422",
            "f90455512ea54d13a838f0763eb7a36e",
            "7649cb6863a1471cba6c7e58a54514c3",
            "43a0f8f3e3134437a230e9f604dcd6d9",
            "4ffb87cebe534110b2c5739b3ef443eb",
            "7f985230985b4ea6b601f9e5625dc725",
            "19ffeeac1e2e48eab93462db3f8dfa47",
            "ea95c46d15eb437faac0cd33bc81f20f",
            "fccfb40ad7ae4d5485a4d64eaaf34685",
            "aa8f2a75afdf4a2bbcd12934d00093fd",
            "4ce355f414b540eebb8327b2026e4ed9",
            "8191b5065b5a47ceb9227c1636229415",
            "85c8a8a2d1224c88b1e9e9513206828e",
            "9e47012cac4f41e9a62dda675509fae3",
            "97e9520bcf1e4bd38bd6ce3a84559924",
            "604ed65a565445879a4b4110a7333c0a",
            "5b1520b5af104118b49cc4e0b74d28d6",
            "afe5cd2e7787461390816dc254669757",
            "48d4c5f00726455cac7113c957411d53",
            "ee7a1c0ef2774e8b811d1a44228ca931",
            "9dfc9184ccfc431ab9d6d02b1ea8f216",
            "edec8002fb084cbb89c1e35b0c79e982",
            "fa1beeb89ea34f8aaa1358180261a503",
            "eddbe440254c438b852984811a070a22",
            "638455344d7540158dd80d399d935fb0",
            "76984f7f058e4989be69faf80ad99991",
            "10e94bcf52dc4418ab2f5fa0c0393db3",
            "84d25e2ee4fb49bb915f8cacff4d8647",
            "4746a7bc30b1437ebab6b78c828ec323",
            "ab4f450abdee4609a32103247ad920c0",
            "df03fb8f870a4dec8f02b8b59c7cea2d",
            "1fb6031822aa438c8d7679f6450b2a5b",
            "31ba0a74852e499099618adb22bbe584",
            "b3263773148d45f9a1321ae7cda45cf3",
            "b049bcc55977405fb126a4971f71c522",
            "7ed13b472c304d8e98885b44f4c4d02b",
            "802027c57f2d4a588ba0d39c9fc6ed25",
            "5b85871d12084e8cbb7310fc33929a44",
            "2bcfdbffc9c643a5bd85c6a22cd29f9c",
            "f0ce564d33dc470b9a4bd5910f1f53c0",
            "03d7dbf5d87d4b3bb80d1fb654fbc130",
            "9fbce1cb223242f7aded3388d2491944",
            "fb98edb35a034030bff8621ca76f7565",
            "c73967a07d7e487ba267fdf74272ebad",
            "319f360d3d12452e9f2ced8820f59398",
            "80807b13d4ce4ee6add2df76fc145df3",
            "d91fe907d7f744e3a4b756c86e999678",
            "941d7fb657fd42a3bab2ab5062ca2aee",
            "c7cb479d052f444d95510f58a289d7b0",
            "b990be73d7094f9383017dc4db681fed",
            "f2c12107ac414ae690edfd0289652037",
            "ac39d9979b5243bc83a82b5ed52685bd",
            "824bb8dd1e1e494d8144c291faa1a506",
            "107771d80b95479ca84d36a5f6f15698",
            "b7ee8eb2430240ab93487efc1b9bb7c4",
            "b89e84105b4644b09da70635455750a8",
            "a7a884c95e1146cfa4cc18a6d2fcd11f",
            "ea90db5d7bbb4d70889e207c2b6765de",
            "241e5fc41a0a486ab63e33c1f6109546",
            "97536dae44ed42c7b4bfb3da555868f9",
            "2fa04913ee0542b9b542cab288108b08",
            "55b66a6a666c4f2cba551e5f3ba6aeaa",
            "3d6152195cdf4928978c52639e1f009f",
            "4f588abd255d47a5a8013f8e88e2ee21"
          ]
        },
        "id": "HPcJ9FTonx6C",
        "outputId": "7c7af488-f378-43ce-95d8-ffe017858589"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_token.py:88: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer_config.json:   0%|          | 0.00/369 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "6ea463461f0349ff84a1342d329d972f"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "vocab.json:   0%|          | 0.00/798k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "df91ea5ee26942638cc47c927e5b8b5a"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "merges.txt:   0%|          | 0.00/456k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "aa8f2a75afdf4a2bbcd12934d00093fd"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer.json:   0%|          | 0.00/2.11M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "9dfc9184ccfc431ab9d6d02b1ea8f216"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "special_tokens_map.json:   0%|          | 0.00/239 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "1fb6031822aa438c8d7679f6450b2a5b"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/1.30k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "fb98edb35a034030bff8621ca76f7565"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "model.safetensors:   0%|          | 0.00/595M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "107771d80b95479ca84d36a5f6f15698"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Some weights of the model checkpoint at nbroad/longformer-base-health-fact were not used when initializing LongformerForSequenceClassification: ['longformer.embeddings.position_ids']\n",
            "- This IS expected if you are initializing LongformerForSequenceClassification from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
            "- This IS NOT expected if you are initializing LongformerForSequenceClassification from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "tokenizer.model_max_length=512"
      ],
      "metadata": {
        "id": "rxhotT2Zux3g"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "train_inputs, train_labels, train_masks=embeddings(train_data, tokenizer)\n",
        "val_inputs, val_labels, val_masks=embeddings(validation_data, tokenizer)\n",
        "contradict_inputs, contradict_labels, contradict_masks=embeddings(contradict_data, tokenizer)\n",
        "original_inputs, original_labels, original_masks=embeddings(original_data, tokenizer)\n",
        "preserving_inputs, preserving_labels, preserving_masks=embeddings(preserving_data, tokenizer)\n",
        "gold_inputs, gold_labels, gold_masks = embeddings(gold_data, tokenizer)"
      ],
      "metadata": {
        "id": "Mf-gfFDsuzSq"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "test_inputs, test_masks=preprocess_data(test_data, tokenizer)"
      ],
      "metadata": {
        "id": "rKR9_tqcvvj2"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from torch.utils.data import TensorDataset, DataLoader, RandomSampler, SequentialSampler\n",
        "import torch.optim as optim\n",
        "\n",
        "batch_size = 8\n",
        "\n",
        "train_data_t = TensorDataset(train_inputs, train_masks, train_labels)\n",
        "train_sampler = RandomSampler(train_data_t)\n",
        "train_dataloader = DataLoader(train_data_t, sampler=train_sampler, batch_size=batch_size)\n",
        "\n",
        "validation_data_t = TensorDataset(val_inputs, val_masks, val_labels)\n",
        "validation_sampler = SequentialSampler(validation_data_t)\n",
        "validation_dataloader = DataLoader(validation_data_t, sampler=validation_sampler, batch_size=batch_size)\n",
        "\n",
        "contradict_data_t = TensorDataset(contradict_inputs, contradict_masks, contradict_labels)\n",
        "contradict_sampler = SequentialSampler(contradict_data_t)\n",
        "contradict_dataloader = DataLoader(contradict_data_t, sampler=contradict_sampler, batch_size=batch_size)\n",
        "\n",
        "original_data_t = TensorDataset(original_inputs, original_masks, original_labels)\n",
        "original_sampler = SequentialSampler(original_data_t)\n",
        "original_dataloader = DataLoader(original_data_t, sampler=original_sampler, batch_size=batch_size)\n",
        "\n",
        "preserving_data_t = TensorDataset(preserving_inputs, preserving_masks, preserving_labels)\n",
        "preserving_sampler = SequentialSampler(preserving_data_t)\n",
        "preserving_dataloader = DataLoader(preserving_data_t, sampler=preserving_sampler, batch_size=batch_size)\n",
        "\n",
        "gold_data_t = TensorDataset(gold_inputs, gold_masks, gold_labels)\n",
        "gold_sampler = SequentialSampler(gold_data_t)\n",
        "gold_dataloader = DataLoader(gold_data_t, sampler=gold_sampler, batch_size=batch_size)\n",
        "\n",
        "test_data_t = TensorDataset(test_inputs, test_masks)\n",
        "test_dataloader = DataLoader(test_data_t, batch_size=batch_size)\n",
        "\n",
        "optimizer = optim.AdamW(model.parameters(), lr=2e-5)\n"
      ],
      "metadata": {
        "id": "r7ePawbXvwY5"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np"
      ],
      "metadata": {
        "id": "XJ1beMBsv-Dd"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
        "print(\"Using device:\", device)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7Zs08aMOx0lg",
        "outputId": "617bad9a-a02e-452f-c190-0135e5caa35c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Using device: cuda\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.metrics import accuracy_score\n",
        "\n",
        "model.train()\n",
        "model = model.to(device)\n",
        "epochs=[]\n",
        "accuracy_values=[]\n",
        "loss_values=[]\n",
        "for epoch in range(50):\n",
        "    total_correct = 0\n",
        "    total_samples = 0\n",
        "    total_loss=0\n",
        "\n",
        "    for step, batch in enumerate(train_dataloader):\n",
        "        batch = tuple(t.to(device) for t in batch)\n",
        "        b_input_ids, b_input_mask, b_labels = batch\n",
        "        optimizer.zero_grad()\n",
        "        outputs = model(b_input_ids, token_type_ids=None, attention_mask=b_input_mask, labels=b_labels)\n",
        "        loss = outputs.loss\n",
        "        loss.backward()\n",
        "        optimizer.step()\n",
        "        total_loss += loss.item()\n",
        "        logits = outputs.logits.detach().cpu().numpy()\n",
        "        preds = np.argmax(logits, axis=1)\n",
        "        labels = b_labels.detach().cpu().numpy()\n",
        "        batch_correct = np.sum(preds == labels)\n",
        "        batch_samples = labels.size\n",
        "        total_correct += batch_correct\n",
        "        total_samples += batch_samples\n",
        "\n",
        "    avg_epoch_loss = total_loss / len(train_dataloader)\n",
        "    loss_values.append(avg_epoch_loss)\n",
        "    epoch_accuracy = total_correct / total_samples\n",
        "    epochs.append(epoch)\n",
        "    accuracy_values.append(epoch_accuracy)\n",
        "\n",
        "    print(f'Epoch {epoch + 1}, Training Accuracy: {epoch_accuracy:.4f}, Loss: {avg_epoch_loss:.4f}')\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Wnj0-aPqwCfS",
        "outputId": "0ff3d645-d3b7-4554-f8ee-a8eeae3be4c4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Initializing global attention on CLS token...\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Epoch 1, Training Accuracy: 0.4994, Loss: 0.7430\n",
            "Epoch 2, Training Accuracy: 0.4676, Loss: 0.7146\n",
            "Epoch 3, Training Accuracy: 0.5224, Loss: 0.7023\n",
            "Epoch 4, Training Accuracy: 0.4959, Loss: 0.7026\n",
            "Epoch 5, Training Accuracy: 0.4912, Loss: 0.7053\n",
            "Epoch 6, Training Accuracy: 0.4900, Loss: 0.7060\n",
            "Epoch 7, Training Accuracy: 0.5024, Loss: 0.6974\n",
            "Epoch 8, Training Accuracy: 0.5376, Loss: 0.6910\n",
            "Epoch 9, Training Accuracy: 0.5094, Loss: 0.6956\n",
            "Epoch 10, Training Accuracy: 0.5371, Loss: 0.6902\n",
            "Epoch 11, Training Accuracy: 0.5541, Loss: 0.6869\n",
            "Epoch 12, Training Accuracy: 0.5518, Loss: 0.6827\n",
            "Epoch 13, Training Accuracy: 0.5600, Loss: 0.6770\n",
            "Epoch 14, Training Accuracy: 0.5718, Loss: 0.6668\n",
            "Epoch 15, Training Accuracy: 0.5876, Loss: 0.6577\n",
            "Epoch 16, Training Accuracy: 0.5941, Loss: 0.6484\n",
            "Epoch 17, Training Accuracy: 0.6218, Loss: 0.6249\n",
            "Epoch 18, Training Accuracy: 0.6382, Loss: 0.6082\n",
            "Epoch 19, Training Accuracy: 0.6441, Loss: 0.5923\n",
            "Epoch 20, Training Accuracy: 0.6641, Loss: 0.5734\n",
            "Epoch 21, Training Accuracy: 0.6882, Loss: 0.5349\n",
            "Epoch 22, Training Accuracy: 0.6929, Loss: 0.5066\n",
            "Epoch 23, Training Accuracy: 0.7312, Loss: 0.4897\n",
            "Epoch 24, Training Accuracy: 0.7235, Loss: 0.4759\n",
            "Epoch 25, Training Accuracy: 0.7382, Loss: 0.4487\n",
            "Epoch 26, Training Accuracy: 0.7576, Loss: 0.4264\n",
            "Epoch 27, Training Accuracy: 0.7665, Loss: 0.3969\n",
            "Epoch 28, Training Accuracy: 0.7594, Loss: 0.3975\n",
            "Epoch 29, Training Accuracy: 0.7876, Loss: 0.3680\n",
            "Epoch 30, Training Accuracy: 0.8012, Loss: 0.3372\n",
            "Epoch 31, Training Accuracy: 0.7812, Loss: 0.3539\n",
            "Epoch 32, Training Accuracy: 0.8071, Loss: 0.3382\n",
            "Epoch 33, Training Accuracy: 0.7994, Loss: 0.3429\n",
            "Epoch 34, Training Accuracy: 0.8182, Loss: 0.3062\n",
            "Epoch 35, Training Accuracy: 0.8176, Loss: 0.2972\n",
            "Epoch 36, Training Accuracy: 0.8194, Loss: 0.3097\n",
            "Epoch 37, Training Accuracy: 0.8329, Loss: 0.2764\n",
            "Epoch 38, Training Accuracy: 0.8241, Loss: 0.2626\n",
            "Epoch 39, Training Accuracy: 0.8329, Loss: 0.2601\n",
            "Epoch 40, Training Accuracy: 0.8382, Loss: 0.2783\n",
            "Epoch 41, Training Accuracy: 0.8394, Loss: 0.2704\n",
            "Epoch 42, Training Accuracy: 0.8418, Loss: 0.2641\n",
            "Epoch 43, Training Accuracy: 0.8441, Loss: 0.2461\n",
            "Epoch 44, Training Accuracy: 0.8476, Loss: 0.2527\n",
            "Epoch 45, Training Accuracy: 0.8347, Loss: 0.2645\n",
            "Epoch 46, Training Accuracy: 0.8465, Loss: 0.2579\n",
            "Epoch 47, Training Accuracy: 0.8500, Loss: 0.2641\n",
            "Epoch 48, Training Accuracy: 0.8329, Loss: 0.2517\n",
            "Epoch 49, Training Accuracy: 0.8506, Loss: 0.2390\n",
            "Epoch 50, Training Accuracy: 0.8541, Loss: 0.2394\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt"
      ],
      "metadata": {
        "id": "xnZGchjZwHjg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "plt.figure(figsize=(20,15))\n",
        "plt.plot(epochs, accuracy_values, marker='o')\n",
        "plt.title('Model Accuracy Over Epochs')\n",
        "plt.xlabel('Epoch')\n",
        "plt.ylabel('Accuracy')\n",
        "plt.grid(True)\n",
        "plt.xticks(epochs)\n",
        "plt.show()\n",
        "plt.figure(figsize=(20,15))\n",
        "plt.plot(epochs, loss_values, marker='o')\n",
        "plt.title('Model Loss Over Epochs')\n",
        "plt.xlabel('Epoch')\n",
        "plt.ylabel('Loss')\n",
        "plt.grid(True)\n",
        "plt.xticks(epochs)\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "ymrJm9nSwNNb",
        "outputId": "4b971c97-6f5e-4deb-d7ae-3d79c5e215f2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2000x1500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2000x1500 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "torch.save(model.state_dict(), 'model_long_weights.pth')"
      ],
      "metadata": {
        "id": "y4oIzEnuwQ8u"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "output_dir = \"/content/drive/MyDrive/training_data\"\n",
        "model.save_pretrained(output_dir)"
      ],
      "metadata": {
        "id": "YnVUJJ6lwZt5"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "from sklearn.metrics import accuracy_score"
      ],
      "metadata": {
        "id": "HVJzP0TSwgef"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.metrics import accuracy_score, f1_score\n",
        "all_true_labels = []\n",
        "all_predicted_labels = []\n",
        "val_accuracy = []\n",
        "val_loss = []\n",
        "\n",
        "with torch.no_grad():\n",
        "    for batch in validation_dataloader:\n",
        "        batch = tuple(t.to(device) for t in batch)\n",
        "        b_input_ids, b_input_mask, b_labels = batch\n",
        "        outputs = model(b_input_ids, token_type_ids=None, attention_mask=b_input_mask, labels=b_labels)\n",
        "        logits = outputs.logits.detach().cpu().numpy()\n",
        "        label_ids = b_labels.to('cpu').numpy()\n",
        "        preds = np.argmax(logits, axis=1).flatten()\n",
        "        batch_accuracy = accuracy_score(label_ids, preds)\n",
        "        val_accuracy.append(batch_accuracy)\n",
        "        val_loss.append(outputs.loss.item())\n",
        "        all_true_labels.extend(label_ids)\n",
        "        all_predicted_labels.extend(preds)\n",
        "\n",
        "avg_val_loss = sum(val_loss) / len(val_loss)\n",
        "avg_val_accuracy = sum(val_accuracy) / len(val_accuracy)\n",
        "\n",
        "macro_f1 = f1_score(all_true_labels, all_predicted_labels, average='macro')\n",
        "\n",
        "print(f'Validation loss: {avg_val_loss:.3f}')\n",
        "print(f'Validation accuracy: {avg_val_accuracy:.3f}')\n",
        "print(f'Macro F1 score: {macro_f1:.3f}')\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GnVXdXNSwqG9",
        "outputId": "4cee0692-e7a0-4358-b4bc-934a2f2da712"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Validation loss: 1.060\n",
            "Validation accuracy: 0.615\n",
            "Macro F1 score: 0.615\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "from sklearn.metrics import accuracy_score, f1_score\n",
        "\n",
        "c_all_true_labels = []\n",
        "c_all_predicted_labels = []\n",
        "c_accuracy = []\n",
        "c_loss = []\n",
        "\n",
        "with torch.no_grad():\n",
        "    for batch in contradict_dataloader:\n",
        "        batch = tuple(t.to(device) for t in batch)\n",
        "        b_input_ids, b_input_mask, b_labels = batch\n",
        "        outputs = model(b_input_ids, token_type_ids=None, attention_mask=b_input_mask, labels=b_labels)\n",
        "        logits = outputs.logits.detach().cpu().numpy()\n",
        "        label_ids = b_labels.to('cpu').numpy()\n",
        "        preds = np.argmax(logits, axis=1).flatten()\n",
        "        batch_accuracy = accuracy_score(label_ids, preds)\n",
        "        c_accuracy.append(batch_accuracy)\n",
        "        c_loss.append(outputs.loss.item())\n",
        "        c_all_true_labels.extend(label_ids)\n",
        "        c_all_predicted_labels.extend(preds)"
      ],
      "metadata": {
        "id": "P6LOy5llwuES"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "from sklearn.metrics import accuracy_score, f1_score\n",
        "\n",
        "o_all_true_labels = []\n",
        "o_all_predicted_labels = []\n",
        "o_accuracy = []\n",
        "o_loss = []\n",
        "\n",
        "with torch.no_grad():\n",
        "    for batch in original_dataloader:\n",
        "        batch = tuple(t.to(device) for t in batch)\n",
        "        b_input_ids, b_input_mask, b_labels = batch\n",
        "        outputs = model(b_input_ids, token_type_ids=None, attention_mask=b_input_mask, labels=b_labels)\n",
        "        logits = outputs.logits.detach().cpu().numpy()\n",
        "        label_ids = b_labels.to('cpu').numpy()\n",
        "        preds = np.argmax(logits, axis=1).flatten()\n",
        "        batch_accuracy = accuracy_score(label_ids, preds)\n",
        "        o_accuracy.append(batch_accuracy)\n",
        "        o_loss.append(outputs.loss.item())\n",
        "        o_all_true_labels.extend(label_ids)\n",
        "        o_all_predicted_labels.extend(preds)"
      ],
      "metadata": {
        "id": "0wRp3___wzcX"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "from sklearn.metrics import accuracy_score, f1_score\n",
        "\n",
        "p_all_true_labels = []\n",
        "p_all_predicted_labels = []\n",
        "p_accuracy = []\n",
        "p_loss = []\n",
        "\n",
        "with torch.no_grad():\n",
        "    for batch in preserving_dataloader:\n",
        "        batch = tuple(t.to(device) for t in batch)\n",
        "        b_input_ids, b_input_mask, b_labels = batch\n",
        "        outputs = model(b_input_ids, token_type_ids=None, attention_mask=b_input_mask, labels=b_labels)\n",
        "        logits = outputs.logits.detach().cpu().numpy()\n",
        "        label_ids = b_labels.to('cpu').numpy()\n",
        "        preds = np.argmax(logits, axis=1).flatten()\n",
        "        batch_accuracy = accuracy_score(label_ids, preds)\n",
        "        p_accuracy.append(batch_accuracy)\n",
        "        p_loss.append(outputs.loss.item())\n",
        "        p_all_true_labels.extend(label_ids)\n",
        "        p_all_predicted_labels.extend(preds)"
      ],
      "metadata": {
        "id": "xI1QC6qRw_L-"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.metrics import accuracy_score, f1_score\n",
        "g_all_true_labels = []\n",
        "g_all_predicted_labels = []\n",
        "g_accuracy = []\n",
        "g_loss = []\n",
        "\n",
        "with torch.no_grad():\n",
        "    for batch in gold_dataloader:\n",
        "        batch = tuple(t.to(device) for t in batch)\n",
        "        b_input_ids, b_input_mask, b_labels = batch\n",
        "        outputs = model(b_input_ids, token_type_ids=None, attention_mask=b_input_mask, labels=b_labels)\n",
        "        logits = outputs.logits.detach().cpu().numpy()\n",
        "        label_ids = b_labels.to('cpu').numpy()\n",
        "        preds = np.argmax(logits, axis=1).flatten()\n",
        "        batch_accuracy = accuracy_score(label_ids, preds)\n",
        "        g_accuracy.append(batch_accuracy)\n",
        "        g_loss.append(outputs.loss.item())\n",
        "        g_all_true_labels.extend(label_ids)\n",
        "        g_all_predicted_labels.extend(preds)\n",
        "\n",
        "avg_g_val_loss = sum(g_loss) / len(g_loss)\n",
        "avg_g_val_accuracy = sum(g_accuracy) / len(g_accuracy)\n",
        "\n",
        "macro_f1 = f1_score(g_all_true_labels, g_all_predicted_labels, average='macro')\n",
        "\n",
        "print(f'Validation loss for gold practice test: {avg_g_val_loss:.3f}')\n",
        "print(f'Validation accuracy for gold practice test: {avg_g_val_accuracy:.3f}')\n",
        "print(f'Macro F1 score for gold practice test: {macro_f1:.3f}')\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JWAZHbgtxHcC",
        "outputId": "21fc08c6-b64a-4d23-c51d-d97594abccd5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Validation loss for gold practice test: 1.251\n",
            "Validation accuracy for gold practice test: 0.532\n",
            "Macro F1 score for gold practice test: 0.522\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "faithfulness = Faithfulness(o_all_predicted_labels, c_all_predicted_labels)\n",
        "consistency = Consistency(o_all_predicted_labels, p_all_predicted_labels)\n",
        "print(faithfulness)\n",
        "print(consistency)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "h2bzfnQ9xNJr",
        "outputId": "88194472-31de-44e5-af9e-45ccdec3a2d0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "0.5183333333333333\n",
            "0.4766666666666667\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "all_predicted_labels = []\n",
        "all_logits = []\n",
        "\n",
        "model.eval()\n",
        "\n",
        "with torch.no_grad():\n",
        "    for batch in test_dataloader:\n",
        "        batch = tuple(t.to(device) for t in batch)\n",
        "        b_input_ids, b_input_mask = batch\n",
        "        outputs = model(b_input_ids, token_type_ids=None, attention_mask=b_input_mask)\n",
        "        logits = outputs.logits.detach().cpu().numpy()\n",
        "        preds = np.argmax(logits, axis=1).flatten()\n",
        "        all_predicted_labels.extend(preds)\n",
        "        all_logits.extend(logits)\n",
        "\n",
        "print(all_predicted_labels)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eMQo8K4_xcVJ",
        "outputId": "5956dc2a-f57d-4cf9-bb79-63723c129dcb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[0, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 0, 1, 0, 0, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 0, 1, 0, 0, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 0, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 1, 0, 0, 1, 0, 0, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 0, 0, 1, 0, 0, 1, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 0, 0, 1, 1, 0, 1, 1, 0, 0, 1, 0, 0, 1, 0, 1, 0, 1, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 0, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 0, 0, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 0, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 0, 0, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 0, 0, 0, 0, 1, 1, 1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 0, 0, 1, 0, 0, 1, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 0, 0, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 1, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 0, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 1, 1, 0, 0, 1, 0, 0, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 0, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 1, 0, 0, 1, 1, 0, 0, 1, 1, 0, 0, 0, 0, 1, 0, 0, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 1, 0, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 0, 1, 0, 1, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 0, 1, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 1, 1, 0, 0, 0, 1, 0, 0, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 0, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 0, 0, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 0, 1, 0, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 0, 0, 1, 1, 0, 0, 1, 1, 0, 0, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 0, 1, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0, 1, 0, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 0, 1, 0, 0, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 0, 1, 0, 0, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 0, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 0, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 1, 0, 1, 0, 0, 0, 1, 0, 1, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 1, 0, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 0, 0, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 0, 0, 1, 0, 1, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 0, 0, 0, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 0, 0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 0, 0, 0, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 0, 0, 0, 0, 1, 0, 0, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 1, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 1, 1, 0, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 1, 0, 0, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 0, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 0, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 1, 1, 0, 0, 1, 1, 0, 1, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1, 1, 0, 0, 1, 0, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 0, 0, 1, 0, 0, 1, 1, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 0, 0, 1, 0, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 0, 1, 0, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 1, 1, 0, 0, 1, 0, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 0, 0, 0, 0, 1, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 0, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 0, 1]\n"
          ]
        }
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4"
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU"
  },
  "nbformat": 4,
  "nbformat_minor": 0
}